Official Protocol Title:
NCT number: [STUDY_ID_REMOVED]
Document Date: 07-NOV-2023
A Phase 2/3, Multicenter, Randomized, Double-
blind, Placebo-Controlled, Adaptive Design 
Study to Evaluate the Efficacy and Safety of 
MK-[ADDRESS_624990]: MK-5475 1
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
TITLE PAGE
THIS PROTOCOL AND ALL OF THE INFORMATION RELATING TO IT ARE 
CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK SHARP & 
DOHME LLC, RAHWAY, NJ, [LOCATION_003] (MSD).
Protocol Title: A Phase 2/3, Multicenter, Randomized, Double -blind, Placebo -Controlled, 
Adaptive Design Study to Evaluate the Efficacy and Safety of MK -5475 in Adults with 
Pulmonary Arterial Hypertension
Protocol Number: 007-03
Compound Number: MK-5475
Sponsor Name: [CONTACT_19519] & Dohme LLC (hereafter called t he Sponsor or MSD)
Legal Registered Address:
[ADDRESS_624991], NJ [ZIP_CODE] [LOCATION_003]
Regulatory Agency Identifying Number(s):
NCT [ADDRESS_624992] Not applicable
WHO Not applicable
UTN U1111 -1278- 4977
IND 149503
Approval Date: 07November [ADDRESS_624993]: MK-5475 2
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
Sponsor Signatory
Typed Name:
[CONTACT_1641]:Date
Protocol -specific Sponsor contact [CONTACT_19372] (or equivalent).
Investigator Signatory
I agree to conduct this clinical study in accordance with the design outlined in this protocol 
and to abide by [CONTACT_19373].
Typed Name:
[CONTACT_1641]:Date
08P53K
PRODUCT: MK-5475 3
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
DOCUMENT HISTORY
Document Date of Issue Overall Rationale
Amendment 3 07-NOV- 2023 Amended to 1) extend the duration of the Phase 2 
Cohort Extension Period to allow participants 
continued access to study intervention ; and 2) add 
a provision to collapse all treatment groups in the 
Phase [ADDRESS_624994]: MK-5475 4
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
PROTOCOL AMENDMENT SUMMARY OF CHANGES
Amendment: 03
Overall Rationale for the Amendment:
This protocol was amended to 1) extend the duration of the Phase 2 Cohort Extension Period
to allow participants continued access to study intervention ;and 2) adda provision to 
collapse all treatment groups in the Phase 2 Cohort Extension Period to a single dose group 
after selection of the Phase 3 dose .
Summary of Changes Table
Section Number and Name [CONTACT_486491] 1.1 ,Synopsis Duration of the Phase 2 Cohort 
Extension Period extended by 
16months .To allow participants continued access to study 
intervention .
Section 1.2 ,Schema
Section 1.3.1 ,Phase 2 Cohort 
Schedule of Activities
Section 4.1 ,Overall Design
Section 6.1 ,Study 
Intervention(s) Administere d
Section 1.1 ,Synopsis Provision added to collapse all 
treatment groups into a single 
group for the remainder of the 
Phase 2 Cohort Extension Period 
after the Phase 3 dose is selected .To permit Phase 2 participants to receive the 
selected Phase 3 dose .
Section 1.2 ,Schema
Section 2.1 ,Study Rationale
Section 4.1 ,Overall Design
Section 6.1 ,Study 
Intervention(s) Administered
Section 6.3.[ADDRESS_624995]: MK-5475 5
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_624996] the 
clinical or regulatory integrity of the protocol. 
All other relevant changes and their primary 
reasons are included for completeness.
Title Page Regulatory Agency identifying 
numbers updat ed.To comply with current industry regulations and 
guidelines .
Section 1.2 ,Schema Phase 2 Cohort Extension Period 
scheduled visit frequency updated .To align with update dinformation about the 
stability of MK -5475 .
Section 1.3 ,Schedule of 
ActivitiesClinic in -person visit guidance 
updated .To clarify that clinic in -person visits may be 
replaced by [CONTACT_756], video, or home visits 
using site staff or a nursing service after 
consultation with the Sponsor.
Option for home delivery of study 
intervention added .To prevent study intervention interruption during 
exceptional situations .
Reference to Appendix 7 for 
country -specific requirements 
added .To align with country -specific pregnancy testing 
requirements .
Section 1.3.1 Phase 2 Cohort 
Schedule of ActivitiesPhase 2 Cohort Extension Period 
scheduled visit frequency updated .Refer to Section 1.2 rationale regarding 
scheduled visit frequency.
Section 4.4.1 ,Clinical Criteria 
for Early Study TerminationCriteria for early study termination 
updated .To clarify that early study termination of both 
the Phase 2 and/or Phase 3 cohorts may be the 
result of the Sponsor’s plan to modify or 
discontinue the development of MK-5475 in 
PAH .
Section 5.1 ,Inclusion Criteria Contraception requirements 
updated .New data available .
Section 6.2.2 ,Handling, 
Storage, and AccountabilityOption for home delivery of study 
intervention added .Refer to Section 1.3 rationale regarding optional 
home delivery .
Section 8 , STUDY 
ASSESSMENTS AND 
PROCEDURESClinic in -person visit guidance 
updated .Refer to Section 1.3 rationale regarding
replacement of clinic in -person visits .
Section [IP_ADDRESS] ,Dispense 
Double -blind Study 
InterventionPhase [ADDRESS_624997]: MK-5475 6
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
Section Number and Name [CONTACT_19523] 10.7 ,Appendix 7: 
Country -specific 
RequirementsCountry -specific requirements 
added .Refer to Section 1.3 rationale regarding country -
specific pregnancy testing requirements and 
Section 8.4.4 rationale regarding regulatory 
requirements for SAEs and AESIs .
Section 10.8 ,Appendix 8: 
Approximate Blood Volume 
Tables, Table 11Phase 2 Cohort Extension Period 
scheduled visit frequency updated .Refer to Section 1.2 rationale regarding 
scheduled visit frequency .
Throughout Minor administrative, formatting, 
grammatical , and/or typographical 
changes were made .To ensure clarity and accurate interpretation of 
the intent of the protocol.
08P53K
PRODUCT: MK-5475 7
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
TABLE OF CONTENTS
DOCUMENT HISTORY ........................................................................................................3
PROTOCOL AMENDMENT SUMMARY OF CHANGES ............................................... 4
1 PROTOCOL SUMMARY ............................................................................................ 15
1.1 Synopsis ................................................................................................................. 15
1.2 Schema .................................................................................................................. 20
2 INTRODUCTION .......................................................................................................... 35
2.1 Study Rationale ....................................................................................................35
2.2 Background .......................................................................................................... 35
2.2.1 Pharmaceutical and Therapeutic Background ............................................. 36
2.2.2 Preclinical and Clinical Studies ...................................................................37
2.2.3 Information on Other Study -related Therapy .............................................. 39
2.3 Benefit/Risk Assessment ...................................................................................... 39
3 HYPOTHESES, OBJECTIVES, AND ENDPOINTS ................................................ 41
4 STUDY DESIGN ............................................................................................................ 44
4.1 Overall Design ......................................................................................................44
4.2 Scientific Rationale for Study Design ................................................................ .47
4.2.1 Rationale for Endpoints ............................................................................... 47
[IP_ADDRESS] Efficacy Endpoints ............................................................................. 47
[IP_ADDRESS] Patient -Reported Outcomes ............................................................... 49
[IP_ADDRESS] Safety Endpoints ................................................................................ 50
[IP_ADDRESS] Pharmacokinetic Endpoints ............................................................... 50
[IP_ADDRESS] Pharmacodynamic Endpoints............................................................. 51
[IP_ADDRESS] Planned Exploratory Biomarker Research .........................................51
[IP_ADDRESS].1 Planned Genetic Analysis ........................................................ 51
[IP_ADDRESS] Future Biomedical Research .............................................................. [ADDRESS_624998]: MK-5475 8
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
5.3.2 Activity Restrictions .................................................................................... 61
5.4 Screen Failures .....................................................................................................61
5.5 Participant Replacement Strategy ......................................................................61
6 STUDY INTERVENTION ............................................................................................ 62
6.1 Study Intervention(s) Administered ...................................................................62
6.2 Preparation/Handling/Storage/Accountability ................................................. 65
6.2.1 Dose Preparation .......................................................................................... 65
6.2.2 Handling, Storage, and Accountability ........................................................ 65
6.3 Measures to Minimize Bias: Randomization and Blinding .............................. [ADDRESS_624999] to Follow -up................................................................................................ .71
8 STUDY ASSESSMENTS AND PROCEDURES ........................................................ 72
8.1 Administrative and Genera l Procedures ........................................................... 72
8.1.1 Informed Consent ......................................................................................... 72
[IP_ADDRESS] General Informed Consent ................................................................ .73
[IP_ADDRESS] Consent and Collection of Specimens for Future Biomedical 
Research ............................................................................................. 73
8.1.2 Inclusion/Exclusion Criteria ........................................................................[ADDRESS_625000] .....................................................................73
8.1.4 Medical History ........................................................................................... 74
8.1.5 Prior and Concomitant Medications Review ............................................... 74
[IP_ADDRESS] Prior Medications ............................................................................... 74
[IP_ADDRESS] Concomitant Medications ..................................................................74
8.1.6 Assignment of Screening Number ............................................................... 74
8.1.7 Assignment of Treatment/Randomization Number .....................................[ADDRESS_625001]: MK-5475 9
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
[IP_ADDRESS] Timing of Dose Administration ......................................................... 75
[IP_ADDRESS] Dry Powder Inhaler Use Training ...................................................... 75
[IP_ADDRESS] Witnessed Dosing .............................................................................. 76
[IP_ADDRESS] Dispense Double -blind Study Intervention ........................................76
[IP_ADDRESS] Dispense/Review Participant Dosing Diary .......................................76
[IP_ADDRESS] Investigational Product Compliance and Accountability .................. 76
[IP_ADDRESS] Telephone Contact [CONTACT_486444] .......................................... 77
8.1.9 Discontinuation and Withdrawal ................................................................ .77
[IP_ADDRESS] Withdrawal From Future Biomedical Research ................................ 77
8.1.10 Participant Blinding/Unblinding ..................................................................[ADDRESS_625002] ..................................................................................... 79
8.2.3 WHO Functional Class ................................................................................ 80
8.2.4 NT-proBNP ..................................................................................................80
8.2.5 Patient -reported Outcomes ........................................................................... 80
......................................................................... 81
8.3 Safety Assessments ............................................................................................... 81
8.3.1 Physical Examinations ................................................................................. 82
8.3.2 Body Weight ................................................................................................ 82
8.3.3 Vital Signs ....................................................................................................82
8.3.4 Pulmonary Function Testing and DLCO ..................................................... 82
8.3.5 Electrocardiograms ...................................................................................... 83
8.3.6 Clinical Safety Laboratory Assessments ..................................................... 83
8.3.7 Pregnancy Testing ........................................................................................ 84
8.3.8 Vital Status Assessment ............................................................................... 84
8.3.9 AE Monitoring ............................................................................................. 84
8.4 Adverse Events, Serious Adverse Events, a nd Other Reportable Safety 
Events .................................................................................................................... 85
8.4.1 Time Period and Frequency for Collecting AE, SAE, and Other 
Reportable Safety Event Information .......................................................... 85
8.4.2 Method of Detecting AEs, SAEs, and Other Reportable Safety Events ......87
8.4.3 Follow -up of AE, SAE, and Other Reportable Safety Event Informa tion...87
8.4.4 Regulatory Reporting Requirements for SAE ............................................. 87
8.4.5 Pregnancy and Exposure During Breastfeeding .......................................... 87
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying 
as AEs or SAEs ............................................................................................ [ADDRESS_625003]: MK-5475 10
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
8.4.8 Medical Device and Drug –Device Combination Products –
PQCs/Malfunctions ...................................................................................... 88
8.5 Treatment of Overdose ........................................................................................ 89
8.6 Pharmacokinetics ................................................................................................ .89
8.6.1 Blood Collection for Plasma MK- 5475 ....................................................... 89
8.7 Pharmacodynamics .............................................................................................. 90
8.8 Biomarkers ........................................................................................................... 91
8.8.1 Planned Genetic Analysis Sample Collection.............................................. 91
8.9 Future Biomedical Research Sample Collection ............................................... 91
8.10 Health Economics Medical Resource Utilization and Health Economics .......91
8.11 Visit Requirements ............................................................................................... 91
8.11.1 Scheduling the Visits ................................................................................... 92
8.11.2 Screening ......................................................................................................92
8.11.3 Randomization ............................................................................................. 94
8.11.4 Treatment Period .......................................................................................... 95
8.11.5 Participants Discontinued From Study Intervention but Continuing to be 
Monitored in the Study ................................................................................ 96
8.11.6 Final Visit.....................................................................................................97
8.11.7 Follow -up Visit ............................................................................................ 97
9 STATISTICAL ANALYSIS PLAN ............................................................................. 98
9.1 Statistical Analysis Plan Summary .....................................................................98
9.2 Responsibility for Analyses/In -house Blinding ............................................... 100
9.3 Hypotheses/Estimation ...................................................................................... 101
9.4 Analysis Endpoints ............................................................................................. 101
9.4.1 Phase 2 Cohort Efficacy Endpoints ........................................................... 101
9.4.2 Phase 3 Cohort Ef ficacy Endpoints ........................................................... 102
9.4.3 Safety Endpoints ........................................................................................ 102
9.4.4 Derivations of Efficacy Endpoints ............................................................. 103
9.5 Analysis Populations .......................................................................................... 103
9.5.1 Efficacy Analysis Population .....................................................................103
9.5.2 Safety Analysis Population ........................................................................103
9.6 Statistical Methods ............................................................................................. 104
9.6.1 Statistical Methods for Efficacy Analyses................................................. 104
[IP_ADDRESS] Phase 2 Cohort ................................................................................. 104
[IP_ADDRESS] Phase 3 Cohort ................................................................................. 107
9.6.2 Analysis Methods for Safety Analyses ...................................................... 109
[IP_ADDRESS] Overall Safety Assessment .............................................................. [ADDRESS_625004]: MK-5475 11
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
9.8 Multiplicity ......................................................................................................... 114
9.9 Sample Size and Power Calculations ............................................................... 114
9.9.1 Efficacy ......................................................................................................114
9.10 Subgroup Analyses ............................................................................................. 115
9.11 Compliance (Medication Adherence) ............................................................... 116
9.12 Extent of Exposure ............................................................................................. 116
10 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS ...................................................................................................117
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ......[ADDRESS_625005] for Interventional Clinical Trials ...................................117
10.1.2 Financial Disclosure ................................................................................... 120
10.1.3 Data Protection ........................................................................................... 121
[IP_ADDRESS] Confidentiality of Data ....................................................................121
[IP_ADDRESS] Confidentiality of Par ticipant Records ............................................. 121
[IP_ADDRESS] Confidentiality of IRB/IEC Information .......................................... 122
10.1.4 Committees Structure ................................................................................. 122
[IP_ADDRESS] Executive Oversight Committee ...................................................... 122
[IP_ADDRESS] Steering Committee ......................................................................... 122
[IP_ADDRESS] External Data Monitoring Committee ............................................. 122
[IP_ADDRESS] Clinical A djudication Committee (CAC) ........................................123
10.1.5 Publication Policy ...................................................................................... 123
10.1.6 Compliance with Study Registration and Results Posting Requirements .124
10.1.7 Compliance with Law, Audit, and Debarment .......................................... 124
10.1.8 Data Quality Assurance ............................................................................. 125
10.1.9 Source Documents ..................................................................................... 126
10.1.10 Study and Site Closure ............................................................................... 126
10.2 Appendix 2: Clinical Laboratory Tests ............................................................ 127
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ............................................................. 129
10.3.1 Definitions of Medication Error, Misuse, and Abuse ................................ 129
10.3.2 Definition of AE ........................................................................................ 129
10.3.3 Definition of SAE ...................................................................................... 130
10.3.4 Additional Events Reported .......................................................................131
10.3.5 Recording AE and SAE ............................................................................. 131
10.3.6 Reporting of AEs, SAEs, and Other Reportable Safety Events to the 
Sponsor ......................................................................................................134
10.4 Appendix 4: Medical Device and Drug –Device Combination Products: 
Product Quality Complaints/Malfunctions: Definitions, Recording, and 
Follow -up............................................................................................................ [ADDRESS_625006]: MK-5475 12
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
10.4.1 Definitions ..................................................................................................136
10.4.2 Recording, Assessing Causality, and Follow- up of PQCs/Malfunctions ..137
10.5 Appendix 5: Contraceptive Guidance .............................................................. 138
10.5.1 Definitions ..................................................................................................138
10.5.2 Contraceptive Requirements ......................................................................139
10.6 Appendix 6: Collection and Management of Specimens for Future 
Biomedical Research .......................................................................................... 140
10.7 Appendix 7: Country -specific Requirements .................................................. 144
10.7.1 Argentina -specific Requirements ............................................................... 144
10.7.2 [LOCATION_009] -specific Requirements ....................................................................144
10.8 Appendix 8: Approximate Blood Volume Tables ........................................... 145
10.9 Appendix 9: Abbreviations ............................................................................... [ADDRESS_625007]: MK-5475 13
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625008] OF TABLES
 
52
Table 2 Study Interventions .......................................................................................... 63
Table 3 Reporting Periods and Time Frames for Adverse Events and Other 
Reportable Safety Events ................................................................................. 86
Table 4 Participant Re -randomization Probability in the Phase 2 Cohort Extension 
Period ............................................................................................................... 94
Table 5 Analysis Strategy for Primary and Secondary Efficacy Endpoints in the 
Phase 2 Cohort ............................................................................................... 107
Table 6 Analysis Strategy for Primary and Secondary Efficacy Endpoints in the 
Phase 3 Cohort ............................................................................................... 109
Table 7 Analysis Strategy for Safety Parameters ........................................................ 111
Table 8 Power to Demonstrate Superiority of MK -5475 vs placebo on the Primary 
Endpoint of % Change in PVR in Phase 2 Cohort Base Period at the 
Interim Analysis ............................................................................................. 112
..................... 113
Table 10 Protocol -required Laboratory Assessments ................................................... 127
Table 11 Phase 2 Cohort Approximate Blood Volumes Drawn/Collected by [CONTACT_486445] ............................................................................ 145
Table 12 Phase 3 Cohort Approximate Blood Volumes Drawn/Collected by [CONTACT_486445] ............................................................................ [ADDRESS_625009]: MK-5475 14
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625010] OF FIGURES
Figure 1 Study Design – Phase 2 Cohort .......................................................................20
Figure 2 Study Design – Phase [ADDRESS_625011]: MK-5475 15
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
1 PROTOCOL SUMMARY
1.1 Synopsis
Protocol Title: A Phase 2/3, Multicenter, Randomized, Double -blind, Placebo -Controlled, 
Adaptive Design Study to Evaluate the Efficacy and Safety of MK -5475 in Adults with 
Pulmonary Arterial Hypertension
Short Title: Phase 2/3 Study of MK- 5475 in Adults with Pulmonary Arterial Hypertension
Acronym: INSIGNIA -PAH
Hypotheses, Objectives, and Endpoints:
This study will be carried out in 2 parts, a Phase 2 dose selection cohort and a Phase 3 
confirmatory cohort . Each cohort includes a Base Period and an Extension Period.
In men and women aged 18 to 75 years (inclusive) with pulmonary arterial hypertension 
(PAH ):
Primary Objective s Primary Endpoint s
Phase 2 C ohort – to evaluate the effect of 
MK-5475 versus placebo on the pulmonary 
vascular resistance (PVR) at Week 12.
Hypothesis: at least one MK -5475 dose is 
superior to placebo in reducing PVR from 
baseline at Week 12.PVR (centrall y assessed)
Phase 3 C ohort – to evaluate the effect of 
MK-5475 versus placebo on 6- minute walk 
distance ( 6MWD )at Week 12.
Hypothesis: MK -[ADDRESS_625012]: MK-5475 16
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625013] of 
MK-5475 versus placebo on hemodynamic 
parameters other than PVR at Week 12.-Mean right arterial pressure (mRAP)
-Cardiac index
-Stroke volume index (SVI)
Phase 3 C ohort – to evaluate the effect of 
MK-[ADDRESS_625014] of 
MK-5475 versus placebo on the WHO 
functional PAH class at Week 12.WHO functional class
Phase 2 and Phase 3 C ohort s 
(independently) –to evaluate the safety 
and tolerability of MK -5475.-Adverse Events (AEs)
-Discontinuation of study intervention due 
to AEs
Overall Design:
Study Phase Phase 2/3
Primary Purpose Treatment
Indication Pulmonary arterial hypertension
Population Men and women aged 18 to 75 years 
(inclusive) with PAH.
Study Type Interventional
Intervention Model Parallel
This is a multi- sitestudy.
Type of Control Placebo
Study Blinding Double -blind
Blinding Roles Participants or Subjects
Investigator
Sponsor
Outcomes Assessor
Estimated Duration of Study The Sponsor estimates that the study will 
require approximately 6years from the time 
the first participant (or their legally 
acceptable representative) provides 
documented informed consent until the last 
participant’s last study- related contact.
08P53K
PRODUCT: MK-5475 17
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
Number of Participants:
Approximately 450 participants will be randomized in this operationally seamless adaptive 
Phase 2/3 study. Approximately 164 participants will be randomized in the Phase 2 dose 
selection cohort and approximately 286 participants will be ran domized in the Phase 3 
confirmatory cohort .
Intervention Groups and Duration:
In the Phase 2 Cohort Base Period, participants will be randomized in a 1:1:1:1 ratio to once -
daily dosing with 1 of 3 doses of MK- 5475 (380 μg, 100 μg, or 32 μg) or placebo. In the 
Phase 2 Cohort Extension Period, the participants who received placebo during the Base 
Period will initially be assigned randomly in a 1:1:1 ratio to 1 of the 3 doses of MK -5475 
(380 μg, 100 μg, or 32 μg) and will be given new randomization numbers. Pa rticipants who 
received MK -5475 during the Base Period will initially receive the same MK -5475 doses in 
the Extension Period and will be assigned new randomization numbers, to maintain the study 
blinding. 
After selection of the MK -5475 dose for Phase 3, the 3 MK -5475 dose groups in the Phase 2 
Cohort Extension Period will be collapsed into a single dose group for the remainder of the 
Phase 2 Cohort Extension Period.
In the Phase 3 Cohort, participants will be randomized in a 1:1 ratio to once -daily dosing
with either placebo or one of the 3 doses of MK -5475 selected in the Phase 2 Cohort Base 
Period.
Arm Name [CONTACT_19524](s)Dosage 
Level(s)Route of 
Adminis -
trationRegimen/
Treatment Period/
Vaccination 
RegimenUse
Phase 2 Cohort 
Group 1MK-5475 380 µg 380 µg Inhalation Oral inhalation once 
daily for 12 weeks 
Base Period
and for ~[ADDRESS_625015]
Phase 2 Cohort 
Group 2MK-5475 100 µg 100 µg Inhalation Oral inhalation once 
daily for 12 weeks 
Base Period
and for ~[ADDRESS_625016]
Phase 2 Cohort 
Group 3MK-5475 32 µg 32 µg Inhalation Oral inhalation once 
daily for 12 weeks 
Base Period
and for ~[ADDRESS_625017]: MK-5475 18
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
Arm Name [CONTACT_19524](s)Dosage 
Level(s)Route of 
Adminis -
trationRegimen/
Treatment Period/
Vaccination 
RegimenUse
Phase 2 Cohort 
Group 4a 
(before Phase 3 
dose selection)MK-5475 380 µg 380 µg Inhalation Oral inhalation once 
daily for ~[ADDRESS_625018]
Phase 2 Cohort 
Group 4 b 
(before Phase 3 
dose selection)MK-5475 100 µg 100 µg Inhalation Oral inhalation once 
daily for ~[ADDRESS_625019]
Phase 2 Cohort 
Group 4c 
(before Phase 3 
dose selection)MK-5475 32 µg 32 µg Inhalation Oral inhalation once 
daily for ~[ADDRESS_625020]
Phase 2 Cohort 
Group 4a, 4b, & 
4c (after 
Phase 3 dose 
selection)MK-5475 380 µg OR 
100 µg OR 
32 µg380 µg 
OR 
100 µg 
OR 
32 µgInhalation Oral inhalation once 
daily for ~[ADDRESS_625021]: MK-5475 19
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
Total Number of 
Intervention Groups/ArmsPhase [ADDRESS_625022]. Participants eligible for enrollment in the 
Phase 2 Cohort Extension Period will be required to provide 
documented informed consent for that study period.
Phase 2 Cohort: After a screening p eriod of up to 28 days, 
each eligible participant will be randomized to receiv e
assigned double -blind study intervention for 12 weeks in 
the Base Period . The participants who complete the Base 
Period and provide documented informed consent will be 
re-randomized to continue treatment in a n~40-month 
Extension P eriod. The participants who discontinue study 
intervention or complete the Base Period before 
Amendment 01 is approved and the Extension Period 
becomes available are not eligible to enroll in the Extension 
Period.
Phase 3 Cohort : After a screening period of up to [ADDRESS_625023] 
study visit, for adverse event monitoring.
Study Governance Committees:
Executive Oversight Committee Yes
Data Monitoring Committee Yes
Clinical Adjudication Committee Yes
Study governance considerations are outlined in Appendix 1.The Data Monitoring 
Committee for this study is external to the Sponsor.
Study Accepts Healthy Participants: No
A list of abbreviations used in this document can be found inAppendix 9.
08P53K
PRODUCT: MK-5475 20
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
1.2 Schema
The study design for Phase 2 Cohort is depi[INVESTIGATOR_6517] 1. The study design for Phase 3 Cohort is depi[INVESTIGATOR_6517] 2 .
Figure 1 Study Design –Phase [ADDRESS_625024]: MK-5475 21
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
Figure 2 Study Design – Phase [ADDRESS_625025]: MK-5475 22
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625026]: MK-5475 23
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625027]: MK-5475 24
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625028]: MK-5475 25
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625029]: MK-5475 26
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625030]: MK-5475 27
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625031]: MK-5475 28
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625032]: MK-5475 29
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625033]: MK-5475 30
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625034]: MK-5475 31
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625035]: MK-5475 32
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625036]: MK-5475 33
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625037]: MK-5475 34
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625038]: MK-5475 35
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
2 INTRODUCTION
MK-5475 is a small -molecule stimulator of sGC, formulated as a dry powder for inhaled 
delivery, which is being developed for the treatment of PAH.
2.1 Study Rationale
PAH defines a group of rare, progressive conditions characterized by [CONTACT_486446], related to pre -capi[INVESTIGATOR_70283]. Despi[INVESTIGATOR_486403], increased awareness ,and multiple PAH -specific 
therapi[INVESTIGATOR_014], the long -term prognosis for PAH patients remains poor and the disease can 
progress to right -sided heart failure and death.
Localized/inhaled delivery of the sGC stimulator MK -5475 is anticipated to provide benefit 
in PAH patients by [CONTACT_486447]/cGMP -mediated pulmonary vasodilation , without lowering systemic vascular resistance 
or BP . Inhalation result s inMK-[ADDRESS_625039] segments of the lung airways 
(respi[INVESTIGATOR_486404]). MK -[ADDRESS_625040] sGC -based effects on endpoints associated 
with PAH, while minimizing systemic sGC pharmacology. 
The purpose of this multicenter, randomized, placebo -controlled, double -blind Phase 2/[ADDRESS_625041] efficacy and safety profile in the Phase 2 Cohort Base 
Period will be evaluat ed inthe subsequent Phase 3 confirmatory cohort .
The design is operationally seamless adaptive; of the [ADDRESS_625042] will be evaluated in the Phase 3 Cohort. In the Phase 3 Cohort of this 
operationally seamless adaptive Phase 2/3 study ,the 12 -week Base Period will be followed 
by[CONTACT_486448] P eriod ,to further inform on the safety and efficacy of
MK-5475 in this population.
2.2 Background
Refer to the IB/approved labeling for detailed background information on MK -5475.
Pulmonary hypertension is a chronic disorder of the pulmonary circulation characterized by 
[CONTACT_486449] , ultimately leading to right ventricular failure and death. The Updated 
08P53K
PRODUCT: MK-5475 36
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
Clinical C lassification of Pulmonary Hypertension ( Nice, 2018) [Simonneau, G., et al 2019]
classifies the numerous conditions that are known to lead to, or to be associated with, the 
development of PH into 5 groups, based on their similar clinical presentation, pathology, 
pathophysiology, prognosis, and therapeutic approach. PAH, or Group 1 PH , may occur in 
the absence of a demonstrable cause or known triggering factor (idiopathic PAH , Group 1.1),
in the context of familia l history of PAH or a gene mutation known to be associated with 
PAH (heritable PAH , Group 1.2), as the result of the use of drugs and toxins (Group 1.3) , or
associated with various conditions including connective tissue diseases, HIV infection, portal 
hypertension, and congenital heart disease (Group 1.4) . PAH in long -term responders to 
calcium channel blockers (Group 1.5), PAH with venous/capi[INVESTIGATOR_486405] t (Group 1.6), 
and persistent PH of the newborn (Group 1.7) are less frequent pre -capi[INVESTIGATOR_486406], also 
included in Group 1, but with a distinct clinical presentation, prognosis, and treatment.
The epi[INVESTIGATOR_486407], probably r elated to selection biases. The
incidence of adult PAH is estimated to be 2.3 cases per million in the [LOCATION_002] [Frost, A. 
E., et al 2011] . European registry data revealed an estimated incidence of PAH rang ing from
2.4to 7.6cases per million [Swinnen, K., et al 2019] [Frost, A. E., et al 2011] . Estimate d
PAH prevalence rate range sfrom 6.6 to 291 per million in the US [Kirson, N. Y., et al 2011] 
[Dubroff, J., et al 2020] [Fenstad, E. R., et al 2019] [Frost, A. E., et al 2011] and from 6.6 to 
52per million in4 European countries ([LOCATION_009], Scotland, [LOCATION_008], and [LOCATION_013])
[Humbert, M., et al 2006] [Peacock, A. J., et al 2007] [Ling, Y., et al 2012] [Hoeper, M. M., 
et al 2016] . Both old and contemporary registries have shown that PAH predominantly 
affects fema les. The NIH cohort noted that females were 1.8 times more likely to be affected 
by [CONTACT_486450]. Both the REVEAL and the French registry found 
the female: male ratio to be 3.6:1 and 1.9:1, respectively [Frost, A. E., et al 2011] [Humbert, 
M., et al 2006] .
2.2.[ADDRESS_625043] sought to achieve vasodilation in the pulmonary arterial circulation
by [CONTACT_486451] 3 specific pathways (the endothelin pathway, the prostacyclin pathway and 
the NO pathway) , thus decreasi ngelevated PVR and lessening right ventricular afterload. 
There are [ADDRESS_625044]: 
PDE5 inhibitors and the oral sGC stimulator, riociguat. In healthy individuals, endothelial 
cell-derived NO acts on smooth muscle cells to induce vasodilation by [CONTACT_486452]. In PAH, the NO- sGC-cGMP 
pathway is downregulated because of endothelial dysfunction leading to reduced NO 
bioavailability and subsequent relative sGC and cGMP deficiency. PDE5 inhibitors act to 
decrease the degradation of cGMP, whereas the sGC stimulator riociguat acts to increase the 
formation of cGMP; both lead to pulmonary vasodilation. However, in addition to pulmonary 
artery vasodilation, the sGC stimulator riociguat also induces systemic vasodilation, which 
08P53K
PRODUCT: MK-5475 37
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625045]: MK-5475 38
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625046]: MK-5475 39
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.3 Information on Other Study -related Therapy
Not applicable.
2.3 Benefit/Risk Assessment
It cannot be guaranteed that participants in clinical studies will directly benefit from 
treatment during participation, as clinical studies are designed to provide information about 
the safety and effectiveness of an investigational product .
Potential participants will be informed of the risks and benefits of, as well as alternatives to, 
study participation. At a minimum, participant management and PAH -specific background 
therapy will take into account the local standard of care. 
CCI
CCI
08P53K
PRODUCT: MK-5475 40
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625047]: MK-5475 41
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
3 HYPOTHESES, OBJECTIVES, AND ENDPOINTS
This study will be carried out in 2 parts, a Phase 2 dose sel ection cohort and a Phase 3 
confirmatory cohort . Each cohort includes a Base Period and an Extension Period.
In men and women aged 18 to 75 years (inclusive) with pulmonary arterial hypertension 
(PAH ):
Primary Objective s Primary Endpoint s
Phase 2 C ohort – to evaluate the effect of 
MK-5475 versus placebo on the pulmonary 
vascular resistance (PVR) at Week 12.
Hypothesis: at least one MK -5475 dose is 
superior to placebo in reducing PVR from 
baseline at Week 12.PVR (centrally assessed)
Phase 3 C ohort – to evaluate the effect of 
MK-5475 versus placebo on 6- minute walk 
distance ( 6MWD )at Week 12.
Hypothesis: MK -[ADDRESS_625048] of 
MK-5475 versus placebo on hemodynamic 
parameters other than PVR at Week 12.-Mean right arterial pressure (mRAP)
-Cardiac index
-Stroke volume index (SVI)
Phase 3 C ohort – to evaluate the effect of 
MK-[ADDRESS_625049]: MK-5475 42
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
Phase 2 and Phase 3 C ohort s 
(independently) –to evaluate the safety 
and tolerability of MK -5475.-Adverse Events (AEs)
-Discontinuation of st udy intervention due 
to AEs
CCI
CCI
08P53K
PRODUCT: MK-5475 43
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625050]: MK-5475 44
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
4 STUDY DESIGN
4.1 Overall Design
This is a multicenter, randomized, placebo -controlled, parallel -group, double -blind P hase 2/3 
operationally seamless adaptive study to evaluate the efficacy, safety, and tole rability of 
inhaled MK -5475 in participants with PAH. This study will be conducted in conformance 
with GCP principles and will be carried out in 2parts: a Phase 2 dose selection cohort and a 
Phase 3 confirmatory cohort, each including a 12 -week Base Period and an Extension Period .
Participants in both cohorts of this Phase 2/3 study will be adults with PAH (Groups 1.1 to 
1.4), as defined in the Updated Clinical Classification of Pulmona ry Hypertension (Nice, 
2018) [Simonneau, G., et al 2019]. The PAH diagnosis must have been established using the 
updated scientific guidelines [Frost, A., et al 2019] and confirmed by a diagnostic RHC 
performed at any time prior to Screening. Participa nts will not be eligible for the study if they 
have been diagnosed with PH associated with left heart disease (Group 2 PH), lung disease 
(Group 3 PH), pulmonary artery ob structions (Group 4 PH) or PH with unclear and/or 
multifactorial mechanisms (Group 5 PH). All participants will continue to receive their PAH -
specific background therapy during the course of the study.
For both cohorts, during the 28-dayscreening period (Visit 1) , participant study eligibility 
will be assessed based on the demographic, disease diagnostic, hemodynamic, functional, 
echocardiographic, pulmonary function, and prior/concomitant therapy I/E criteria outlined 
in Sections 5.1 and 5.2. Consented pa rticipants will complete all Visit 1 procedures, as 
detailed in the SoA s.
Participants meeting all study entry eligibility criteria at Screening may be considered for 
randomization after Sponsor concurrence on key I/E criteria (See Section 8.11.2). Eligib ility 
for study participation will be reassessed by [CONTACT_486453] (Visit 2)to 
determine if participants continue to meet the I/E criteria and if , between Screening and 
Randomization, they experience devents that would exclude them for participating in the 
study, eg, acutely decompensated right heart failure or changes in PAH -specific therapy.
Participants who have completed or prematurely discontinued the Phase 2 Cohort are not 
eligible to participate in the Phase 3 Cohort.
At Visit 2, participants who meet study eligibility criteria will enter the double -blind 
treatment period, as described below for each cohort.  
 
Phase 2 Cohort 
In the P hase 2 Cohort Base Period , 3doses of MK -5475 (380 µg, 100 µg, and32µg)will be
compared to placeb o. The e fficacy, safety, and tolerability of each MK -[ADDRESS_625051] completed or 
discontinued the 12 -week treatment period .An IA for efficacy and futility (nonbinding) is 
CCI
08P53K
PRODUCT: MK-5475 45
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625052] completed or discontinued the Phase 2 
Cohort Base Period. The Phase 2 Cohort Base Period may stop at the IA and a dose for the 
Phase 3 Cohort may be selected at that time OR the study may be stopped early for futility 
(Section 9.7).
The primary objective of the Phase [ADDRESS_625053] of 
MK-5475 versus placebo on PVR in participants with PAH at Week 12. O f the 3 MK-5475 
doses studi ed, the dose (380 µg, 100 µg, or 32 µg) with the best efficacy and sa fety profile in 
the Base Period of this cohort will be selected for evaluat ionin the subsequent Phase 3 
confirmatory cohort, alongside a placebo control group.
Participants who remain on study intervention and complete the Visit 6/Week 12 assessments
(including RHC )may enroll in the ~40-month blinded Extension Period if they satisfy the
SpO 2and seated BP study eligibility criteria (Section 5.2) at Week [ADDRESS_625054] ete 
the Phase 2 Cohort Base Period before Amendment 01is approved and the Extension Period 
becom esavailable will not be eligible to enroll in the Extension Period .
The objective of the Phase 2 Cohort Extension Period is to evaluate the longer -term safety
and tolerability of the 3 doses of MK-5475 (380 µg, 100 µg, or 32 µg)in this participant 
population.
Tosupplement the routine blinded trial monitoring outlined in this study, an external DMC 
will monitor the interim data (Sec tion9.7).
This Phase 2/3 study may be stoppedif analysis of the data collected either at the time of the
IA or at the end of the Phase 2 Cohort Base Period shows that none of the MK- 5475 doses 
hasa desirable efficacy and safety profile.
Participants will take part in t he Phase 2 Cohort Base Period for approximately 16weeks, 
including a screening period of up to 4 week s and a 12-week double -blind treatment period.
Approximately 164 eligible participants will be randomized in a 1:1:1:1 ra tio to MK -5475 
380µg, MK -5475 100 µg, MK -5475 32 µg, and placebo. Participants will be instructed to 
inhale 1 dose per day, in the morning, for 84 consecutive days. At the end of the 12- week 
treatment period, pulmonary vascular hemodynamics will be assessed via RHC, following 
the same pr ocedures as for the baseline measurements. In the Extension Period, the 
participants who received placebo during the Base Period will initially be assigned randomly 
in a 1:1:1 ratio to once -daily dosing with 1 of the 3 doses of MK- 5475 (380 µg, 100 µg, or 
32µg)and will be given new randomization numbers. The p articipants who received 
MK-[ADDRESS_625055]: MK-5475 46
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
Phase 3 Cohort
In both the Base and the Extension Period of the Phase 3 Cohort, the MK -5475 dose ( either 
380 µg, 100 µg, or 32 µg) selected in the Phase [ADDRESS_625056] 
of MK -5475 versus placebo on 6MWD in participants with PAH at Week 12. The Base 
Period will be followed by a double -blind Extension P eriod, to further inform on the efficacy, 
safety, and tolerability of MK -5475 in this participant population.
In the Phase 3 Cohort Base Period, participants will take part in the study for approximately 
16weeks, including a screening period of up to 4 week s and a 12-week double -blind 
treatment period. Approximately 286 eligible participants will be randomized in a 1:1 ra tio to 
MK-5475 and placebo. Participants will be instructed to inhale 1 dose per day, in the 
morning, for 84 consecutive days. 6MWD wil l be measured, using the same procedure as for 
the baseline measurement, every 4 weeks and at the end of Phase 3 C ohort Base Period. All 
participants will continue treatment in an Extension Period until a requisite number of 
clinical worsening events are observed in the Phase 3 Cohort and a second Phase 3 study. 
The second Phase 3 study will be described in a separate protocol. A separate integrated 
analysis plan will be written, providing more details. A CAC , whose members are blinded to 
the study group as signments, will review all reported clinical events and adjudicate the 
clinical events related to clinical worsening ( See Appendix 1) . 
In both Phase 2 and Phase 3 Cohorts, a ddition al hemodynamic parameters, changes in 
symptoms, biomarkers, and participant self -rated quality- of-life questionnaire scores will be 
used to evaluate response to treatment throughout the study.
Selected members of the Sponsor study team and management will be unblinded to results 
from Phase 2 Cohort Base Period and Phase 3 Cohort Base Period, to evaluate the efficacy 
and safety profile of MK -5475 (Section 9.7). For the Phase 2 Cohort Extension Period and 
Phase 3 Cohort Extension Period, separate blinded Sponsor study team swill monitor the 
ongoing study.
For each cohort, t he double -blind treatment period concludes with a final visit.All 
participants will complete a telephone follow -up visit 14 days (+ 2 days) after the final visit, 
for AE monitoring.
AEs will be monitored throughout the study and graded in severity according to the 
guidelines outlined in Section 10.3.4. Regular safety assessments will be performed during 
the study (Section 8.3.9 ).
To supplement the routine trial monitoring outlined in this study, an externa l DMC will 
monitor interim data (Sec tion9.7).
Specific procedures to be performed during the study, including prescribed times and 
associated visit windows, are outlined in Section 1.3of the SoA. Details of each procedure 
are provided in Section 8.
08P53K
PRODUCT: MK-5475 47
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
4.2 Scien tific Rationale for Study Design
This operationally seamless adaptive Phase 2/[ADDRESS_625057] a dose for the Phase 3 Cohort after reviewing all safety and efficacy information 
collected in the Phase 2 Cohort Base Period. Given the severity of the disease and the unmet 
medical nee d, this study design allows expedite dclinical drug development andaccelerated 
timeline for potential registration and patient access, while ensuring study integrity [Food 
and Drug Administration 2019] .
4.2.1 Rationale for Endpoints
[IP_ADDRESS] Efficacy Endpoints
Pulmonary Vascular Hemodynamics
PAH is characterized by [CONTACT_486454]. 
Hemodynamic measures ,such as pulmonary arterial pressure , pulmonary vascular resistance, 
right atrial pressure ,andcardiac index, are the cornerstones of diagnosis and risk 
stratification in PAH and play an important role during early drug development, to elucidate 
the mechanism of action and to define the dos e-response relationship . Several studies have 
evaluated the prognostic utility of hemodynamic variables after PAH -specific treatment 
initiation [Weatherald, J., et al 2018] [Tiede, H., et al 2013] . Invasi ve assessment of
pulmonary vascular hemodynamics is a reliable indicator of treatment efficacy and reduction 
in PVR induced by [CONTACT_308757] -specific therapi[INVESTIGATOR_486408], supporting the use of PVR as the primary or 
secondary endpoint in Phase 2 studies of investigational PAH therapi[INVESTIGATOR_98479] a signal for 
efficacy [Savarese, G., et al 2013] .The variables used for the calculation of PVR, as well as 
other hemodynamic variables, are obtained during RHC. The p ercent change from baseline in 
PVR at Week [ADDRESS_625058]: MK-5475 48
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625059] during which the distance walked (6MWD),
oxygen saturation, systemic BP, heart rate, and the degree of dyspnea and fatigue (Borg 
CR10 S cale) areevaluated. The 6MWT provides an indirect estimate of aerobic capacity and 
correlates with pulmonary vascular hemodynamics. In particular, 6MWD is directly 
correlated with cardiac index increase and inversely correlated with PVR decrease [Savarese, 
G., et al 2013] .The use of thechange in 6MWD as a primary endpoint in clinical trials is 
based on findings from studies which demonstrated that increases in 6MWD are associated 
with improved clinical outcomes among patients with PAH . A clinically meaningful 6MWD 
increase of 30 to 50meters is considered predictive of better long -term prognosis and reflects 
positively in patient -important outcomes, such as HRQoL [Mathai, S. C., et al 2012] [Divers, 
C., et al 2017] .Change in 6MWD at Week 12 will be the primary efficacy endpoint of the 
Base Period of the Phase 3 Cohort. T he change in 6MWD will be a secondary efficacy 
endpoint for the Phase 2 Cohort Base Period at Week 12 and for the Extension Period of 
Phase 3 Cohort at Week 24, and an exploratory endpoint for the Phase 2 Cohort Extension 
Period at Week 24.
Time to Clinical Worsening 
TTCW is a composite endpoint of morbidity and mortality in a time -to-event analysis
[Sitbon, O., et al 2015] [Pulido, T., et al 2013] [Galie, N., et al 2015] . The components of this 
composite endpoint include death, PAH -related hospi[INVESTIGATOR_059], and disease progression.
WHO Functional Class
The WHO classifi cation of functional status is a measure of disease severity, based on a 
patient ’s description of their level of functioning and symptoms of disease in relation to their 
everyday activity. Patients are assigned 1 of 4 WHO -FC, dependent on limits of physica l 
activity. As WHO -FC increases from I to IV, limits of physical activity increase. WHO -FC is 
a predictor of survival, both before and during treatment [Waxman, A. B. 2015], and remains 
an important part of the ongoing assessment of patients with PAH. I mprovement in WHO -FC 
predi cts survival independently of PAH cause or time of diagnosis. Furthermore , changes in 
CCI
08P53K
PRODUCT: MK-5475 49
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
6MWD correlate with WHO -FC;increase sin 6MWD are observed for those who show 
improve ment in WHO -FC anddecrease sin 6MWD are observed for those who show
worsen ing of WHO -FC[Divers, C., et al 2017] . As such, the effect of MK -[ADDRESS_625060] widely studied biomarker in PAH is brain (B -type) natriuretic peptide, secreted by 
[CONTACT_486455]. Serum levels of its N- terminal fragment 
(NT-proBNP) have been correlated with right ventricular functionin PAH and high plasma 
levels of NT- proBNP with additional serial increases have a strong independent association 
with mortality [Lewis, R. A., et al 2020] . As such, the effect of MK -5475 on NT -proBNP 
serum level will be assessed during the Phase 2 Cohort up to Week 24 and throughout the 
Phase 3 Cohort .
[IP_ADDRESS] Patient -Reported Outcomes
Physical/functional, emotional and social aspects of HRQoL are negatively impacted by 
[CONTACT_308757]. The clinical definition of disease sever ity, including invasive and noninvasive 
measurements, does not capture the extensive realm of physical, emotional and psychosocial 
issues which affect PAH patients . PAH -targeted therapi[INVESTIGATOR_486409] a variable benefit in 
HRQoL, and s ome measures of HRQoL may also correlate with survival prognosis . The 
effect of treatment on PROs will be evaluated using a disease -specific QoL questionnaire, t he 
LPH questionnaire . Interpretation of the magnitude of change in the LPH questionnaire (total 
and physical dimension) scores will be based on clinically meaningful thresholds estimated 
using the PGI -S and PGI -C questions. The PROs will be assessed during the Phase 2 Cohort
Base Period and throughout the Phase 3 Cohort .
Living With Pulmonary Hypertension (LPH) Questionnaire
A [ADDRESS_625061] of PAH on 
HRQoL. Adapted from the Minnesota Living with Heart Failure Questionnaire for use in 
patients with PAH, the LPH questionnaire has demonstrated strong cont ent and psychometric 
validity [Bonner, N., et al 2013]. Participants are asked to recall how their PAH impacted 
their life during the past week. It takes approximately 5 minutes to complete. Response 
options are on a 6- point Likert -type scale ranging from 0 ‘No’ to 5 ’Very much’. A total 
(overall) score is calculated by [CONTACT_486456]. A physical dimension 
score and an emotional dimension score can also be calculated [Bonner, N., et al 2013] . A 
higher score indicates that the participants are more affected by [CONTACT_486457] (ie, 
have worse QoL). The total (overall) and physical dimension scores will be the key PRO 
endpoints in the study, as they have shown to be more responsive to change over time 
compared to the emotional score [Bonner, N., et al 2013] .
Patient Global Impression of Change (PGI -C) and Severity (PGI -S)
Considering that minimally important difference thresholds indicating clinically significant 
changes or differences using anchor -based approaches for the LPH questionnaire have not 
yet been established, PGI -C and PGI -S questionnaires will be used to validate clinically 
08P53K
PRODUCT: MK-5475 50
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
meaningful t hresholds for the total and physical dimension scores from the LPH 
questionnaire in the study population.
The PGI -C will include 2 single -item questionnaires for assessing overall change in the 
disease and disease -related physical limitations, respectively , compared with the start of 
treatment. Each PGI -C questionnaire contains one question (1a) asking the participant to 
assess the degree of change compared to the start of the treatment using the following 
response options: “much better”, “a little better”, “no change”, “a little worse”, or “much 
worse”. A subsequent question (1b) then asks the participant to indicate whether he/she feels 
the degree of change (improvement or worsening) reported is important or not (yes/no). 
The PGI -S will include 2 single -item questionnaires for assessing the current severity of 
disease and disease -related physical limitations, respectively, using the following response 
options: “None”, “Mild”, “Moderate”, “Severe”, or “Very severe.” 
It is anticipated to take approximately 4 minutes to answer all PGI -C and PGI -S questions. 
Data from these questions will be used to provide anchors for estimating minimally 
important differences in the total and physical dimension scores from the LPH questionnaire.
[IP_ADDRESS] Safety Endpoints
The safety data for MK -5475 to date is described in the IB. General safety and tolerability 
will be evaluated by [CONTACT_486458], including AEs, physical
exam inations, vital signs (ie, pulse rate, BP, temperature , arterial oxygen saturation, 
respi[INVESTIGATOR_697] ), PFTs, [ADDRESS_625062] s (blood chemistry, hematology, 
anticoagulation tests ,urinalysis, and urine pregnancy testing for all WOCBPs) at prespecified 
time points.
AEs associated with symptomatic hypotension, pulmonary hemorrhage, and hemoptysis are 
prespecified safety topi[INVESTIGATOR_23254] (See Section [IP_ADDRESS]) .
All procedures will be conducted at the time points specified in the SoA. AEs will be 
recorded according to Section 8.4 and assessed as defined in Section 10.3.4.
[IP_ADDRESS] Pharmacokinetic Endpoints
MK-[ADDRESS_625063] of 
assessments of systemic AUC 0-24 andCmax. Acknowledging the limitations of these data, they 
will be us ed for PKmodeling to determine systemic exposure s and to explore their 
relationship with pharmacodynamic endpoints and systemic hemodynamic measurements. 
PK samples wil l be collected from all participants as described in the SoA (Section 1.3) and 
Section 8.6.1.
08P53K
PRODUCT: MK-5475 51
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
[IP_ADDRESS] Pharmacodynamic Endpoints
Reduction in PVR is being employed as the primary pharmacodynamic endpoint in the 
Phase 2 Cohort Base Period. This measurement directly reflects disease severity and 
response to therapy, as it incorporates measurements of pulmonary vasoconstriction 
(pulmonary artery pressure) and cardiac performance (cardiac output), in the context of a 
well-established relationship between PVR and the clinical endpoint of 6MWD.
[IP_ADDRESS] Planned Exploratory Biomarker Research
[IP_ADDRESS].[ADDRESS_625064] a participant’s response to therapy, susceptibility to, severity, 
and progression of disease. Variable response to therapy may be due to ge netic determinants 
that impact drug ADME ,mechanism of action of the drug ,disease etiology, and/or molecular 
subtype of the disease being treated. Therefore, where local regulations and IRB/IEC allow, a 
sample will be collected for DNA analysis from consenting participants.
DNA samples may be used for research related to the study intervention(s), the disease under 
study, or related diseases. They may also be used to develop tests/assays including diagnostic 
tests related to the disease under study, relate d diseases, and study intervention(s). Genetic 
research may consist of the analysis of 1 or more candidate genes, the analysis of genetic 
markers throughout the genome, or analysis of the entire genome. Analysis may be 
conducted if it is hypothesized that this may help further understand the clinical data.
The samples may be analyzed as part of a multistudy assessment of genetic factors involved 
in the response to understand study disease or related conditions.
[IP_ADDRESS] Future Biomedical Research
The Sponsor will co nduct FBR on specimens for which consent was provided during this 
study. This research may include genetic analyses (DNA), gene expression profiling (RNA), 
proteomics, metabolomics (serum, plasma), and/or the measurement of other analytes, 
depending on whi ch specimens are consented for FBR.
Such research is for biomarker testing to address emergent questions not described elsewhere 
in the protocol and will only be conducted on specimens from appropriately consented 
participants. The objective of collecting/ retaining specimens for FBR is to explore and 
identify biomarkers that inform the scientific understanding of diseases and/or their 
therapeutic treatments. The overarching goal is to use such information to develop safer, 
more effective drugs/vaccines, and /or to ensure that participants receive the correct dose of 
the correct drug/vaccine at the correct time. The details of FBR research are presented i n 
Appendix [ADDRESS_625065]: MK-5475 52
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625066]: MK-5475 53
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
The proposed doses will be administered once per day; the regimens were selected based on 
the following considerations :
Data from Study PN002 at single nominal doses of 120, 240, and 360 µg in 23PAH 
participan tswith RHC, showing mean peak reduction in PVR from baseline of 
approximately 26% , with no clear relationship between the magnitude of PVR reduction 
and the evaluated doses.
Data from Study PN002 at single nominal doses of 120, 240, and 360 µg i n 23 PAH 
participants with functional respi[INVESTIGATOR_125304], showing maximal pulmonar y blood 
volume increase from baseline at 8 hours postdose of approximately 5%, with generally 
no clear relationship between pulmonary blood volume change and the evaluated doses, 
except that significant pulmon ary blood volume increase was observed at 24 hours 
postdose only with the 360 µgdose. 
Based on in vitro data, MK -5475 dissociates slowly in the MK- 5475- sGC complex, with 
an estimated  for the complex. In addition, a 
 
 
 
Based on data from Study PN002 across dose levels evaluated with RHC (up to 360 µg), 
there was no evidence of decreasing systolic BP or increasing heart rate with increasing 
plasma MK -[ADDRESS_625067] 
is expected following inhaled MK- 5475 administration at doses up to 360 µg .
Data from Study PN008 showed that MK- 5475 plasma exposure following 
administration using the single -actuation inhaler at 380 µg and 100 µg was generally 
within the predefined PK comparability bounds of the multiple -actuation Phase 1 inhaler 
at the 360 (6 x 60) µg dose and the 120 (2 x 60) µg dose, respectivel y.
Based on all the considerations, the top dose selected for the Phase 2 Cohort of this study is 
380 µg. A low dose of 32 µg is selected for evaluation in the Phase 2 Cohort, to expand the 
exposure- response dataset that can be used to inform dose selectio n for the Phase 3 Cohort 
and for future studies and to define a minimally efficacious dose. The 32 µg inhaler 
formulated for the Phase 2/[ADDRESS_625068] feasible strength that can be developed using 
a conventional formulation .The mid dose of 100 µg is selected for evaluation in the Phase 2 
Cohort based on minimal overlap of plasma exposures from that at the high dose at 380 µg
and the low dose at 32 µg. 
Participant response to the 3 different doses of MK- 5475 ( 32µg, 100 µg, and 380 µg) will be 
assessed in the Phase [ADDRESS_625069]: MK-5475 54
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625070] participant (or their legally acceptable representative) 
provides documented informed consent. The overall study ends when the last participant 
completes the last study -related contact, withdraws consent, or is lost to follow- up (Section 
7.3).For purposes of analysis and reporting, the overall study ends when the Sponsor 
receives the last laboratory test result or at the time of final contact [CONTACT_26355], 
whichever comes last.
If the study includes countries in the European Economic Area (EEA), the local start of the 
study in the EEA is defined as First Site Ready (FSR) in any Member State.
4.4.1 Clinical Criteria for Early Study Termination
The clinical study may be terminated early if the extent (incidence and/or severity) of 
emerging effects is such that the risk/benefit ratio to the study population as a whole is 
unacceptable. In addition, further recruitment in the study or at (a) particular study site(s) 
may be stopped as described in Appendix 1.10 .
Early study termination of both the Phase 2 and/or Phase 3 cohorts may be the result of the 
Sponsor ’splan to modify or discontinue the development of MK-[ADDRESS_625071]: MK-5475 55
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
5 STUDY POPULATION
Adult participants with PAH will be enrolled in this study. All I/E criteria apply to both 
Phase [ADDRESS_625072] for Clinical Trials ( Appendix 1.1), this study includes 
participants of varying age (as applicable) , race, ethnicity, and sex (as applicable) . The 
collection and use of these demographic data will follow all local laws and participant 
confidentiality guidelines while supporting the study of the disease, its related factors, and 
the IMP under investigation.
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1 Inclusion Criteria
An individual iseligible for inclusion in the study if the individual meets all of the following 
criteria :
Type of Participant and Disease Characteristics
1.Has the following PAH groups, as defined by [CONTACT_486459] (Nic e,2018) [Simonneau, G., et al 2019] :
a.Group 1.1 Idiopathic PAH
b.Group 1.2 Heritable PAH
c.Group 1.3 Drug and toxin -induced PAH
d.Group 1.4 PAH associated with:
Connective tissue disease
HIV infection
Simple repaired congenital systemic -to-pulmonary shunt (atrial septal defect, 
ventricular septal defect, patent ductus arteriosus) with persistent PH ≥[ADDRESS_625073] of care, per scientific guidelines, and 
documented by [CONTACT_486460]; if participant is 
postsurgical repair of systemic -to-pulmonary shunt, diagnostic RHC must have been 
performed at least 1 year after surgery.
3.Has an el igibility RHC, meeting all the following criteria: 
mean pulmonary artery pressure (mPAP) ≥25 mmHg
PVR of ≥3 Wood units
PCWP or LVEDP ≤15 mmHg.
For the Phase 2 Cohort, the eligibility RHC should be performed during Screening and 
will be centrally reviewed. A participant with RHC performed prior to 
Visit 1/Screening m ay have the RHC results submitted for central review and, if deemed 
CCI
08P53K
PRODUCT: MK-5475 56
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
adequate, the RHC may count as baseline. In each case, the RHC should be performed 
after at .
For the Phase 3 C ohort, an RHC performed  prior to Visit 1/Screening 
may count for eligibility assessment. An RHC will be performed during Screening if an 
RHC performed  prior to Visit 1/Screening is not available.
4.Has WHO -FC symptoms Class II to IV.
5.Has two 6MWD measurements between 150 and 500 meters, 1 at S creening and 1at 
Randomization . The relative difference between the 2 measurements (ie,absolute 
difference/mean) must be ≤15%. If the relative difference between the two 6MWD 
measurements is >15%, the Randomization 6MWT may be repeat edafter at least 4 hours.
If the relative difference between the 2 Randomization 6MWD measurements is ≤15%, 
the participant can be randomized an d the last 6MW Dwill be considered the baseline 
value .
6.Has stable concomitant background PAH -specific therapy  
 
 with any of the following ag ents:
an ERA and/or
a PDE5i and/or
an oral prostacyclin analogue or oral prostacyclin receptor agonist ( eg, oral 
beraprost, oral treprostinil , oral selexipag), an intravenous prostacyclin analogue
(eg, IV treprostinil, IV epoprostenol , IV iloprost ) or a subcutaneous prostacyclin 
analogue ( eg, SC treprostinil) .
7.If on vasodilators other than PAH -specific therapy (including calcium channel blockers 
or L- arginine supplementation), has stable concomitant use ( no change in dose for at least 
 to and over the duration of Screening ).
8.If on calcium channel blockers, a participant from Groups 1.1, 1.[ADDRESS_625074] a 
history of being a nonresponder to acute pulmonary vasoreactivity testing.
9.Ifon anticoagulants, has stable concomitant use (the same dosage of direct oral 
anticoagulants and in the same therapeutic range for vitamin K antagonist s)for at  
toand over the duration of Screening.
Demographics
10.Ismale or female, from 18 years to 75years of age inclusive, at the time of signing the 
informed consent.
11. Has a BMI between 18.5 kg/m2and 40 kg/m2.
12.Is willing to comply with scheduled visits, treatment plan, laboratory tests, and/or other 
study procedures and study restrictions (see Section 5.3 for a complete summary of study 
restrictions).
13.Agrees to allowing site contact [CONTACT_486461] e mail for follow -up purposes.
CCI
CCI
CCI
CCI
CCI
CCI
08P53K
PRODUCT: MK-5475 57
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625075] 
one of the following conditions applies :
•Is not a WOCBP
OR
•Is a WOCBP and:
-Uses an acceptable contraceptive method, or is abstinent from penile -vaginal 
intercourse as their preferred and usual lifestyle (abstinent on a long- term and 
persistent basis), as described in Appendix [ADDRESS_625076] dose of study intervention. The investigator should 
evaluate the potential for contracep tive method failure (ie, noncompliance, recently 
initiated) in relationship to the first dose of study intervention. Contraceptive use by 
[CONTACT_486462] c linical studies. If the contraception 
requirements in the local label for any of the study interventions are more stringent 
than the requirements above, the local label requirements are to be followed.
-Has a negative highly sensitive pregnancy test ( urine or serum) as required by [CONTACT_326643] 24 hours (for a urine test) or 72 hours (for a serum test) before the 
first dose of study intervention. If a urine test cannot be confirmed as negative (eg, an 
ambiguous result), a serum pregnancy test is required. In such cases, the participant 
must be excluded from participation if the serum pregnancy result is positive.
Additional requirements for pregnancy testing during and after study intervention are 
in Section 8.3.7.
- Medical history, menstrual histo ry, and recent sexual activity has been reviewed by 
[CONTACT_93301] a WOCBP with an early 
undetected pregnancy.
Informed Consent
16.The participant (or legally acceptable representative) has provided documented in formed 
consent/assent for the study. A supplemental documented informed consent/assent is 
required for participation in the Phase 2 Cohort Extension Period. The participant may 
also provide consent/assent for future biomedical research. However, the participant m ay 
participate in the main study without participating in future biomedical research.
08P53K
PRODUCT: MK-5475 58
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625077] be obtained before the participant is 
randomized into the study .
Notes:
Procedures performed as standard of care for PAH (clinical assessments, diagnostic 
investigations) prior to and during Screening may be used to determine eligibility. 
The investigator must provide the required supporting documentation ( eg, specific 
information about a participan t’s medical history and prior hemodynamic diagnosis of 
PAH) to the Sponsor, to support participan t’s eligibility for participation in the study.
5.[ADDRESS_625078] be excluded from the study if the individual meets any of the following 
criteria:
Medical Conditions
1.Has Group 2 PH, Group 3 PH (including PH associated with idiopathic interstitial 
pneumonia ), Group 4 PH, or Group 5 PH according to the Updated Clinical 
Classification of Pulmonary Hypertension (Nice, 2018) [Simonneau, G., et al 2019] .
2.Has Group 1.[ADDRESS_625079] 1 year on CCBs only.
3. Has Group 1.6 PAH, with overt features of venous/capi[INVESTIGATOR_1396] (PVOD/PCH) involvement. 
4.For participants with Group 1.4 HIV- associated PAH, has any of the following within 
90days prior to and for the duration of Screening: 
concomitant active opportunistic infections; 
plasma HIV- 1 RNA ≥50 copi[INVESTIGATOR_014]/mL or CD4+ T- cell count <200/mm3; 
changes in antiretroviral regimen.
5.Has evidence of more -than-mild obstructive lung disease on PFT at Screening with
FEV1/FVC <70% andFEV1 <60% of predicted value after bronchodilator 
administration .
6.Has evidence of more -than-mild parenchymal lung disease based on medical history and 
chest imaging (eg, high -resolution CT), and/or restrictive lung disease with Total Lung 
Capacity (TLC) < 60% of predicted on PFT at Screening. 
7.Has evidence o f more -than-mild OSA that is untreated. Participants with well- controlled, 
treated OSA are eligible.
8.Has evidence or history of left heart disease, including any of the following:
left ventricular ejecti on fraction (LVEF) ≤45%; 
08P53K
PRODUCT: MK-5475 59
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
moderate or severe left -sided valvular disease (aortic or mitral valve stenosis or 
regurgitation); 
Grade 3 and 4 left ventricular diastolic function on echocardiographic evaluation.
A historical transthoracic Doppler echocardiogr am performed  prior to 
Screening is acceptable to demonstrate echocardiographic eligibility criteria. If a 
historical echocardiogram is not available, a transthoracic Doppler echocardiogram will 
be performed during Screening.
9.Has 3 or more of the following risk factors for heart failure with preserved ejection 
fraction: 
BMI >30 kg/m2; 
history of essential systemic hypertension; 
diabetes mellitus of any type; 
history of coronary artery disease established by [CONTACT_486463]: history of 
stable angina, history of myocardial infarction, previous or planned percutaneous 
coronary intervention or coronary artery by[CONTACT_9292], angiographic evidence of 
significant coronary artery disease (>70% stenosis in more than 1 vessel), po sitive 
stress test.
10.Has oxygen saturation measured by [CONTACT_406] (SpO 2) <90%, despi[INVESTIGATOR_486410]. In case the accuracy of oxygen saturation measurement by [CONTACT_486464], arterial blood gas sampling (SaO 2) should be performed .
11.Had clinically unstable or acutely decompensated right heart failure within 30 days prior 
to and over the duration of Screening including, but not limited to, hospi[INVESTIGATOR_486411].
12.Has s eated systolic BP >160 mmHg or <90 mmHg or seated diastolic BP >100 mmHg.
13. Has significant chronic renal insufficiency, as defined by [CONTACT_67889] <30 mL/min/1.73 m2
(calculated using the MDRD equation) or by [CONTACT_486465].
14.Has evidence of chronic liver di sease (ie, Child- Pugh B or C), portal hypertension, 
cirrhosis, or hepatic laboratory abnormalities (ALT or AST ≥[ADDRESS_625080] or total 
bilirubin ≥[ADDRESS_625081]).
15.Is included in a cardiopulmonary rehabilitation program initiated within 90 days prior to 
Screening or is planning to initiate cardiopulmonary rehabilitation during the study.
16.Has acute or chronic impairment(s) (other than dyspnea), limiting the ability to perform 
6MWT.
17.Is a current smoker or currently uses electronic cigarettes (vapes). 
18.Is unable to correctly use the DPI [INVESTIGATOR_486412], but not limited to, 
cognitive impairment or physical limitations.
CCI
08P53K
PRODUCT: MK-5475 60
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
19.Has other severe acute or chronic medical or laboratory abnormality that may increase 
the risk associated with study participation or tha t would confound study analysis or 
impair study participation or cooperation.
20.Has a history of cancer (malignancy). Exceptions: (1) Adequately treated 
nonmelanomatous skin carcinoma or carcinoma in situ of the cervix or; (2) Other 
malignancies which have b een successfully treated, with appropriate follow- up, and 
therefore unlikely to recur for the duration of the study, in the opi[INVESTIGATOR_871] 
(eg, malignancies which have been successfully treated ≥5 years prior to Screening).
21.Has a known hyperse nsitivity to any of the ingredients or excipi[INVESTIGATOR_31625].
22.At the time of signing the informed consent, is a user of illicit drugs or has had a recent 
history (within the last year) of drug or alcohol abuse or dependence.
23.Has a known psychiatric or any other cognitive disorder that would, in the opi[INVESTIGATOR_1070], interfere with the participant’s ability to cooperate with the requirements of 
the study.
24.Is a WOCBP who has a positive urine pregnancy test within [ADDRESS_625082] dose 
of study intervention (see Appendix 5). If the urine test cannot be confirmed as negative, 
a serum pregnancy test is required. In such cases, the participant must be excluded from 
participation if the serum pregnancy result is positive.
Prior/Concomitant Thera py
25.Has u sed intravenous inotropes including, but not limited to levosimendan, dopamine, 
dobutamine, epi[INVESTIGATOR_238], norepi[INVESTIGATOR_238], noradrenaline or milrinone within 30 days 
prior to and over the duration of Screening.
26.Has concomitant use of inhaled prostacyc lin analogues (eg, inhaled iloprost, inhaled 
epoprostenol or inhaled treprostinil), inhaled NO, or oral sGC modulators (eg, riociguat, 
vericiguat), or has used these medications within 90 days prior to and over the duration of 
Screening.
Prior/Concurrent C linical Study Experience
27.Has participated in another investigational study  
 prior to Screening. This window will be derived from the date of 
the last dose of study medication taken in the previous study. Participants enrolled in 
observational studies may be included and will be reviewed on a case -by-case basis for 
approval by [CONTACT_1034].
28.For Phase 2 Cohort Extension Period: has not completed Visit 6/Week 12 study 
assessments, as listed in the SoA.
29.For Phase 2 Cohort Extension Period: has discontinued study intervention or completed 
the Phase 2 Cohort Base Period before Amendment 01was approved and the Extension 
Period became available.
30. For Phase 3 Cohort enrollment: is currently participating in, h as prematurely
discontinued, or has completed the Phase [ADDRESS_625083]: MK-5475 61
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
Other Exclusions
31.Is or has an immediate family member (eg, spouse, parent/legal guardian, sibling, or 
child) who is investigational site or Sponsor staff directly involved with this study.
5.3 Lifestyle Considerations
No restrictions are required.
5.3.1 Caffeine, Alcohol, and Tobacco Restrictions
No caffeine or alcohol restrictions are required. Use of tobacco products will not be allowed 
for the duration of the study. Tobacco use will be assessed as indicated in the SoA 
(Section 1.3).
5.3.[ADDRESS_625084]: MK-5475 62
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
6 STUDY INTERVENTION
Study intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study participant according to 
thestudy protocol.
Clinical supplies (study intervention(s) provided by [CONTACT_1034] )will be packaged to support 
enrollment as required. Clinical supplies will be affixed with a clinical label in accordance 
with regulatory requirements.
6.1 Study Intervention(s) Administered
The study intervention(s) to be used in this study areoutlined in Table 2.
08P53K
PRODUCT: MK-5475 63
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
Table 2 Study Interventions
Arm Name [CONTACT_486492] -
tion 
NameInterven -
tion 
TypeDose 
FormulationUnit Dose 
Strength(s)Dosage 
Level(s)Route of 
Adminis-
trationRegimen/ Treatment 
Period/ Vaccination 
RegimenUse IMP or 
NIMP/
AxMPSourcing
Phase 2 Cohort 
Group 1Experimental MK-5475 Drug Powder 380 µg 380 µg Inhalation Oral inhalation once 
daily for 12 weeks 
Base Period
and for ~[ADDRESS_625085] 
ProductIMP Sponsor
Phase 2 Cohort 
Group 2Experimental MK-5475 Drug Powder 100 µg 100 µg Inhalation Oral inhalation once 
daily for 12 weeks 
Base Period
and for ~[ADDRESS_625086] 
ProductIMP Sponsor
Phase 2 Cohort 
Group 3Experimental MK-5475 Drug Powder 32 µg 32 µg Inhalation Oral inhalation once 
daily for 12 weeks 
Base Period
and for ~[ADDRESS_625087] 
ProductIMP Sponsor
Phase 2 Cohort 
Group 4Placebo 
ComparatorPlacebo Drug Powder 0 µg 0 µg Inhalation Oral inhalation once 
daily for 12 weeks
Base PeriodPlacebo IMP Sponsor
Phase 2 Cohort 
Group 4a (before 
Phase 3 dose 
selection)Experimental MK-5475 Drug Powder 380 µg 380 µg Inhalation Oral inhalation once 
daily for ~[ADDRESS_625088] 
ProductIMP Sponsor
Phase 2 Cohort 
Group 4b (before 
Phase 3 dose 
selection)Experimental MK-5475 Drug Powder 100 µg 100 µg Inhalation Oral inhalation once 
daily for ~[ADDRESS_625089] 
ProductIMP Sponsor
Phase 2 Cohort 
Group 4c (before 
Phase 3 dose 
selection)Experimental MK-5475 Drug Powder 32 µg 32 µg Inhalation Oral inhalation once 
daily for ~[ADDRESS_625090]: MK-5475 64
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
Arm Name [CONTACT_486492] -
tion 
NameInterven -
tion 
TypeDose 
FormulationUnit Dose 
Strength(s)Dosage 
Level(s)Route of 
Adminis-
trationRegimen/ Treatment 
Period/ Vaccination 
RegimenUse IMP or 
NIMP/
AxMPSourcing
Phase 2 Cohort 
Group 4a, 4b, & 
4c (after Phase 3 
dose selection)Experimental MK-5475 Drug Powder 380 µg OR
100 µg OR
32 µg380 µg 
OR 
100 µg 
OR 
32 µgInhalation Oral inhalation once 
daily for ~[ADDRESS_625091] 
ProductIMP Sponsor
Phase 3 Cohort 
Group 2Placebo 
ComparatorPlacebo Drug Powder 0 µg 0 µg Inhalation Oral inhalation once 
daily for 12 weeks 
Base Period
and up to 60 -month 
Extension PeriodPlacebo IMP Sponsor
EEA=European Economic Area; IMP=investigational medicinal product; NIMP /AxMP =noninvestigational/ auxiliary medicinal product.
The classification of IMP and NIMP /AxMP in this table is based on guidance issued by [CONTACT_19411]. Country differences
with respect to the definition/classification of IMP and NIMP /AxMP may exist. In these circumstances, local legislation is followed.
08G9QY
08P53K
PRODUCT: MK-5475 65
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
All supplies indicated in Table 2will be provided per the “Sourcing” column depending on 
local country operational requirements. If local sourcing, every attempt should be made to 
source these supplies from a single lot/batc h number where possible (eg, not applicable in the 
case where multiple lots or batches may be required due to the length of the study, etc) .
Refer to Section 8.1.[ADDRESS_625092].
6.2 Preparation/Handling/Storage/Accountability
6.2.[ADDRESS_625093] b e stored 
in a secure, environmentally controlled, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with access limited to the investigator and 
authorized site staff.
The investigator, institution, or the head of th e medical institution (where applicable) is 
responsible for study intervention accountability, reconciliation, and record maintenance (ie, 
receipt, reconciliation, and final disposition records).
For all study sites, the local country Sponsor personnel or designee will provide appropriate 
documentation that must be completed for drug accountability and return, or local discard 
and destruction if appropriate. Where local discard and destruction is appropriate, the 
investigator is responsible for ensuring tha t a local discard/destruction procedure is 
documented.
The study site is responsible for recording the lot number, manufacturer, and expi[INVESTIGATOR_19333] (if applicable) as per local guidelines unless otherwise 
instructed by [CONTACT_1034].
The investigator shall take responsibility for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution, and usage of study 
interventions in accordance with the protocol and any applicab le laws and regulations.
08P53K
PRODUCT: MK-5475 66
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
Study intervention may be dispensed via home delivery to the participant if allowed per local 
guidelines. Home delivery should only be used inexceptional circumstance s(eg, DPI 
[INVESTIGATOR_486413]) and after consultation with the Sponsor. Only authorized site staff are permitted 
to organize the shipment of the study intervention from the site to the participant .Refer to the 
Study Operations Manual forprocedure sto ensure participant data privacy, ensure 
temperature control, manage temper ature excursions, maintain full traceability, return of used 
and unused study interven tion,and preserve the study blind.
6.3 Measures to Minimize Bias: Randomization and Blinding
6.3.1 Intervention Assignment
Intervention randomization will occur centrally using an IRT system. This study has 2 parts, 
a Phase 2 dose selection cohort and a Phase 3 confirmatory cohort. There are 4 study 
intervention arms in the Phase 2 C ohort Base Period, 3 study intervention arms in the Phase 2 
Cohort Extension Period, and 2 s tudy intervention arms in the Phase 3 Cohort. Participants in 
the Phase 2 C ohort Base Period will be assigned randomly in a 1:1:1:1 ratio to 1 of 3 doses of 
MK-5475 (380 µg, 1 00µg, or 32 µg) or a matching placebo study intervention, respectively .
In the P hase 2 Cohort Extension Period, the participants who received placebo during the 
Base Period will initially be assigned randomly in a 1:1:1 ratio to 1 of the 3 doses of 
MK-5475 (380 µg, 100 µg, or 32 µg) and will be given new randomization numbers. The 
participants who received MK -5475 during the Base Period will initially receive the same 
MK-5475 doses in the Extension Period and will be assigned new randomization numbers, to 
maintain study blind ing.
After selection of the MK -5475 dose for Phase 3, the 3 MK-5475 dose groups in the Phase 2 
Cohort Extension Period will be collapsed into a single dose group for the remainder of the 
Phase 2 Cohort Extension Period.
Participants in the Phase 3 Cohort will be assigned random lyin a 1:1 ratio to the MK -5475 
dose selected 
inthe Phase 2 Cohort Base Period or matching placebo study intervention.
6.3.2 Stratification
Intervention randomization will be stratified according to the following factors:
1.WHO -FC at the time of randomization (Class II or Class III/IV).
6.3.[ADDRESS_625094]: MK-5475 67
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
Selected members of the Sponsor study team and management will be unblinded to data 
analysis results from the Phase 2 Cohort Base Pe riodand the Phase 3 Cohort Base Period, to 
evaluate the efficacy and safety profile of MK -5475 . For the Phase 2 Cohort Extension 
Period and the Phase 3 Cohort Extension Period, separate blinded Sponsor study team swill 
monitor the ongoing study (Section 9.7). Individuals directly involved with study conduct 
will not be unblinded. 
Blinding to intervention assignment will be maintained at all investigational sites. For both 
Phase 2 Cohort Base Period and Phase 3 Coh ort Base Period, the data analysis r esults will 
not be shared with the investigators before the completion of each respective cohort of the 
study, inclusive of each cohort’s Extension Period.
See Section 8.1.10 for a description of the method of unblinding a participant during the 
study, should such action be warranted.
6.4 Study Intervention Compliance
Interruptions from the protocol -specified treatment for 3consecutive days OR compliance 
≤90% require consultation between the investigator and the Sponsor and written 
documentation of the collaborative decision on participant management.
Records of study intervention compliance for each participant will be kept during the study. 
The investigator or qualified designees will review study intervention compliance during
each site visit and at the completion of the study. 
Participants are expected to self -administer an inhaled dose every morning and record each 
administration (ie, date and time) in their medication diary. Compliance assessments will be 
based on participant reporting (medication diary), c orroborat ed with inspection of the 
returned DPIs during the site visits. Data in the medication diary will be documented in the 
source documents and the eCRF. Compliance calculations will be defined in the sSAP. Issues 
with compliance should be discussed with the participant and addressed as deemed 
appropriate by [CONTACT_093].
A record of the number of MK- [ADDRESS_625095] be maintained and reconciled with study intervention and compliance 
records. Deviation(s) from the prescribed dosage regimen should be recorded in the eCRF. 
Intervention start and stop dates, including dates for intervention delays will also be recorded 
in the eCRF.
6.[ADDRESS_625096]: MK-5475 68
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
supportive therapy rests with the investigator and/or the participant’s primary physician. 
However, the decision to continue the participant on study intervention requires the mutual 
agreement of the investigator, the Sponsor, and the participant.
Any medication or vaccine (including OTC or prescription medicines, vitamins, and/or 
herbal supplements or other specific categories of interest) that the pa rticipant is receiving at 
the time of enrollment or receives during the study must be recorded along with:
•Reason for use
•Dates of administration including start and end dates
•Dosage information including dose and frequency
The Medical Monitor should be contact[CONTACT_63193].
Listed below are specific examples of prohibited concomitant therapy:
•Any inhaled prostacyclin or prostacyclin analogue (eg, inhaled iloprost, inhaled 
epoprostenol, or inhaled tre prostinil)
•Any sGC stimulators (eg, riociguat, vericiguat)
•Inhaled NO
•Inhaled nitrates (eg, amyl nitrite)
Note: A medication should not be stopped for the purpose of meeting study inclusion criteria. 
The decision to stop/interrupt medication is based on in vestigator’s judgment.
Long- term chronic oxygen therapy use is allowed. Oxygen should be given at the standard 
flow rate used at home at each assessment throughout the study, including the administration 
of 6MWT. Note: the 6MWT should be performed with the same oxygen equipment used at 
home.
6.5.1 Rescue Medications and Supportive Care
CRUs will be staffed with medically trained personnel with appropriate access to full -service 
acute care hospi[INVESTIGATOR_210631].
6.6 Dose Mod ification
Participants will be randomized to a fixed- doseregimen of MK -5475 or matching placebo 
for the duration of Phase 2 Cohort Base Period (380 µg, 100 µg, 32µg, or placebo) and 
Phase 3 Cohort (the MK -5475 dose selected inthe Phase 2 Cohort Base Period or placebo).
In the Phase 2 Cohort Extension Period, the participants who received placebo during the 
Base Period will initially be assigned randomly in a 1:1:1 ratio to 1 of the 3 doses of 
MK-5475 (380 µg, 100 µg, or 32 µg)and will be given new randomization numbers . 
Participants who received MK -[ADDRESS_625097]: MK-5475 69
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
MK-5475 doses in the Extension Period and will be assigned new randomization numbers, to 
maintain the study blind ing.
After selection of the MK-5475 dose for Phase 3, the 3 MK -5475 dose groups in the Phase 2 
Cohort Extension Period will be collapsed into a single dose group for the remainder of the 
Phase 2 Cohort Extension Period.
No other dose modifications are permitted.
6.7 Intervention After the End of the Study
There is no study -specified intervention after the end of the study.
6.8 Clinical Supplies Disclosure
The emergency unblinding call center will use the intervention/randomization schedule for 
the study to unblind participants and to unmask study intervention identity . The emergency 
unblinding call center should only be used in cases of emergency (see Section 8.1.10). If the 
emergency unblinding call center is not available for a given site in this study, the central 
electronic interve ntion randomization system (IRT) should be used to unblind participants 
and to unmask study intervention identity. The Sponsor will not provide random 
code/disclosure envelopes or lists with the clinical supplies.
6.[ADDRESS_625098]: MK-5475 70
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625099] be collected through the participant’s last scheduled follow -
up, even if the participant has discontinued study intervention. Therefore, all participants 
who discontinue study intervention before completion of the protocol -specified treatment 
period will still continue to be monitored in the study and participate in the study visits and 
procedures as specified in Section 1.[ADDRESS_625100] 
occur. In addition, a participant may be d iscontinued from study intervention by [CONTACT_19419], the study plan is violated, or 
for administrative and/or other safety reasons.
A participant must be discontinued from study intervention, but co ntinue to be monitored in 
the study for any of the following reasons:
•The participant or participant’s legally acceptable representative requests to discontinue 
study intervention.
•The participant’s treatment assignment has been unblinded by [CONTACT_093], MSD 
subsidiary, or through the emergency unblinding call center.
•The participant has a change in medical condition, change in medical treatment or 
personal circumstance which, in the opi[INVESTIGATOR_11922]/or Sponsor, placed 
the part icipant at unnecessary risk from continued administration of study intervention.
•The participant has a confirmed pregnancy.
•The participant fails to comply with the dosing, evaluations, or other requirements of the 
study, despi[INVESTIGATOR_486414]’s repeated ef forts to reinforce compliance.
•An individual participant reports an SAE considered related to the study intervention by 
[CONTACT_093].
For participants who are discontinued from study intervention, but continue to be monitored 
in the study, all visits and procedures, as outlined in the SoA, should be completed.
Discontinuation from study intervention is “permanent.” Once a participant is discontinued 
from study intervention, they shall not be allowed to restart study intervention.
08P53K
PRODUCT: MK-5475 71
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625101] be withdrawn from the study if the participant or participant’s legally 
acceptable representative withdraws consent from the study.
If a participant withdraws from the study, they will no longer receive study intervention or be 
followed at scheduled protocol visits.
Specific details regarding procedures to be performed at the time of withdrawal from the 
study, as well as specific details regarding withdrawal from FBR, are outlined in 
Section 8.1.9. The procedures to be perf ormed should a participant repeatedly fail to return 
for scheduled visits and/or if the study site is unable to contact [CONTACT_88683] 7.3.
7.[ADDRESS_625102] to Follow -up
If a participant fails to return to the clinic for a required study visit and/or if the site is unable 
to contact [CONTACT_2299], the following procedures are to be performed:
•The site must attempt to contact [CONTACT_19423]. If the 
participant is contact[INVESTIGATOR_530], the participant should be counseled on the importance of 
maintaining the protocol -specified visit schedule.
•The investigator or designee must make every effort to regain contact [CONTACT_19424] (eg, telephone calls and/or a certified letter to the participant’s last 
known mailing address or locally equivalent methods). These contact [CONTACT_19425]’s medical record.
08P53K
PRODUCT: MK-5475 72
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
8 STUDY ASSESSMENTS AND PROCEDURES
•Study procedures and their timing are summarized in the SoA.
•Adherence to the study design requirements, including those specified in the SoA, is 
essential and required for study conduct.
•The investigator is responsible for ensuring that procedures are conducted by 
[CONTACT_19426] (by [CONTACT_8640], training, and experience) staff. D elegation of 
study- site personnel responsibilities will be documented in the Investigator Trial File 
Binder (or equivalent).
•All study- related medical decisions must be made by [CONTACT_19427] a qualified 
physician.
•All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as applicable.
•Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before providing documented informed consent may be used for 
screening or baseline purposes provided the procedures meet the protoco l-specified 
criteria and were performed within the time frame defined in the SoA .
•Additional evaluations/testing may be deemed necessary by [CONTACT_88686]. In some cases, such evaluation/testin g 
may be potentially sensitive in nature (eg, HIV, hepatitis C), and thus local regulations 
may require that additional informed consent be obtained from the participant. In these 
cases, such evaluations/testing will be performed in accordance with those r egulations.
•Clinic in -person visit may be replaced by [CONTACT_756], video, or home visit using site staff 
or a nursing service ,if circumstances do not support an in -person site visit and after 
consultation with the Sponsor .
•The maximum amount of blood colle cted from each participant over the duration of the 
study will not exceed approximately 500 mL ( Table 11, Table 12).
•Repeat or unscheduled samples may be taken for safety reasons or for technical issues 
with the samples.
8.1 Administrative and General Procedures
8.1.1 Informed Consent
The investigator or medically qualified designee (consistent with local requirements) must 
obtain documented informed consent from each potential participant (or their legally 
acceptable representative) prior to participating in this clinical study or FBR . If there are 
changes to the participant’s status during the study (eg, health or age of majority 
requirements), the investigator or medically qualified designee must ensure the appropriate 
documented informed consent is in place.
08P53K
PRODUCT: MK-5475 73
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
[IP_ADDRESS] General Informed Consent
Informed consent given by [CONTACT_19429] a consent form. The form must include the study protocol number, study 
protocol title, dated signature, and agreement of the participant (or his/her legally acceptable 
representa tive) and of the person conducting the consent discussion.
A copy of the signed and dated informed consent form should be given to the participant (or 
their legally acceptable representative) before participation in the study.
The initial ICF, any subsequent revised ICF, and any written information provided to the 
participant must receive the IRB/IEC’s approval/favorable opi[INVESTIGATOR_19349]. The 
participant or his/her legally acceptable representative should be informed in a timely manner 
if new infor mation becomes available that may be relevant to the participant’s willingness to 
continue participation in the study. The communication of this information will be provided 
and documented via a revised consent form or addendum to the original consent form that 
captures the participant’s or the participant’s legally acceptable representative’s dated 
signature.
Specifics about the study and the study population are to be included in the study informed 
consent form.
Informed consent will adhere to IRB/IEC requirements, applicable laws and regulations, and 
Sponsor requirements.
[IP_ADDRESS] Consent and Collection of Specimens for Future Biomedical Research
The investigator or medically qualified designee will explain the FBR consent to the 
participant, or the par ticipant’s legally acceptable representative, answer all his/her questions, 
and obtain documented informed consent. before performing any procedure related to FBR. 
A copy of the informed consent. will be given to the participant before performing any 
proce dure related to FBR.
8.1.2 Inclusion/Exclusion Criteria
All I/Ecriteria will be reviewed by [CONTACT_093], who is a qualified physician, to ensure 
that the participant qualifies for the study. The Sponsor will review participant’s key I/E 
criteria prior to r andomization into the study. The investigator will make the final decision to 
include a participant in the study.
8.1.[ADDRESS_625103] information (including direct 
telephone numbers) to be used in the event of an emergency. The investigator or qualified 
designee will provide the participant with a participant identification card im mediately after 
the participant provides documented informed consent. At the time of intervention
randomization, site personnel will add the treatment/randomization number to the participant 
08P53K
PRODUCT: MK-5475 74
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625104] with their new Extension Period
treatment/randomization number.
The participant ID card also contains contact [CONTACT_93307] a health care provider can obtain information about study intervention in 
emergency situations where the investigator is not available.
8.1.4 Medical History
Participants’ m edical h istory, including medical conditions, diagnostic results, allergies ,and 
relevant physical examination findings , will be obtained by [CONTACT_148914] . The site must provide the required supporting documentation (specific infor mation 
about a participant’s medical history and prior hemodynamic diagnosis of PAH) to support 
participant’s eligibility for participation in the study.
8.1.5 Prior and Concomitant Medications Review
[IP_ADDRESS] Prior Medications
The investigator or qualified designee will review prior medication use and record prior 
medication taken by [CONTACT_78772] 90 days before starting the study.
[IP_ADDRESS] Concomitant Medications
The investigator or qualified designee will record medication taken by [CONTACT_486466] (See Sections 1.3 and 6.5) .
8.1.[ADDRESS_625105] not be reused f or different participants.
Any participant who is screened multiple times will retain the original screening number 
assigned at the Screening Visit. Specific details on the screening/rescreening visit 
requirements are in Section 8.11.2.
8.1.7 Assignment of Treatment/Randomization Number
All eligible participants will be randomly allocated and will receive a 
treatment /randomization number. The treatment/randomization number , in a numerical 
sequence specific for each cohort (Sec tion8.11.3), identifies the participant for all 
procedures occ urring within the cohort after treatment randomization. Once a 
treatment /randomization number is assigned to a participant, it can never be re -assigned to 
another participant.
08P53K
PRODUCT: MK-5475 75
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
In the Phase 2 Cohort, each participant who completes the Base Period and provides 
documented informed consent for the Extension Period will be assigned a new 
treatment/randomization number for the Extension Period. 
In the Phase 3 Cohort , asingle partici pant cannot be assigned more than 1 
treatment /randomization number.
8.1.[ADDRESS_625106] dose of study intervention will be administered at the study site at Visit 2 . 
Subsequent dosing will be performed once daily by [CONTACT_2299] (ie, unsupervised at 
his/her home) at approximately the same time each day.
[IP_ADDRESS] Timing of Dose Administration
Study intervention will be administered once daily, in the morning, at approximately the 
same time throughout the duration of the study.
[IP_ADDRESS] Dry Powder I nhaler Use Training 
Participants will be trained by [CONTACT_486467].
At Visit 1/Screening
1.Participants will receive training from the site staff and will review instructions for DPI
[CONTACT_3225].
2.Participants will be expected to administer a placebo dose under the guidance of the site 
staff.
3.Participants unable to correctly use the DPI(after instruction by [CONTACT_7893]) at this visit 
due to, but not limited to, physical limitations or cognitive impairment, are not eligible 
for study enrollment.
At Visit 2/Randomization
1.Site staff will review the process for DPI[INVESTIGATOR_486415].
2.The site will document that re training occurred.
3.Participants will administer the double -blind study intervention (MK -5475 or matching 
placebo) in the presence of the site staff.
08P53K
PRODUCT: MK-5475 76
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
At Visit 3/Day 7 (+ 2days) –Telephone visit
The site staff will contact [CONTACT_486468][INVESTIGATOR_486416]. If the participant is experiencing DPI [INVESTIGATOR_486416] , site staff 
will re -review the process for DPI [INVESTIGATOR_486417]/or caregiver. An unscheduled 
visit will occur i f the issues cannot be addressed via telephone.
[IP_ADDRESS] Witnessed Dosing
Administration of study intervention will be witnessed by [CONTACT_1755]/or qualified 
study staff at the randomization visit.
[IP_ADDRESS] Dispense Double -blind Study Intervention
For both cohorts, the double -blind study intervention for the Base Period (MK- 5475 or 
matching placebo) will be dispensed to participants at Visit 2/Day 1, Visit 4/Week 4, and 
Visit 5/Week 8. Study intervention for the Extension Period of Phase 2 Cohort (MK -5475 
380 µg, 100 µg, or 32 µg ) will be dispensed starting at Visit 6 and every 6weeks thereafter , 
until the end of the Extension Period . For participants already enrolled in the Phase 2 Cohort 
Extension Period, the transition to an every 6 -week visit frequency will occur at Week 24 or 
at the next visit that falls on a 12 -week interval (eg, Week 36, 48, 60. and every 12 wee ks 
thereafter through study completion) .Study intervention for the Extension Period of Phase 3 
Cohort (MK -5475 or matching placebo) will be dispensed starting at Visit 6 and every 
12weeks thereafter, until the end of the Extension Period.
Defective DPI s will be replaced by [CONTACT_456038]. Refer to the Study Operations Manual
for further details.
[IP_ADDRESS] Dispense/Review Participan t Dosing Diary
Participants will receive paper -based dosing diaries as specified in the SoA (Section 1.3) to 
document administering the study intervention and to include any comments related to the 
DPI[CONTACT_3225]. Participants should bring their completed diary to all study visits. Site personnel 
should review the diaries at each study visit to monitor compliance and review for any 
potential AEs from the comments entered. 
[IP_ADDRESS] Investigational Product Compliance and Accountability
Adherence to study intervention will be assessed by [CONTACT_486469] -
blind treatment period as described in the SoA (Section 1.3). Ever y effort will be made to 
maintain adherence as close to 100% as possible. Interruptions from the protocol -specified 
treatment plan for 3 consecutive days or compliance ≤ 90% (defined as 3 or m ore missed 
doses of study intervention within 30 days, between sc heduled study visits) requires 
consultation between the investigator and the Sponsor and written documentation of the 
collaborative decision on participant management.
Refer to Section 6.[ADDRESS_625107]: MK-5475 77
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
[IP_ADDRESS] Telephone Con tact Between Study Visits
Unscheduled telephone contact [CONTACT_486470]. Unscheduled 
visit(s) may be performed as needed , orif the participant requires retraining on study 
intervention administration.
8.1.9 Discontinuation and Withdrawa l
Participants who discontinue study intervention before completion of the treatment period 
should be encouraged to continue to be followed for all remaining study visits (including 
vital status assessment at the end of the study) as outlined in the SoA and Section 8.11.5, to 
minimize missing outcome data .
Participants who withdraw from the study should be encouraged to complete all applicable 
activities scheduled for the final visit for that study period at the time of withdrawal. Any 
AEs that are presen t at the time of withdrawal should be followed in accordance with the 
safety requirements outlined in Section 8.4 and additional Visit Requirements (refer to SoA, 
Section 1.3) .
[IP_ADDRESS] Withdrawal From Future Biomedical Research
Participants may withdraw their consent for FBR. Participants may withdraw consent at any 
time by [CONTACT_88690]. If medical records for the study are still available, 
the investigator will contact [CONTACT_75355] 
(clinical.specimen.management@MSD. com). Subsequently, the participant’s consent for 
FBR will be withdrawn. A letter will be sent from the Sponsor to the investigator confirming 
the withdrawal. It is the responsibility of the investigator to inform the participant of 
completion of withdrawa l. Any analyses in progress at the time of request for withdrawal or 
already performed before the request being received by [CONTACT_88691]. No new analyses would be generated 
after the request is received.
If the medical records for the study are no longer available (eg, if the investigator is no longer 
required by [CONTACT_88692]) or the specimens have been 
completely anonymized, there will no longer be a link between the participant’s personal 
information and their specimens. In this situation, the request for specimen withdrawal 
cannot be processed.
8.1.10 Participant Blinding/Unblinding
STUDY INTERVENTION IDENTIFICATION INFORMATION IS TO BE UNMASKED 
ONLY IF NECESSARY FOR THE WELFARE OF THE PARTICIPANT. EVERY 
EFFORT SHOULD BE MADE NOT TO UNBLIND.
For emergency situations where the investigator or medically qualified designee (consistent 
with local requirements) needs to identify the intervention used by a participant and/or the 
dosage administered, he/she will contact [CONTACT_88693] a request for emergency unblinding. As requested by [CONTACT_180632] 
08P53K
PRODUCT: MK-5475 78
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
qualified designee, the emergency unblinding call center will provide the information to 
him/her promptly and report unblinding to the Sponsor. Before contact[CONTACT_88694] a participant’s intervention assignment, the 
investigator who is a qualified physician should make reasonable attempts to enter the
intensity of the AEs observed, the relation to study intervention, the reason thereof, etc, in the 
medical record. If it is not possible to record this assessment in the medical record before the 
unblindi ng, the unblinding should not be delayed.
If unblinding has occurred, the circumstances around the unblinding (eg, date, reason, and 
person performing the unblinding) must be documented promptly, and the Sponsor Clinical 
Director notified as soon as possib le.
Once an emergency unblinding has taken place, the investigator, site personnel, and Sponsor 
personnel may be unblinded so that the appropriate follow -up medical care can be provided 
to the participant.
Participants whose treatment assignment has been unblinded by [CONTACT_486471]/or nonstudy treating physician must be discontinued from study 
intervention, but should continue to be monitored in the study.
Additionally, the investigator or medically qualified designee must go into the IRT system 
and perform the unblind in the IRT system to update drug disposition. In the event that the 
emergency unblinding call center is not available for a given site in this study, the IRT 
system should be used for emergency unbli nding in the event that this is required for 
participant safety.
At the end of the study, random code/disclosure envelopes or lists and unblinding logs are to 
be returned to the Sponsor or designee.
8.1.11 Calibration of Equipment
The investigator or qualified designee has the responsibility to ensure that any device or 
instrument used for a clinical evaluation/test during a clinical study that provides information 
about inclusion/exclusion criteria and/or safety or efficacy parameters shall be suitabl y 
calibrated and/or maintained to ensure that the data obtained are reliable and/or reproducible. 
Documentation of equipment calibration must be retained as source documentation at the 
study site.
All measuring instruments used for hemodynamic measurements must be calibrated 
according to the hospi[INVESTIGATOR_486418]/or manufacturer’s instructions. Additional details are 
provided in the RHC Guidance Document.
The spi[INVESTIGATOR_486419]/ERS technical standards [Graham, B. L., 
et al 2019] and the device manual, on the days when spi[INVESTIGATOR_106433]. It is preferred 
that the calibration equipment used to calibrate the spi[INVESTIGATOR_125379] a validated 
calibration, according to manufactur er’s specifications.
08P53K
PRODUCT: MK-5475 79
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
8.2 Efficacy Assessments
Refer to the SoA sfor the planned time points of these assessments.
8.2.1 Right Heart Catheterization
Pulmonary vascular hemodynamic measurements are necessary to confirm study 
participants’ eligibility in the Phase 2 and Phase 3 Cohorts and for primary and secondary 
endpoint analyses in Phase 2 Cohort (Section 1.3). RHC using a pulmonary artery floating 
catheter (eg,Swan -Ganz catheter) will be performed for pulmonary vascular hemodynamic 
assessment ,if not available within the required time frame for both cohorts (Section 5.1) .
For Phase [ADDRESS_625108] 
morning dose of study intervention. Participants who withdraw early from the study will be 
encouraged to complete the RHC at the Week 12 visit.
Both RHC procedures will include complete hemodynamic profile, cardiac output, arterial 
oxygen saturation (SaO 2, %), mixed venous oxygen saturation (SvO 2, %), hemoglobin, 
systemic BP (noninvasive), heart rate, and body weight. If, despi[INVESTIGATOR_321510], PCWP is 
deemed unreliable, left heart catheterization must be performed to measure LVEDP. 
Standards for RHC performance and invasive pressure measurement are described in the 
RHC Guidance Document. To guarant ee standardized conditions for RHC and hemodynamic 
measurements across participating study centers, investigators must follow the principles 
defined in the RHC Guidance Document.
All RHC measurements should be recorded on source documents and entered into the 
respective eCRF. RHC pressure tracings will be labeled in accordance with the blinding 
process described in the RHC Guidance Document and submitted for central review.
8.2.[ADDRESS_625109]
The 6MWT (including Borg CR10 Scale rating) will be performed at Screening, 
Randomization, Week 12, and Week [ADDRESS_625110] be between 
150and 500 meters ,with the 2 value swithin ± 15% of each other .If the relative difference 
between the two 6MWD measurements is >15%, the Randomization 6MWT may be repeated 
after at least 4 hours. If the relative difference between the 2 Randomization 6MWD 
measurements is ≤ 15%, the participant can be random ized and the last 6MWT (including 
Borg Scale assessment) will be considered the baseline test.
The 6MWT will be performed in accordance with the official European Respi[INVESTIGATOR_16362]/American Thoracic Society technical standard for field walking tests in c hronic 
respi[INVESTIGATOR_3765] [Holland, A. E., et al 2014] . Technicians performing the test will be 
trained according to these published procedures [Holland, A. E., et al 2014] . Participants will 
refrain from physical exercise for a minimum of [ADDRESS_625111]: MK-5475 80
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625112] flow 
rate andwith the same equipment used at home. Sites will be provided with detailed 
instructions in the Study Operations Manual.
8.2.3 WHO Functional Class
The WHO -FC will be assessed at every site visit in the Phase 2 Cohort Base Period, every 
12weeks in the Phase 2 Cohort Extension Period, and throughout the Phase 3 Cohort. 
Participa nts will be assigned 1 of 4 functional classes, according to the modified WHO 
classification of functional status of patients with pulmonary hypertension [Stuart, R. 1998] :
Class I –Patients with pulmonary hypertension in whom there is no limitation of usual 
physical activity; ordinary physical activity does not cause increased dyspnea, fatigue, chest 
pain, or near syncope.
Class II –Patients with pulmonary hypertension who have mild limitation of physical 
activity. There is no discomfort at rest, but normal physical activity causes increased 
dyspnea, fatigue, chest pain, or near syncope.
Class III – Patients with pulmonary hypertension who have a marked limitation of physical 
activity. There is no discomfort at rest but less than ordinary activity causes incr eased 
dyspnea, fatigue, chest pain, or near syncope.
Class IV –Patients with pulmonary hypertension who are unable to perform any physical 
activity and who may have signs of right ventricular failure. Dyspnea and/or fatigue may be 
present at rest and symp toms are increased by [CONTACT_180547]. 
PAH pa rticipa nts who have experienced a syncopal epi[INVESTIGATOR_486420] -FCIV.
8.2.4 NT-proBNP
Blood samples for assessment of NT -proBNP will be collected as specified in the SoA for 
Phase 2 Cohort (at bas eline [Visit 2], Week 12, and Week 24) and in the SoA for Phase 3 
Cohort ( at baseline [V isit 2], Visit6[Week 12], and every other visit thereafter [every 
24weeks]). As NT -proBNP may be affected by [CONTACT_486472], participants will be advised 
to abstain from exercise before each study visit requiring blood collection for clinical 
laboratory tests . Similarly, NT -proBNP plasma samples must be taken prior to the 6MWT. 
This sample should be collected with the participant in the same position at each visit 
(eg,sitting or semi -recumbent).
8.2.5 Patient -reported Outcomes
All PRO questionnaires will be administered by [CONTACT_486473]: LPH, PGI -S(physical limitations), 
PGI-S (overall), PGI-C(physical limitations) and PGI -C (overall). The questionnaires should 
be administered according to the SoA s (Section 1.3). It is best practice and strongly 
08P53K
PRODUCT: MK-5475 81
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625113] procedure performed during each site visit . If the visit is 
expected to extend over multiple days (Visit 2/Randomization and/or Visit 6), the PROs will 
be administered as the first procedure on the first day of that visit. 
If a participant discontinues the study intervention or withdraws consent during the Base 
Period of either cohort, Visit 6/Week 12 PROs will be administered. If a Phase 3 Cohort 
participant prematurely discontinues study intervention and agrees to be followed for the 
remaining study duration, he/she will be asked to complete the PROs up to the final visit, 
according to the SoA (Section 1.3.2). If the participant does not complete the ePROs at a 
scheduled time point, the MISS_MODE form must be completed to capture the reason the 
assessment was not performed. In the eventuality tha t electronic administration of the PROs 
is not available, study teams can use the paper back -up process, if allowed per the Site 
Monitoring Plan (see Study Operations Manual). 
8.3 Safety Assessments
Details regarding specific safety procedures/assessments to be performed in this study are 
provided. The total amount of blood to be drawn/collected over the course of the study, 
CCI
08P53K
PRODUCT: MK-5475 82
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
including approximate blood volumes drawn/collected by [CONTACT_180635], can be found in Appendix 8 ( Table 11, Table 12).
Planned time points for all safety assessments are provided in the SoA.
8.3.1 Physical Examinations
Comple te and directed physical examinations will be conducted by [CONTACT_306171] (consistent with local requirements) per institutional standard 
and as outlined in the SoAs (Section 1.3). Height and weight will be measured and recorded. 
The complete physical examinations will ,at a minimum, include assessments of general 
appearance, skin, lymphatic system, eyes, ears, nose, throat, CV system, respi[INVESTIGATOR_2133], 
abdomen/gastrointestinal system, musculoskeletal system, and neurological system. The 
directed physical examinations will ,at a minimum, include assessment of the cardiovascular 
and respi[INVESTIGATOR_27441] . Other body systems may be evaluated with either type of 
examination. Abnormalities considered clinically significant should be reported as AEs.
Investigators should pay special attention to clinical signs related to previous serious 
illnesses. A physical examination (complete or directed) may be performed at any 
unscheduled visit if deemed necessary by [CONTACT_941] i nvestigator or medically qualified designee.
8.3.2 Body Weight
Body weight (kg) will be measured using a standardized scale at each of the predefined time 
points outlined in SoA s(Section 1.3) . Participant will be weighed wearing light clothing and 
no shoes. Bod y weight should be reported with precision to 1decimal place (eg, 0.1 kg).
8.3.[ADDRESS_625114] ing and DLCO
Pulmonary function testing and single -breath carbon monoxide uptake should be performed 
in accordance with the technical standards established by [CONTACT_58286]/ERS [Miller, M. R., et al 
2005] [Graham, B. L., et al 2019] [Graham, B. L., et al 2017] . PFT includes spi[INVESTIGATOR_486421]. Spi[INVESTIGATOR_486422] 
08P53K
PRODUCT: MK-5475 83
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
responsiveness testing in participants who do not meet the PFT inclusion criteria of either 
FEV1/FVC <70% orFEV1 <60% of predicted value .
FVC , FEV1, FEV1/FVC ratio, FEF25 -75, PEF, TLC and DLCO will be recorded at 
Visit 1/Screening and Visit 6, in both Phase 2 and Phase 3 Cohort s, as outlined in the SoA 
(Section 1.3). The largest FEV1 and the largest FVC, as well as their ratio (FEV1/FVC), 
shoul d be reported, even if they were not recorded during the same measurement.
The spi[INVESTIGATOR_486423]/ERS technical standards and the 
device manual. Spi[INVESTIGATOR_486424]/ERS technical 
standards will follow site SOPs and manufacturer’s specifications. Spi[INVESTIGATOR_486425]/ERS technical standards document will follow site SOPs and 
manufacturer’s specifications. Every effort should be made to use the same spi[INVESTIGATOR_486426]. 
Report data from each PFT must be available in the source documents.
8.3.[ADDRESS_625115] supi[INVESTIGATOR_050] 12 -lead ECG will be obtained and reviewed by [CONTACT_306171] (consistent with local requirements) as outlined in the SoA 
(Section 1.3) using an ECG machine that automatically calculates the heart rate and measures 
PR, QRS, QT, and QTc intervals. 
ECGs should be performed after the participant has rested quietly for at least [ADDRESS_625116] of clinical laboratory tests to be performed and to the SoA for 
the timing and frequency.
•The investigator or medically qualified designee (consistent w ith local requirements) 
must review the laboratory report, document this review, and record any clinically 
relevant changes occurring during the study in the AE section of the CRF. The laboratory 
reports must be filed with the source documents. Clinically significant abnormal 
laboratory findings are those which are not associated with the underlying disease, unless 
judged by [CONTACT_19448]’s condition.
•All protocol -required laboratory assessments, as def ined in Appendix [ADDRESS_625117] be 
conducted in accordance with the laboratory manual and the SoA s(Section 1.3) .
08P53K
PRODUCT: MK-5475 84
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
•If laboratory values from nonprotocol -specified laboratory assessments performed at the 
institution’s local laboratory require a change in study participant management or are 
considered clinically significant by [CONTACT_093] (eg, SAE or AE or dose 
modification), then the results must be recorded in the appropriate CRF (eg, SLAB).
•For any laboratory tests with values considered clinically signif icantly abnormal during 
participation in the study or within 14days after the last dose of study intervention, every 
attempt should be made to perform repeat assessments until the values return to normal or 
baseline or if a new baseline is established as determined by [CONTACT_093] .
•Serum hCG testing will be performed in female participants where a pregnancy is 
suspected.
8.3.7 Pregnancy Testing
•Pregnancy testing:
-Pregnancy testing requirements for study inclusion are described in Section 5.1.
-Pregnancy testing (urine or serum as required by [CONTACT_427]) should be 
conducted at all site visits, as specified in the SoA (Section 1.3).
-Pregnancy testing (urine or serum as required by [CONTACT_427]) should be 
conducted at the end of relevan t systemic exposure.
-Additional serum or urine pregnancy tests may be performed, as determined 
necessary by [CONTACT_31837], to establish the 
absence of pregnancy at any time during the participant 's participation in the study.
Refer to Appendix [ADDRESS_625118] the 
participant in source documents.
8.3.9 AE Monitoring
The investigator or qualified designee will assess each participant to evaluate for potential 
new or worsening AEs, as specified in the SoAs (Section 1.3), and more frequently if 
clinically indicated. AEs will be graded and recorded throughout the study and during the 
follow -up period (Section 10.3.4).
The criteria for discontinuation of study intervention for individual participants are in 
Section 7.1.
08P53K
PRODUCT: MK-5475 85
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
8.4 Adverse Events, Serious Adverse Events, and Other Reportable Safety Events
The definitions of an AE or SAE, as well as the method of recording, evaluating, and 
assessing causality of AE and SAE and the procedures for completing and transmitting AE, 
SAE, and other reportable safety event reports can be found in Appendix 3 .
Adverse events, SAEs, and other reportable safety events will be reported by [CONTACT_2299] 
(or, when appropriate, by a caregiver, surrogate, or the participant ’s legally authorized 
representative).
The investigator and any designees are responsible for detecting, documenting, and reporting 
events that meet the definition of an AE or SAE as well as other reportable safety events. 
Investigators need to document if an SAE was associated with a medication error, misuse, or
abuse.
Investigators remain responsible for following up AEs, SAEs, and other reportable safety 
events for outcome according to Section 8.4.3. The investigator, who is a qualified physician, 
will assess events that meet the definition of an AE or SAE as w ell as other reportable safety 
events with respect to seriousness, intensity/toxicity ,and causality.
8.4.[ADDRESS_625119] promptly notify the Sponsor.
All initial and follow -up AEs, SAEs, and other reportable safety events will be recorded and 
reported to the Spons or or designee within the time frames as indicated in Table 3.
Exception: A positive pregnancy test at the time of initial screening is not a reportable event 
unless the participant has received study intervention.
08P53K
PRODUCT: MK-5475 86
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
Table 3 Reporting Periods and Time Frames for Adverse Events and Other Reportable 
Safety Events
Type of Event Reporting Time 
Period:
Consent to 
Randomization/ 
AllocationReporting Time 
Period:
Randomization/ 
Allocation 
through 
Protocol -
specified Follow -
up PeriodReporting Time 
Period:
After the Protocol -
specified Follow -up 
PeriodTime Frame to 
Report Event 
and Follow- up 
Informat ion to 
Sponsor:
NSAE Report if:
-due to protocol -
specified 
intervention
-causes 
exclusionReport all Not required Per data entry 
guidelines
SAE Report if:
-due to protocol -
specified 
intervention
-causes 
exclusionReport all Report if:
-drug/vaccine related.
(Follow ongoing to 
outcome)Within 24 hours 
of learning of 
event
Pregnancy/
Lactation ExposureReport if:
-participant has 
been exposed to 
any protocol -
specified 
intervention
Exception: A 
positive 
pregnancy test at 
the time of initi al 
screening is not a 
reportable event.Report all Report if participant 
has been exposed to 
any protocol -specified 
intervention. 
Previously reported –
Follow to completion/
termination; report 
outcomeWithin 24 hours 
of learning of 
event
ECI (require 
regulatory reporting)Report if:
-due to 
intervention
-causes 
exclusionReport
-Potential DILI
-Require 
regulatory 
reportingNot required Within 24 hours 
of learning of 
event
ECI (do not require 
regulatory reporting)Report if:
-due to 
intervention
-causes 
exclusionReport
-non-DILI ECIs 
and those not 
requiring 
regulatory 
reportingNot required Within 5 
calendar days of 
learning of event
Cancer Report if:
-due to 
intervention
-causes 
exclusionReport all Not required Within 5 
calendar days of 
learning of event
(unless serious)
Overdose Not applicable Report all Not required Within 5 
calendar days of 
learning of event
DILI=drug -induced liver injury; ECI=event of clinical interest; NSAE=nonserious adverse event; SAE=serious adverse 
event
08P53K
PRODUCT: MK-5475 87
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
8.4.2 Method of Detecting AEs, SAEs, and Other Reportable Safety Events
Care will be taken not to introduce bias when detecting AEs and/or SAEs and other 
reportable safety events . Open- ended and nonleading verbal questioning of the part icipant is 
the preferred method to inquire about AE occurrence.
8.4.3 Follow -up of AE, SAE, and Other Reportable Safety Event Information
After the initial AE/SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. All AEs, SAEs, and other reportable safety events, 
including pregnancy and exposure during breastfeeding, ECIs, cancer, and overdose will be 
followed until resolution, stabilization, until the event is otherwise explained, or the 
participant is los t to follow -up (as defined in Section 7.3). In addition, the investigator will 
make every attempt to follow all nonserious AEs that occur in randomized participants for 
outcome. Further information on follow -up procedures is given in Appendix 3.
8.4.4 Regulatory Reporting Requirements for SAE
Prompt notification (within 24 hours) by [CONTACT_113809] a study interv ention under clinical investigation are met.
The Sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under clinical investigation. The 
Sponsor will comply w ith country- specific regulatory requirements and global laws and 
regulations relating to safety reporting to regulatory authorities, IRB/IECs, and investigators.
Investigator safety reports must be prepared for S[LOCATION_003]Rs according to local regulatory 
requirem ents and Sponsor policy and forwarded to investigators as necessary.
An investigator who receives an investigator safety report describing an SAE or other 
specific safety information (eg, summary or listing of SAEs) from the Sponsor will file it 
along with the IB and will notify the IRB/IEC, if appropriate according to local requirements.
Refer to Appendix 7 for country- specific requirements.
8.4.5 Pregnancy and Exposure During Breastfeeding
Although pregnancy and infant exposure during breastfeeding are not cons idered AEs, any 
pregnancy or infant exposure during breastfeeding (spontaneously reported to the 
investigator or their designee) that occurs in a participant during the study are reportable to 
the Sponsor.
All reported pregnancies must be followed to the c ompletion/termination of the pregnancy.
Any pregnancy complication will be reported as an AE or SAE.
08P53K
PRODUCT: MK-5475 88
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
The medical reason (example: maternal health or fetal disease) for an elective termination of 
a pregnancy will be reported as an AE or SAE. Prenatal testin g showing fetus will be born 
with severe abnormalities/congenital anomalies that leads to an elective termination of a 
pregnancy will be reported as an SAE for the fetus.
Pregnancy outcomes of ectopic pregnancy, spontaneous abortion, missed abortion, benig n 
hydatidiform mole, blighted ovum, fetal death, intrauterine death, miscarriage, and stillbirth 
must be reported as serious events (Important Medical Events). If the pregnancy continues to 
term, the outcome (health of infant) must also be reported.
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying as 
AEs or SAEs
Disease -related events and or disease -related outcomes not qualifying as AEs or SAEs are 
not applicable to this study.
8.4.[ADDRESS_625120] for this study include:
1.Symptomatic hypotension, defined as a physical finding of systolic BP <90 mmHg or 
systolic BP decrease of more than 40 mmHg below the participant’s baseline which is 
accompanied by [CONTACT_2669] 1 symptom, such as presyncope, dizziness, mental status 
changes, etc. (reported by [CONTACT_486474]).
2.Pulmonary hemorrhage
3.Hemoptysis
4.Potential DILI events defined as an elevated A ST or ALT lab value that is greater than or 
equal to 3X the upper limit of normal and an elevated total bilirubin lab value that is 
greater than or equal to 2X the upper limit of normal and, at the same time, an alkaline 
phosphatase lab value that is less than 2X the upper limit of normal, as determined by 
[CONTACT_13149] -specified laboratory testing or unscheduled laboratory testing.*
*Note: These criteria are based upon available regulatory guidance documents. The purpose 
of the criteria is to specify a t hreshold of abnormal hepatic tests that may require an 
additional evaluation for an underlying etiology. The study site guidance for assessment and 
follow -up of these criteria can be found in the Investigator Study File Binder (or equivalent).
8.4.8 Medical Devi ce and Drug–D evice Combination Products –
PQCs/Malfunctions
The method of documenting and reporting of such events (ie, complaints associated with 
medical devices including PQCs/malfunctions) will occur as below and in Appendix 4.
08P53K
PRODUCT: MK-5475 89
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
To fulfill regulatory reporting obligations worldwide, medical device information associated 
with AEs will be collected and reported to the Sponsor in the same time frame as AEs per 
Section 8.4.1 via CRF (paper or electronic) and as per data entry guidelines.
PQCs/malfunctions ,including those that involve a participant or any user/associated person, 
must be reported to the Sponsor. Sponsor shall review reported events by [CONTACT_301807]- device combination 
products being used in clinical studies.
During the course of the study, a participant may provide feedback related to the device or 
devicelike features of a drug delivery system. This “customer feedback” is defined as a report 
that does not allege a PQC or defect and has no relevant safety information/untoward event 
associate d with it (eg, goodwill or courtesy replacement, consumer preference or suggestion, 
remark thatmay suggest an improvement in the functionality or quality of a medical device 
or devicelike features of a drug delivery system). All reports of customer feedba ck must be 
reported to the Sponsor within [ADDRESS_625121] information 
can be found in the Investigator Trial File Binder (or equivalent).
The investigator is responsible for ensuring that follow- up includes any supplemental 
investigations as indicated to elucidate the nature and/or causality between the AE and the 
medical device or device constituent of combination product.
8.5 Treatment of Overdose
In this study, an overdose will be defined as any dose of study intervention admin istered as 
part of the study exceeding the dose prescribed by [CONTACT_760] (ie, >1 inhalation/day). It is 
up to the investigator to decide on the treatment of an overdose, based on the clinical 
evaluation of the participant , in consultation with the Sponso r.
Decisions regarding dose interruptions will be made by [CONTACT_180636].
8.6 Pharmacokinetics
The decision as to which plasma samples collected will be assayed for evaluation of PK will 
be collaboratively determined by [CONTACT_486475] (Department of Quantitative 
Pharmacology and Pharmacometrics and the appropriate department within Clinical 
Research) in the Sponsor’s organization. If indicated, these samples may also be assayed
and/or pooled for assay in an exploratory manner for metabolites and/or additional 
pharmacodynamic markers.
8.6.1 Blood Collection for Plasma MK -5475
Sample collection, storage, and shipment instructions for plasma samples will be provided in 
the Operations/Laboratory Manual.
08P53K
PRODUCT: MK-5475 90
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
PK samples will be collected from all randomized participants according to the PK sampling 
timelines outlined in the SoA (Section 1.3). At all study visits during the double -blind 
treatment peri od where a PK sample will be collected, the participant must ensure that their 
MK-5475/matching placebo dose aligns with the clinic visit time and PK sample collection. 
The date and time of the lastMK-5475/matching placebo dose taken before PK sample 
collection will be recorded. The date and time of each PK sample will also be recorded. The 
PK sampling will occur after the administration of study intervention, as follows: 
For participants who prematurely discontinue study intervention, a PK sample should be 
collected during t he discontinuation visit. For the PK samples collected during the 
discontinuation visit, t he date and time of the last MK-5475/matching placebo dose taken 
before sample collection, as well as t he date and time of PK sample collection will be 
recorded.
8.7 Phar macodynamics
Sample collection, storage, and shipment instructions for pharmacodynamic samples will be 
provided in the O perations/ Laboratory M anual .
CCI
08P53K
PRODUCT: MK-5475 91
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
8.8 Biomarkers
Collection of samples for other biomarker research is also part of this study. The following 
samples for biomarker research will be collected from all participants as specified in the 
SoA:
•Blood for genetic analysis
8.8.1 Planned Genetic Analysis Sample Collection
The planned genetic analysis sample should be collected for planned analysis of the 
association between genetic variants in DNA and drug response. This sample will not be 
collected at the site if there is either a local law or regulation prohibiting collec tion, or if the 
IRB/IEC does not approve the collection of the sample for these purposes. If the sample is 
collected, leftover extracted DNA will be stored for FBR if the participant provides 
documented informed consent for FBR. If the planned genetic analysis is not approved, but 
FBR is approved and consent is given, this sample will be collected for the purpose of FBR.
The planned genetic analysis sample should be obtained predose on Day [ADDRESS_625122] e collection, storage, and shipment 
instructions for planned genetic analysis samples will be in the Operations/Laboratory 
Manual.
8.9 Future Biomedical Research Sample Collection
If the participant provides documented informed consent for FBR, the following s pecimens 
will be obtained as part of FBR:
Leftover DNA for future research
Serum for future research
Plasma for future research
8.[ADDRESS_625123] the ‘external contact [CONTACT_9702]’ identified by [CONTACT_39581] S creening ( see Section 1.3), to collect participant’s vital status (Section 8.3. 8).
08P53K
PRODUCT: MK-5475 92
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
8.11.1 Scheduling the Visits
For both Phase 2 and Pha se 3 Cohorts, the screening RHC (if applicable) will be scheduled in 
advance at the initial screening visit. For the Phase 2 Cohort , the Visit 6 RHC will be 
scheduled in advance at Visit 2/Randomization.
During the double -blind treatment period, at the end of each study visit, the next study visit 
should be scheduled. Every effort should be made to adhere to the visit schedule 
(Section 1.3). For both Phase 2 and Phase 3 Cohorts, Visit 3/ Day 7 should be scheduled 
within + 2 days, Visit 4/Week 4 and Visit 5/ Week 8 within ± 5 days, and Visit 6/Week 12 
within + 7 days. During the Phase 2 Cohort Extension Period, all visits (except Final Visit)
should be scheduled within ± 5days; during the Phase 3 Cohort Extension Period, all visits 
(except Final Visit) should be scheduled within ± [ADDRESS_625124] be adjusted so that the total 
duration of the double -blind treatment period is as close as possible to 12 weeks for the Base 
Period in both cohorts. 
Visits should be scheduled relative to the date of Visit 2/ Day 1. If a visit is scheduled at a 
time other than the protocol designated time, careful consideration must be given to the 
amount of investigational product the participant has available.
Study sites should update IRT at each scheduled study visit (except screening visits) for 
purposes of enrollment tracking.
8.11.2 Screening
Over a period of a pproximately 28days (Visit 1/Screening) , consented potential participants 
will be evaluated to determine that they fulfill the entry requirements as set forth in 
Section 5. The screening period may be extended, under special circumstances (eg, 
scheduling issues) ,with the explicit approval of the Sponsor Clinical Director. If a 
participant fails to meet the study entry criteria during Visit 1/Screening, procedures 
(except RHC) may be repeated once, based on investigator judgment and after consultation 
with the Sponsor. Participants may only be rescreened once. Unless otherwise indicated, all 
screening procedures apply for both Phase 2 and Phase 3 Cohort participants.
Participants will be assigned unique screening number s,specific for each cohort. The 
Screening procedures will be performed such that the RHC (if required) is performed last, 
whenever possible. Determination of eligibility will be assessed based on the demographic, 
disease diagnostic, hemodynamic, functional, echocardiographic, pulmonary function, and 
prior/concomitant therapy criteria outlined in Sections 5.1 and 5.2. Potential participants will 
also be assessed for the availability of adequate historical PAH diagnostic data (RHC and 
echocardiography ).
08P53K
PRODUCT: MK-5475 93
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
RHC
For Phase [ADDRESS_625125] the 
RHC results reviewed by a blinded independent central reviewer. 
For Phase [ADDRESS_625126] had an RHC pe rformed  prior 
to Visit 1/Screening will have the RHC results reviewed by [CONTACT_093].
If an adequate historical RHC is not available, a n eligibility RHC will be performed during 
Screening, preferably after the participant has satisfied all other criteria specified in 
Sections 5.1 and 5.2 . 
If the results of an adequate RHC do not meet study eligibility criteria, the participant will be 
screen failed.
If the RHC results meet study eligibility criteria AND all the other entry criteria are met, the 
participant will progress to Visit 2/Randomization (both cohorts) and the RHC results will 
count as baseline (Phase 2 C ohort).
Echocardiography
Participants who had a transthoracic D oppler echocardiogram p erform ed 
prior to Visit 1/Screening will have the test results reviewed by [CONTACT_486476]. If performed outside the 
180-day window or not available for review, the procedure will be performed during 
Screening. 
Considering the documented overlappi[INVESTIGATOR_486427], accurate PAH 
differential diagnosis remains a challenge and requires various invasive and non invasive
investigations. Simult aneously, pi[INVESTIGATOR_486428]. The precise identification of PAH clinical and 
hemodynamic phenotype in the overall PH population is fundamental to safe study conduct, 
given that pharmacological strategies being developed for treatment of PAH may be 
deleterious to non- PAH PH patients. As such, a Sponsor Concurrence process is warranted to 
ensure that key I/E crit eria for the study are met and that the selected population accurately 
reflects the PAH clinical and hemodynamic profile to be studied ( see “Sponsor Concurrence 
Process” section in the Study Operations Manual).
The sites are responsible for entering partic ipant data in the central database. This data will 
be reviewed by [CONTACT_51872]. Eligible participants will proceed to 
Visit 2/Randomization following completion of all screening procedures and Sponsor review 
and concurrence of key I/E criteria.
After completion of all screening procedures as specified in the SoA (Section 1.3), eligible 
participants will be provided instruction and be witnesse d in the administration of the 
investigational product using the placebo DPI. Participants will be re -instructed on 
CCI
CCI
CCI
08P53K
PRODUCT: MK-5475 94
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
appropriate inhalation administration technique as needed. See Section [IP_ADDRESS] for details. 
Participants who have completed or prematurely d iscontinued the Phase 2 Cohort are not 
eligible to participate in the Phase 3 Cohort .
8.11.3 Randomization
At Visit 2/Randomization (Day 1), eligibility for study participation will be reassessed to 
determine if participants continue to meet the I/E criteria and if, between Screening and 
Randomization, they experience devents that would exclude them for participating in the 
study, eg ,acutely decompensated right heart failure or changes in PAH -specific therapy.
Participants who meet all study entry criteria will b e randomized as follows :
1.Phase 2 Cohort
Participants in the Phase 2 Cohort Base Period will be assigned randomly in a 1:1:1:1 ratio to 
1 of 3 doses of MK- 5475 (380 µg, 1 00µg, or 32 µg) or a matching placebo, respectively, and 
will each be assigned a unique , cohort -specific randomization number .
At Visit 6 (Week 12), the participants who complete the Phase 2 Cohort Base Period, Visit 6 
assessments (including RHC ),and provide documented informed consent for the Extension 
Period will be re -randomized in the Extension Period according to their Base Period 
treatment assignment and will receive another unique, cohort -specific randomization number. 
The re -randomization probability is shown in Table 4 . 
Table 4 Participant Re -randomization Probability in the Phase 2 Cohort Extension 
Period 
Phase 2 Base Period 
Treatment GroupPhase 2 Extension Period 
Assigned Treatment GroupRe-randomization
Probability 
Placebo MK-5475   32 µg 1/3
Placebo MK-5475   100 µg 1/3
Placebo MK-5475   380 µg 1/3
MK-5475 32 µg MK-5475   32 µg 1
MK-5475 100 µg MK-5475   100 µg 1
MK-5475 380 µg MK-5475   380 µg 1
2.Phase 3 Cohort 
Participants in Phase 3 Cohort will be assigned random lyin a 1:1 ratio to MK -5475 or 
matching placebo and will each be assigned a unique , cohort -specific randomization number . 
For both c ohorts , at Visit 2/Randomization , blood samples for PK analysis should be 
collected before study intervention administration and after dosing (Section 8.6.1). Study 
intervention will be administered by [CONTACT_486477] a witnessed dose at the study site.
08P53K
PRODUCT: MK-5475 95
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
Visit 2 procedures should preferab ly be completed in 1 day. In special circumstances (eg, 
scheduling issues, repeat 6MWT), Visit 2 may be extended to 2days.
8.11.4 Treatment Period
Visit requirements are outlined in the SoAs (Section 1.3). Specific procedure -related details 
are provided in Sections 8.1 through 8.9. 
At all scheduled site visits from Visit 2/Day [ADDRESS_625127], the site will dispense (supported by 
[CONTACT_12067]) the appropriate numbe r of DPIs for study intervention administration until the next 
scheduled site visit.
For both c ohorts , Visit 6 (Week 12) is the last visit for the Base Period and the baseline visit 
for the Extension Period. If necessary, Visit [ADDRESS_625128] visit for the Base Period and the Baseline Visit for the Extension Period. At 
Visit 6, which may occur over multiple days , the participants will complete the Base Period 
study procedures (including RHC ),as scheduled and specified in the SoA, and a 
reevaluation of SpO 2and seated systolic BP. If the SpO 2andseated BP measurements satisfy 
the study eligibility criteria (Section 5.2), the consented participants will be re -randomized in 
the Extension Period (Section 8.11.3) on the last day of Visit 6 and will be given new 
participant ID cards, medication diarie s, and s tudy intervention (MK -5475 380 µg, 100 µg, 
or 32 µg). The first study intervention administration of the Extension P eriod will be 
unsupervised, on the day following the last day of Visit 6. Site staff will contact [CONTACT_2416] s by [CONTACT_486478] (+2days), to assess whether the participants are
experiencing any potential AEs. Participants in the Phase 2 Cohort Extension Period will 
receive study intervention every 6 weeks until Final Visit (Section [IP_ADDRESS]) .For participants 
already enrolled in the Phase 2 Cohort Extension Period, the transition to an every 6- week 
visit frequency will occur at Week 24 or at the next visit that falls on a 12 -week interval 
(eg,Week 36, 48, 60, and every 12 weeks thereafter through study complet ion).
2.Phase [ADDRESS_625129] visit for the Base Period and the Baseline Visit for the Extension Period. At 
Visit 6, the participants will complete the Base Period study procedures as scheduled and 
specified in the SoA and will be given medication diaries and s tudy intervention (MK -5475 
or placebo ) for the next 12weeks. Participants in the Phase 3 Cohort Extension Period will 
receive study intervention every 12 weeks until Final Visit (Section [IP_ADDRESS]) .
Participants in both cohorts will record i n their medication diary the date and time of 
investigational product administration as well as any comments related to the administration 
experience (eg, device issues). Participants will return their diary and used and unused DPIs 
at every scheduled site visit.
08P53K
PRODUCT: MK-5475 96
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
If, at any time during the study, aparticipant require sa reassessment of study -related clinical, 
functional, and/or analytical parameters (eg, 6MWD, WHO -FC), an unscheduled visit may 
occur. In the event of an unscheduled visit, vital signs, AEs, clinical events, and concomitant 
medication may be assessed, in addition to the procedure(s) that required reassessment.
Clinic in -person visit may be replaced by [CONTACT_756], video or home visit using a site staff or a 
nursing service if circumstance sdo not support an in- person site visit and after consultation 
with the Sponsor .
8.11.5 Participants Discontinued From Study Intervention but Continuing to be 
Monitored in the Study
All randomized participants should be followed through completion of the study, regardless 
of premature discontinuation of study intervention, unless the participant withdraws consent 
from any study follow -up. Participants who discontinue study intervention during the Phase 2 
Cohort Base Period should be followed through c ompletion of that study period (Visit 6). 
In both Phase 2 and Phase 3 Cohorts, if a participant is discontinued from the study 
intervention at any time before the completion of the study (or study period, for participants 
who discontinue during the Phase 2 Cohort Base Period), the participant will complete the 
Discontinuation Visit procedures at the time of discontinuation and a follow -up visit 14 days 
(+ 2 days) after the last dose of study intervention, as specified in the SoA (Section 1.3).
After the di scontinuation of study intervention, the site visits should continue to be 
performed at time points that correspond to each remaining study visit through the end of the 
study (or study period , for participants who discontinue during the Phase 2 Cohort Base
Period) .
If a participant is discontinued from the study intervention at any time during the Base 
Period of either cohort, the participant will return to the clinic at Week 12 and will 
complete all Visit 6 procedures , as scheduled and specified in the SoA (Section 1.3).
At each post -discontinuation visit (other than Week 12 visit), Phase [ADDRESS_625130] their vital signs ( pulse rate, BP, temperature , pulse oximetry, and respi[INVESTIGATOR_862])recorded and a review of AEs/SAEs. Participants who discontinue study 
intervention during the Extension Period on or before Week 24 will complete the 
WHO -FC assessment , the 6MWT, and NT -proBNP measurement, as specified in the SoA 
(Section 1.3), in addition to the review of AEs/SAEs and recording of their vit al signs 
(pulse rate, BP, temperature, pulse oximetry, and respi[INVESTIGATOR_697]).
At each post -discontinuation visit (other than Week 12 visit) , Phase 3 Cohort participants
will complete the WHO -FC assessment and 6MWT, as specified in the SoA 
(Section 1.3),in addition to the review of AEs/SAEs and recording of their vital signs 
(pulse rate, BP, temperature ,pulse oximetry, and respi[INVESTIGATOR_697] ).
Concomitant therapi[INVESTIGATOR_486429] (Section 5.2) while the part icipant was 
receiving study intervention are no longer prohibited starting [ADDRESS_625131]: MK-5475 97
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625132] 
information (eg, home telephone, work telephone, mobile telephone). Sites must document 
the outcome of the te lephone contact(s) to demonstrate diligent efforts have been made.
Additionally, the ICF will explain the importance of continued data collection from 
participants, including the use of continued contact [CONTACT_107461].
8.11.6 Final Visit
If applicable, participant s will continue study intervention until Week 12 (participants in 
Phase 2 Cohort Base Period) or until the Final Visit (participants in Phase 2 Cohort 
Extension Period and in Phase 3 Cohor t). For Phase [ADDRESS_625133] dose 
of study intervention (Visit 6/Week 12, for the participants in Phase 2 Cohort Base Period 
who do not enroll in the Extension Period, or Final Visit, for the participants in Phase 2 
Cohort Extension Period and the participants in Phase 3 Cohort) to determine if any A Es 
have occurred s ince the last clinic visit.
08P53K
PRODUCT: MK-5475 98
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
9 STATISTICAL ANALYSIS PLAN
This section outlines the statistical analysis strategy and procedures for the study. If, after the 
study has begun, but prior to any unblinding, changes are made to primary and/or key 
secondary hypothe ses, or the statistical methods related to those hypotheses, the protocol will 
be amended (consistent with ICH Guideline E -9). Changes to exploratory or other non -
confirmatory analyses made after the protocol has been finalized, but prior to final database
lock, will be documented in a supplemental SAP (sSAP) and referenced in the Clinical Study 
Report (CSR) for the study. Post hoc exploratory analyses will be clearly identified in the 
CSR.
Other planned analyses (ie, those specific to the analysis of PK data and future biomedical 
research ) are beyond the scope of this document.
In this operationally seamless adaptive Phase 2/3 study, all statistical analyses will be 
separated to address the primary/secondary/exploratory objectives in the Phase 2 Cohort and 
the Phase 3 Cohort independently. The dose of MK- 5475 used in the Phase 3 Cohort will be 
determined based on the analysis of data collected in the Phase 2 Cohort Base Period. 
9.1 Statistical A nalysis Plan Summary
Key elements of the statistical analysis plan are summarized below; the comprehensive plan 
is provided in Sections 9.2 through 9.12.  
Phase 2 Cohort
Study Design Overview
Treatment Assignment Base Period: Participants ( approximately 41 /group) will be 
randomized in a 1:1:1:1 ratio among 4treatment groups: 
1)MK-5475 380 µg
2)MK-5475 100 µg
3)MK-5475 32 µg
4)placebo matching MK -5475
Extension Period: Participants inthe 3 active treatment groups
in the Base Period will initially maint ain the same treatment 
assignment in the Extension Period ;participants who received 
placebo during the Base Period will initially be random ized in a 
1:1:1 ratio among the 3 treatment groups: 
1)MK-5475 380 µg
2)MK-5475 100 µg
3)MK-5475 32 µg
After the Phase 3 dose is selected, all participants in the Phase 2 
Cohort Extension will receive the selected Phase 3 dose 
regardless of their randomized treatment group.
Analysis Populations Efficacy: FAS
Safety: APaT
08P53K
PRODUCT: MK-5475 99
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
Primary Endpoint Percent Change from baseline in PVR at Week 12 
Key Secondary Endpoints N/A
Statistical Methods for Key Efficacy 
AnalysesThe differences ( each MK-5475 dose minus placebo ) in percent 
change from baseline and the associated 95% CIsand p-values 
will be provided based on a robust regression model. Missing 
PVR observations at Week 12 from participants in all treatment 
groups will be imputed based on the observed PVR observati ons
at Week 12 from the placebo group .
Statistical Methods for Key Safety 
AnalysesFor analyses in which 95% CIs will be provided for between -
treatment differences ( each MK-5475 dose minus placebo ) in 
the percentage of participants with events, these anal yses will be 
performed using the M&N method.
Interim Analyses One interim analysis is planned when  
 have completed or discontinued the Phase 2 
Cohort Base Period. The purpose of the IA is to allow an early 
stop for Phase 2 Cohort Base Period for efficacy (including 
selection of the Phase 3 dose) or to stop the study for futility.
Results will be reviewed by [CONTACT_140245].
The primary analysis of efficacy data from the Phase [ADDRESS_625134] completed 
(or discontinued prior to the end of )the Base Pe riod. Although 
the Phase 2 Cohort can continue in the study (in the Extension 
Period ), the Base Period analysis is not considered an interim 
analysis.
Multiplicity There are 3treatment group comparisons that may be tested to 
address the primary hypothesi s. Testing will be done in a 
sequential manner in descending order of MK- 5475 randomized 
dose group ,stoppi[INVESTIGATOR_486430].
Sample Size and Power The planned sample size is approximately 164 participants. For 
the percent change from baseline in PVR at Week 12, the study 
has 85% power to demonstrate that MK- 5475 380 µg is superior 
to placebo group at an overall one-sided 2.5% alpha level.
CCI
08P53K
PRODUCT: MK-5475 100
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
Phase 3 Cohort
Study Design Overview
Treatment Assignment Participants ( approximately 143/group ) will be randomized in a 
1:1 ratio between 2treatment groups: 
1)MK-5475
2)placebo matching MK -5475
Analysis Populations Efficacy: FAS
Safety: APaT
Primary Endpoint Change from baseline in 6MWD at Week 12 
Key Secondary Endpoints N/A
Statistical Methods for Key Efficacy 
AnalysesThe difference (MK -5475 minus placebo) in change from 
baseline and the associated 95% CIand p-value will be 
provided based on a robust regression model. Missing 6MWD
observations at Week 12 from participants in both treatment 
groups will be imputed based on the observed 6MWD
observation sat Week 12 from the placebo group .
Statistical Methods for Key Safety 
AnalysesFor analyses in which 95% CIs will be provided for between -
treatment differences (MK -5475 minus placebo ) in the 
percentage of participants with events, these analyses will be 
performed using the M&N method.
Interim Analyses No interim analyses are planned. ( The primary analysis of 
efficacy data from the Phase [ADDRESS_625135] complete d [or discontinued prior 
to the end of ]the B ase Period. Although the Phase 3 Cohort will 
continue in the study [in the E xtension P eriod ], the B ase Period 
analysis is not considered an interim analysis. )
Multiplicity As there is a single hypothesis test involving a single endpoint 
and a single between -treatment comparison, no multiplicity 
adjustment is required.
Sample Size and Power The planned sample size is approximately 286participants. For 
the change from baseline in 6MWD at Week 12, the study has 
90% power to demonstrate that MK -5475 is superior to placebo 
group at a one -sided 2.5 % alpha level.
9.2 Responsibility for Analyses/In -house Blinding
The statistical analysis of the data obtained from this study will be the responsibility of the 
Clinical Biostatistics department of the Sponsor.
This study (both cohorts, B ase and Extension P eriods) will be conducted as a double -blind 
study under in -house blinding procedures. At the end of each Base Period of the study, a 
copy of the database will be frozen after medical/scientific review has been completed and 
data from the B ase Period have been declared final and complete. The study team will be 
unblinded to perform and review the full analysis of data from the Base Period as well as 
author a CSR. A separate, blinded Sponsor team (ie, blinded to participant -level treatment 
08P53K
PRODUCT: MK-5475 101
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
assignment) will then be assigned to continue the conduct of each Extension Period. All 
personnel w ho are unblinded for each Base Period data analysis will be excluded from any 
future data review at the individual participant level. For the purpose of the final analysis, the 
official clinical database will not be unblinded until medical/scientific review has been 
completed and data have been declared final and complete.  
Results of this study will be presented in 4 separate reports based on DBLs : 
1.At the end of the Phase 2 Base Period for Phase 2Cohort primary analysis
2.At the end of the Phase 2 Extension Period for the Phase 2 C ohort final analysis
3.At the end of the Phase 3 Base Period for the Phase 3 Cohort primary analysis 
4.At the end of the Phase 3 Extension Period for the Phase 3 Cohort final analysis
The Sponsor will generate the randomized allocation schedules for study intervention 
assignment for this protocol, and the randomization will be implemented in the interactive 
voice response system.
Blinding issues related to the analyses to be conducted while the study is still ongoing are 
described in Section 9.7.  
9.3 Hypotheses/Estimation
Objectives and hypothesis of the Phase 2 Cohort and Phase 3 Cohort are stated in Section 3
separately.
9.4 Analysis Endpoints
9.4.1 Phase 2 Cohort Efficacy Endpoints
Primary Efficacy Endpoint
Mean percent c hange from baseline in PVR at Week 12
Secondary Efficacy Endpoints
Mean change from baseline in 6MWD at Week 12
Mean change from baseline in selected hemodynamic parameters at Week [ADDRESS_625136]: MK-5475 102
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
9.4.2 Phase 3 Cohort Efficacy Endpoints
Primary Efficacy Endpoint
Mean change from baseline in 6MWD at Week 12
Secondary Efficacy Endpoint
Mean change from baseline in 6MWD at Week 24
Proportion of participants whose WHO -FC is not worse at Week 12 relative to baseline
9.4.3 Safety Endpoints 
Safety parameters are described in Section [IP_ADDRESS]
CCI
CCI
08P53K
PRODUCT: MK-5475 103
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
Safety and tolerability will be assessed by [CONTACT_113824], vital signs , laboratory safety tests and pulmonary function tests .
9.4.4 Derivations of Efficacy Endpoints 
Computational details for selected efficacy endpoints in Sectio ns9.4.1 and 9.4.2 are provided 
below:



PAH -related mortality TTCW is defined as the time from randomization to the first 
occurrence of PAH- related death, PAH -related hospi[INVESTIGATOR_059], or disease progression.
All-cause mortality TTCW is defined as the time from randomization to the first 
occurrence of all-cause death, PAH -related hospi[INVESTIGATOR_059], or disease progression.
LPH physical dimension score = sum of scores from the questions 2, 3, 4, 5, 6, 7, 12, 13
in the LPH q uestionnaire (each scored 0 to 5 allowing a score in the range of 0 to 40) 
[Bonner, N., et al 2013] .
LPH total score = sum of all scores from the 21 questions in the LPH q uestionnaire (each 
scored 0 to 5 allowing a total score in the range of 0 to 105) [Bonner, N., et al 2013] .
9.[ADDRESS_625137] 1 observation 
(baseline or post- baseline) . Participants will be included in the treatment group to which they 
are randomized.
9.5.[ADDRESS_625138]: MK-5475 104
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625139] study treatment for the 
entire treatment period; such participants will be incl uded in the treatment group 
corresponding to the study treatment actually received.
At least [ADDRESS_625140] 1 dose 
of study treatment is required for inclusion in the analysis of the respective safety parameter. 
To assess change from baseline, a baseline measurement is also required.
9.6 Statistical Methods
Statistical testing and inference for safety analyses are described in Sec tion9.6.2. Efficacy 
results that will be deemed to be statistically significant after consideration of the Type I 
error control strategy are described in Section 9.8. Nominal p-values for secondary endpoints 
may be provided as an assessment of strength of evidence without intent to make inferential 
claims. A ll statistical tests will be conducted at the α=0.0 25(one-sided) level.
For analysis purposes, the baseline assessment is considered the one closest to but before or 
on the day of randomization (Day 1).
9.6.1 Statistical Methods for Efficacy Analyses
This section describes the statistical methods that address the primary and secondary 
objectives. Methods related to the exploratory objectives will be described in the sSAP.
Efficacy analyses of the Phase 2 Cohort and the Phase 3 Cohort will be performed separately.
The analyses at the end of the Extension Period will include data collected in both the Base 
and Extension Period of each study cohort. No statistical comparisons will be made for either 
Extension Period.
[IP_ADDRESS] Phase [ADDRESS_625141] is Week 24. Summary statistics will be provided for 
every planned data collection timepoint described in the SoA (Section 1.3). 
Primary Endpoint
Following the ICH E9 (R1) guidance [European Medicines Agency 2020] , The primary 
estimand for the primary obj ective used for the Phase 2 Cohort contains 5 attributes:
The treatment condition of interest is MK -[ADDRESS_625142]: MK-5475 105
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
The population of participants targeted by [CONTACT_486479]/female 
participants with PAH between the ages of 18 and 75 years (inclusive).
The variable to address the clinical question is PVR at Week 12.
The following are intercurrent events, along with the approaches to handle them:
oDeath: hypothetical strategy to evaluate PVR at Week 12 as though death would not 
occur.
oTreatment discontinuation: treatment policy strategy seeking to use every 
participant’s actual Week 12 value, regardless of whether they are still taking study 
medication.
The approach to handling missing data for these intercurrent events is described 
below.
The population- level summary is mean percent change from baseline in PVR at Week 12. 
For this estimand, the primary approach will use a robust regression method to addre ss the 
primary hypothesis. Robust regression method will be used because percent change from 
baseline in PVR is not expected to follow a normal distribution, based on other Phase [ADDRESS_625143] used non- parametric methods for analyzing PVR [Simonneau, G., 
et al 2012] [Ghofrani, H. A., et al 2010] . The robust regression model will include terms for 
treatment and WHO -FC (Class II and Class III/IV). Missing PVR observations at Week [ADDRESS_625144] outcome among all observed data. Missing data due to 
treatment discontinuation will be imputed based on the observed PVR observations at Week 
12 from the placebo group referred as J2R (detailed below). If there are missing Week 12 
data for other reasons, J2R will also be used. The randomization seed for imputations will be 
5475007.
The difference (MK -5475 minus placebo) in percent change f rom baseline and the associated 
95% CI and p-value will be provided. A p -value for the comparison of MK -5475 versus 
placebo < 0.025 (one-sided) will be considered statistically significant contingent upon the 
multiplicity strategy (Section 9. 8).  
The follo wing steps will be taken to perform the primary analysis, including imputation for 
missing data. Percent change from baseline in PVR at Week 12 is the response variable:
1.Define imputation model for different missingness patterns:
a.Obtain the worst outcome a mong all observed data.
b.Within the placebo group, for participants with both baseline and Week 12 data, fit an 
ANCOVA model including terms for treatment and WHO -FC (Class II and 
Class III/IV). 
08P53K
PRODUCT: MK-5475 106
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
2.Impute missing data for different missingness patterns:
a.Death : for participants (in both treatment groups) who died before Week 12, the worst 
outcome among all observed data will be used to impute the missing Week 12 values. 
b.Reasons other than death: For participants (in both treatment groups) missing the 
response variable, the fitted model in Step [ADDRESS_625145] regression based on a Huber -type M estimator [Huber, P. J. 1973] will be 
performed for the imputed dataset. The model will include terms for treatment and 
WHO -FC (Class II and Class III/IV). 
4.Steps [ADDRESS_625146]: MK-5475 107
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
Section 9.4.1. Table 5 summarizes the analysis strategy for efficacy endpoints in the Phase 2 
Cohort.
Table 5 Analysis Strategy for P rimary and Secondary Efficacy Endpoints in the Phase 
2 Cohort
EndpointType Statistical 
MethodAnalysis 
PopulationMissing Data 
Approach
Primary Endpoint
Percent Change from baseline in PVR at 
Week 12P
Sen
SenRR
RR
RRFAS
FAS
FASPMM -J2R
PMM -Tippi[INVESTIGATOR_486431] -Washout
Secondary Endpoints
Change from baseline in 6MWD at Week 
12P RR FAS PMM -J2R
Change from baseline in selected 
hemodynamic parameters at Week 12P SS FAS N/A
6MWD=6 -minute walk distance; FAS=full analysis set; J2R=jump -to-reference; N/A=not applicable; P=Primary; 
PMM=pattern mixture model; PVR=pulmonary vascular resistance; RR=robust regression; Sen=Sensitivity; 
SS=summary statistics.
[IP_ADDRESS] Phase [ADDRESS_625147] is Week 24. Summary statistics will be provided for 
every planned data collection timepoi nt described in the SoA (Section 1.3).  
Primary Endpoint
The primary estimand for the primary objective used for the Phase 3 Cohort contains 
5attributes:
The treatment condition of interest is MK -5475 or matching placebo on background 
stable concomitant PAH -specific therapy, as defined in Section 5.1. 
The population of participants targeted by [CONTACT_486479]/female 
participants with PAH between the ages of 18 and 75 years (inclusive).
The variable to address the clinical question is 6MWD at Week 12.
The following are intercurrent events, along with the approaches to handle them:
oDeath: hypothetical strategy to evaluate 6MWD at Week [ADDRESS_625148]: MK-5475 108
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
oTreatment discontinuation: treatment policy strategy seeking to use every 
participant’s actual Week 12 value, regardless of whether they are still taking study 
medication.
The approach to handling missing data for these intercurrent events is described 
below.
The population- level summary is mean change from baseline in 6MWD at Week 12.
For this estimand, the primary approach will use a robust regression method to address the 
primary hypothesis. Robust regression method will be used because change from baseline in 
6MWD is not expected to follow a normal distribution, based on other Phase [ADDRESS_625149] used non -parametric methods for analyzing 6MWD [Rubin, L. J., et al 2002] 
[Rubin, L. J., et al 2015] . The robust regression model will include a term for treatm ent and 
WHO -FC (Class II and Class III/IV). Missing 6MWD observations at Week [ADDRESS_625150] outcome among all observed data. Missing data due 
to treatment discontinuation will be imputed based on the observed 6MWD observations at 
Week 12 from the placebo group referred as J2R (detailed below). If there are missing Week 
12 data for other reasons, J2R will also be used. The randomizatio n seed for imputations will 
be 5475007. 
The difference in change from baseline and the associated 95% CI and p-value will be 
provided (MK- [ADDRESS_625151] bo). A p-value for the comparison of MK -5475 versus 
placebo < 0.025 (one-sided) will be considered statistically significant .  
The following steps will be taken to perform the primary analysis, including imputation for 
missing data. Percent change from baseline in 6MWD at Week 12 is the response variable:
1.Define imputation model for different missingness patterns:
a.Obtain the worst outcome among all observed data. 
b.Within the placebo group, for participants with both baseline and Week 12 endpoint, 
an MMRM model including terms for treatment and WHO -FC (Class II and 
Class III/IV) will be fit. 
2.The same procedure in Steps 2 through 6 described in Section [IP_ADDRESS] will be used for 
analysis.  
Two sensitivity analyses of the estimand for change from baseline in 6MWD will be 
performed to assess the impact of missing data imputation. Within t he same PMM structure 
in the primary analysis, for missing data due to reasons other than death, 1 analysis will use a 
tippi[INVESTIGATOR_486432]. The analysis approaches are the sam e as in the 2 sensitivity analyses described in 
Section [IP_ADDRESS] except the missing data due to reasons other than death will be imputed by 
[CONTACT_486480]. 
08P53K
PRODUCT: MK-5475 109
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625152] regression method in Section 9.6.1. 1. Summary statistics will be 
provided for the p roportion of participants whose WHO- FC is not worse at Week 12 relative 
to baseline .Table 6 summarizes the analysis strategy for efficacy endpoints in the Phase 3 
Cohort. 
Table 6 Analysis Strategy for Primary and Secondary Efficacy Endpoints in the Phase 
3 Cohort
EndpointType Statistical 
MethodAnalysis 
PopulationMissing Data 
Approach
Primary Endpoint
Change from baseline in 6MWD at 
Week 12P
Sen
SenRR
RR
RRFAS
FAS
FASPMM -J2R
PMM -Tippi[INVESTIGATOR_486431] -Washout
Secondary Endpoints
Change from baseline in 6MWD at 
Week 24
Proportion of participants whose WHO 
functional class does not worsen at 
Week 12 relative to baseline.P
PRR
SSFAS
FASPMM -J2R
N/A
6MWD=6 -minute walk distance; FAS=full analysis set; J2R=jump -to-reference; N/A=not applicable; P=Primary; 
PMM=pattern mixture model; RR=robust regression; Sen=Sensitivity; SS=summary statistics; WHO=World Health 
Organization.
9.6.[ADDRESS_625153] 
dose of study medication. All safety endpoints will be analyzed for the time frame consisting 
of the treatment period + [ADDRESS_625154]: MK-5475 110
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625155] MedDRA and grouped according to SOC .
[IP_ADDRESS] Overall Safety Assessment 
The overall safety evaluation will include a summar y by [CONTACT_486481], drug -related AE, SAE, and drug-related 
SAE, as well as who discontinued from study intervention due to an AE and who had an AE 
resulting in death. Point estimates and 95% CIs for the differences between treatment groups 
in the percentages of participants with these events will be p rovided.
The number and percentage of participants with specific AEs will also be provided. Point 
estimates and 95% CIs for the differences between treatment groups in the percentages of 
participants with specific AEs will be provided for AEs that occur in at least 4 participants in 
any treatment group. This threshold for the numbers of events was chosen because the 95% 
CI for the between -group difference in percent incidence will always include zero when 
fewer participants per group have events and thus wo uld add little to the interpretation of 
potentially meaningful differences.
Point estimates and 95% CIs will be provided for the percentage of participants with safety 
parameters that meet predefined limits of change based on the same criteria used above f or 
the specific AEs.
CIs for between -treatment group differences will be provided using the Miettinen and 
Nurminen (M&N) method [Miettinen, O. and Nurminen, M. 1985] . These CIswill not be 
adjusted for multiplic ity and should be regarded only as helpful descriptive measures for the 
review of the safety profile and not as a formal method for assessing statistical significance 
of between -group differences. Rainfall plots with point estimates and 95% CIs will be 
displayed for AEs that occur in at least [ADDRESS_625156] will be summarized by [CONTACT_486482]. Point estimates and 95% CIs for between-
group differences will be provided based on the criteria described above for specific AEs. 
A summary of the analysis strategy for safety parameters is provided in Table 7.
08P53K
PRODUCT: MK-5475 111
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
Table 7 Analysis Strategy for Safety Parameters
Analysis Part Safety EndpointDescriptive 
Statistics95% 
Between -
group CIaGraphical 
Displaya
Overall Safety 
AssessmentAny AE X X
Any serious AE X X
Any drug- related AE X X
Any serious and drug- related AE X X
Discontinuation due to AE X X
Death X X
SOCs, PDLCs (incidence ≥4of 
participants in any treatment 
groups)X X
Specific AEs (incidence ≥4of 
participants in any treatment 
groups)X X X
Specific AEs, SOCs, PDLCs
(incidence <4of participants in 
any treatment groups)X
Change from Baseline results 
(laboratory tests, ECGs, vital 
signs)X
Safety Topi[INVESTIGATOR_486433] X X
AE=adverse event; CI=confidence interval; ECGs=electrocardiograms; PDLC=predefined limit of change; 
SOC=system organ class; X=results will be provided.
a95% between -group CI and graphical display will not be provided for the analysis of the Phase 2 Cohort 
Extension Period.
9.6.3 Summaries of Demographic and Baseline Characteristics
The comparability of the treatment groups for each relevant demographic and baseline 
characteristic will be assessed separately for each cohort by [CONTACT_113827]/or graphs. 
No statistical hypothesis tests wil l be performed on these characteristics. The number and 
percentage of participants screened and randomized and the primary reasons for screening 
failure and discontinuation will be displayed. Demographic variables (eg, age) , baseline 
characteristics, prima ry and secondary diagnoses, and prior and concomitant therapi[INVESTIGATOR_486434].
For analysis purposes, the baseline assessment is considered the one closest to but before or 
on the day of randomization (Day 1).
08P53K
PRODUCT: MK-5475 112
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
9.7 Interim Analyses
Analyses of data to be performed while the study is in progress are described below. 
The O'Brien –Fleming alpha -spending function [Lan, K. K . G. and DeMets, D. L. 1983] will 
be used for the efficacy IA to assess the superiority of MK -5475 versus placebo. The 
spending function can be expressed as
where ‘t’ denotes the percentage of information included at the IA, and ‘Ф’ denotes the 
standa rd normal cumulative distribution function.
With this alpha spending approach, the cumulative significance level will be approximately 
 (one -sided) at the IA and  at the final analysis of the Phase 2 Cohort Base Period, 
respectively. This testing approach controls the one -sided alpha between the efficacy IA and 
final analysis at 0.025. The operating characteristics for the interim efficacy analysis are 
shown in Table 8 .
Table 8 Power to Demonstrate Superiority of MK -5475 vs placebo on the Primary 
Endpoint of % Change in PVR in Phase 2 Cohort Base Period at the Interim Analysis
Analysis timepoint Cumulative α Spent 
(one-sided)Power (%) for Various True Effect Sizes
-30% -35% -40% -45% -50%
 59.5 75.0 86.7 93.9 97.6
IA=interim analysis ; PVR= pulmonary vascular resistance .
 
 
CCI
CCI
CCI
CCI
CCI
CC
I
CCI
08P53K
PRODUCT: MK-5475 113
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
 
 
 
Study enrollment will not be paused while the IA is being conducted. Blinding to treatment 
assignment will be maintained at all investigational sites. Participant -level unblinding will be 
restricted to an internal unblinded statistician and a scientific programmer performing the IA. 
Treatment -level results and/or participant -level data from the IA will be provided by [CONTACT_151564]. Limited additional Sponsor personnel may be unblinded 
to the treatment -level results of the IA, if required, to act on the recommendations of the 
eDMC. The processes by [CONTACT_486483]. Before final study unblinding, 
individuals who have been unblinded at a ny level will not be involved in any discussions 
regarding modifications to the protocol, statistical methods, identification of protocol 
deviations, or data validation efforts after the IA. The results of the IA will not be shared 
with the investigators b efore completion of the Phase 2 Cohort.
Phase 2 Cohort Base Period
If the IA is cancelled, a t the end of the Phase 2 Cohort Base Period, selected members of the 
Sponsor study team and management will be unblinded to comprehensive results from the 
Phase 2 C ohort Base Period to evaluate the efficacy and safety profile of MK -5475 for 
selecting a dose for the Phase 3 Cohort. The MCP -Mod method [Center for Drug Evaluation 
and Research 2015] may be used to support the finding of a suitable dose for Phase [ADDRESS_625157]: MK-5475 114
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625158] will not be unblinde d. 
Data Monitoring Committee 
To supplement the routine trial monitoring outlined in this study, an external DMC will 
monitor the interim data. The DMC will not be invo lved in the dose selection decision. More 
details are described in Section [IP_ADDRESS].
9.8 Multiplicity
Multiplicity for the Phase 2 Cohort and the Phase 3 Cohort will be considered separately in 
this operationally seamless adaptive design study.
Phase 2 Cohort
For the Phase 2 Cohort Base Period, t here are 3 treatment group comparisons that may be 
tested to address the primary hypothesis. Testing will be done in a sequential manner in 
descending order of MK -5475 randomized dose group, stoppi[INVESTIGATOR_486435]. 
The multiplicity strategy strongly controls the Type I error at 2.5% ( one-sided) to address the 
primary hypothesis.
Phase [ADDRESS_625159] been 
performed separately in this operationally seamless adaptive design study.
9.9.1 Efficacy
Phase 2 Cohort
The study design assumptions are based on results from other Phase 2 clinical trials in the 
literature for PAH participants with similar design. In the Phase 2 study assessing selexipag, 
the observed mean percent change from baseline PVR was 33% with standard deviation 0.34, 
08P53K
PRODUCT: MK-5475 115
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
and the overall study completion rate was 91% [Simonneau, G., et al 2012] . Comparable 
results were reported in a Phase 2 study assessing riociguat [Ghofrani, H. A., et al 2010] . 
Through [ADDRESS_625160] -randomization, drop- out is expected to be approximately 10% in 
each treatment group. However, based on the approach to missing data, all randomized 
participants per grou p are expected to be included in the primary analysis and are the basis 
for sample size and power calculations, accounting for imputation of missing data. 
Power and sample size are based on the percent change from baseline in PVR at Week 12. 
Assuming the true percent change from baseline in PVR at Week 12 is -30% for each 
MK-5475 dose versus 0% for placebo, the assumed percent change from baseline in PVR at 
Week 12 using J2R to impute missing data would be 27% for each MK- 5475 dose versus 0% 
for placebo. The assumed standard deviation of the difference of percent change from 
baseline in PVR at Week [ADDRESS_625161] deviation, a sample size of 41/group provides more 
than 85% power (ap proximately 86.4%) to demonstrate superiority for each of the MK -5475 
treatment comparisons using a one -sided alpha=0.025. 
With respect to the secondary endpoint of change from baseline in 6MWD at Week 12, a 
sample size of 41/group will provide ahalf-width of the 95% CI to be [ADDRESS_625162] deviation of the change from baseline in 6MWD is 70.
Phase 3 Cohort
The study design assumptions are based on results from Phase 3 PAH clinical studies in the 
literature with similar design [Ghofrani, H. A., et al 2013] [Galie, N., et al 2008] [Galie, N., 
etal 2005] [Rubin, L. J., et al 2002] . A clinically relevant increase in 6MWD (>30 meters)
correlates with improved clinical outcomes in PAH (Section [IP_ADDRESS]).
Through [ADDRESS_625163] -randomization, drop- out is expected to be approximately 10% in 
each treatme nt group. However, based on the approach to missing data, all randomized 
participants per group are expected to be included in the primary analysis and are the basis 
for sample size and power calculations, accounting for imputation of missing data. 
Power and sample size are based on the change from baseline in 6MWD at Week 12. 
Assuming the true change from baseline in 6MWD at Week [ADDRESS_625164] de viation, a sample size of 143/group provides 90% power to demonstrate
superiority for each of the MK -5475 treatment comparisons using a one -sided alpha=0.025. 
9.[ADDRESS_625165]: MK-5475 116
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625166] (with a nominal 95% CI) for the pr imary 
endpoint will be estimated and plotted within each category of each subgroup. The following 
are examples of classification variables (the subgroup categories will be defined in the sSAP 
and other subgroups may be defined and described in the sSAP) :
Age 
Sex 
PAH subtypes 
Number of background PAH -specific therapi[INVESTIGATOR_014] 
Type of background PAH -specific therapy
6MWD at baseline 
PVR at baseline (Phase 2 Cohort only)
9.11 Compliance (Medication Adherence)
Analyses for the Phase [ADDRESS_625167]: MK-5475 117
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.[ADDRESS_625168] for Interventional Clinical Trials
[COMPANY_006] Sharp & Dohme LLC, Rahway, NJ, [LOCATION_003] (MSD)
I.Introduction
A.Purpose
[COMPANY_006] Sharp & Dohme LLC, Rahway, NJ, [LOCATION_003] (MSD), through its subsidiaries, 
conducts clin ical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, planning, conducting, analyzing, 
and reporting these trials in compliance with the highest ethical and scientific 
standards. Protection of participants in clinical trials is the overriding concern in the 
design and conduct of clinical trials. In all cases, MSD clinical trials will be 
conducted in compliance with MSD’s global standards, local and/or national 
regulations (including all appli cable data protection laws and regulations), and 
International Council for Harmonisation Good Clinical Practice (ICH GCP) E6 and 
ICH General Considerations for Clinical Studies E8, and in accordance with the 
ethical principles that have their origin in the Declaration of Helsinki.
B.Scope
Highest ethical and scientific standards shall be endorsed for all clinical 
interventional investigations sponsored by [CONTACT_19481] (parties) 
employed for their execution (e.g., contract research organiza tions, collaborative 
research efforts). This Code is not intended to apply to trials that are observational in 
nature, or which are retrospective. Further, this Code does not apply to investigator -
initiated trials, which are not under the full control of M SD.
II.Scientific Issues
A.Trial Conduct
1.Trial Design
Except for pi[INVESTIGATOR_19354], clinical trial protocols will be hypothesis -
driven to assess safety, efficacy, and/or pharmacokinetic or pharmacodynamic 
indices of MSD or comparator products. Alternatively, MSD may conduct 
outcomes research trials, trials to assess or validate various endpoint measures, or 
trials to determine patient preferences, etc.
The design (i.e., participant population, duration, statistical power) mu st be 
adequate to address the specific purpose of the trial and shall respect the data 
protection rights of all participants, trial site staff and, where applicable, third 
parties. Input may be considered from a broad range of stakeholders, including 
patient advocacy groups/patients representing the trial population, caregivers, and 
healthcare providers to ensure operational feasibility. Trial design also includes 
08P53K
PRODUCT: MK-5475 118
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625169] meet 
protocol entry criteria to be enrolled in the trial.
2.Site Selection
MSD’s clinical trials are conducted globally in many different countries and in 
diverse populations, including people of varying age, race, ethnicity, gender, and 
accounting for other potential disease related f actors. MSD selects investigative 
sites based on medical expert[INVESTIGATOR_18700], access to appropriate participants, adequacy of 
facilities and staff, previous performance in clinical trials, as well as budgetary 
considerations. Prior to trial initiation, sites are eva luated by [CONTACT_26397] (or 
individuals acting on behalf of MSD) to assess the ability to successfully conduct 
the trial. Individuals involved in trial conduct receive training commensurate with 
their role prior to their becoming involved in the trial.
Whe re appropriate, and in accordance with regulatory authority guidance, MSD 
will make concerted efforts to raise awareness of clinical trial opportunities in 
various communities. MSD will seek to engage underrepresented groups and 
those disproportionately im pacted by [CONTACT_26398]. MSD will support 
clinical trial investigators to enroll underrepresented groups and expand access to 
those who will ultimately use the products under investigation.
3.Site Monitoring/Scientific Integrity
Investigative tr ial sites are monitored to assess compliance with the trial protocol 
and Good Clinical Practice (GCP). MSD reviews clinical data for accuracy, 
completeness, and consistency. Data are verified versus source documentation 
according to standard operating proc edures. Per MSD policies and procedures, if 
potential fraud, scientific/research misconduct, privacy incidents/breaches or 
Clinical Trial -related Significant Quality Issues are reported, such matters are 
investigated. When necessary, appropriate corrective and/or preventative actions 
are defined and regulatory authorities and/or ethics review committees are 
notified.
B.Publication and Authorship
Regardless of trial outcome, MSD commits to publish the primary and secondary 
results of its registered trials o f marketed products in which treatment is assigned, 
according to the pre -specified plans for data analysis. To the extent scientifically 
appropriate, MSD seeks to publish the results of other analyses it conducts that are 
important to patients, physicians, and payers. Some early phase or pi[INVESTIGATOR_326633]; in such cases, 
publication of results may not be appropriate since the trial may be underpowered and 
the analyses complicated by [CONTACT_486484].
08P53K
PRODUCT: MK-5475 119
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
MSD’s policy on authorship is consistent with the recommendations published by [CONTACT_19483] (ICMJE). In summary, 
authorship should reflect significant contribution to the design and conduct of the 
trial, performance or interpretation of the analysis, and/or writing of the manuscript. 
All named authors must be able to defend the trial results and conclusions. MSD 
funding of a trial will be acknowledged in publications.
III.Participan t Protection
A.Regulatory Authority and Ethics Committee Review (Institutional Review Board 
[IRB]/Independent Ethics Committee [IEC])
All protocols and protocol amendments will be submitted by [CONTACT_113833]/authorization prior to implementation of the trial or amendment, 
in compliance with local and/or national regulations.
The protocol, protocol amendment(s), informed consent form, investigator’s 
brochure, and other relevant trial documents must be reviewed and approved by [CONTACT_113834]/IEC before being implemented at each site, in compliance with local and/or 
national regulations and ICH Guidelines. Changes to the protocol that are required 
urgently to eliminate an immediate hazard and to protect participant safety may be 
enacted in ant icipation of ethics committee approval. MSD will inform regulatory 
authorities of such new measures to protect participant safety, in compliance with 
local and/or national regulations.
B.Safety
The guiding principle in decision -making in clinical trials i s that participant welfare is 
of primary importance. Potential participants will be informed of the risks and 
benefits of, as well as alternatives to, trial participation. At a minimum, trial designs 
will take into account the local standard of care.
All participation in MSD clinical trials is voluntary. Participants enter the trial only 
after informed consent is obtained. Trial designs include procedures and systems for 
the identification, monitoring, and reporting of safety concerns. Participants may 
withdraw from an MSD trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
During trial planning, the need for an independent Data Monitoring Committee 
(DMC) is assessed. DMC review of data accumulated during the conduct of the trial 
is integral to the well -being of trial participants.
C.Confidentiality
MSD is committed to safeguarding participant confidentiality, to the greatest extent 
possible, as well as all applicable data protection rights. Unless required by [CONTACT_2371], only 
the investigator, Sponsor (or individuals acting on behalf of MSD), ethics committee, 
and/or regulatory authorities will have access to confidential medical records that 
might identify the participant by [CONTACT_2300] .
08P53K
PRODUCT: MK-5475 120
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
D.Genomic Research
Genomic research will only be conducted in accordance with a protocol and informed 
consent authorized by [CONTACT_19486].
E.Trial Results
At the time of providing informed consent and in accordance with local laws and 
regulations, participants should be informed about the plans for availability of trial 
results.
IV.Financial Considerations
A.Payments to Investigators
Clinical trials are time -and labor -intensive. It is MSD’s policy to compensate 
investigators (or the sponsoring institution) in a fair manner for the work performed 
in support of MSD trials. MSD does not pay incentives to enroll participants in its 
trials. However, when enrollment is particularly challenging, additional payments 
may be made to compensate for the time spent in extra recruiting efforts.
MSD does not pay for participant referrals. However, MSD may compensate 
referring physicians for time spent on medical record review and medical evaluation 
to identify potentially eligible participants.
B.Clinical Research Funding
Informed consent forms will disclose that the trial is sponsored by [CONTACT_19487], and that the 
investigator or sponsoring institution is being paid or provided a grant for performing 
the trial. However, the local ethics committee may wish to alter the wording of the 
disclosure statement to be consistent with financial practices at that institution. As 
noted above, all publications resulting from MSD trials will indicate MSD as a source 
of funding.
C.Funding for Travel and Other Requests
Fund ing of travel by [CONTACT_19488] (e.g., to scientific meetings, 
investigator meetings, etc) will be consistent with local guidelines and practices.
V.Investigator Commitment
Investigators will be expected to review MSD’s Code of Conduct as an appendix to the 
trial protocol, and in signing the protocol, agree to support these ethical and scientific 
standards.
10.1.2 Financial Disclosure
Financial disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disc losure by [CONTACT_6230] (21 CFR Part 54). It is the 
Sponsor’s responsibility to determine, based on these regulations, whether a request for 
08P53K
PRODUCT: MK-5475 121
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
financial disclosure information is required. It is the investigator’s/subinvestigator’s 
responsibility to comply with any such request.
The investigator/subinvestigator(s) agree, if requested by [CONTACT_19489] 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements. 
The investigator/subinvestigator(s) further agree to provide this information on a 
Certification/Disclosure Form, frequently known as a financial disclosure form, provided by 
[CONTACT_1034]. The investigat or/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the [LOCATION_002] for these purposes. This may involve the 
transmission of information to countries that do not have laws protecting personal data.
10.1.[ADDRESS_625170] this study in compliance with all applicable data protection 
regulations.
Participants will be assigned a unique identifier by [CONTACT_1034]. Any participant records or 
datasets that are transferred to the Sponsor will contain the i dentifier only; participant names 
or any information that would make the participant identifiable will not be transferred.
The participant must be informed that his/her personal study -related data will be used by [CONTACT_19490]. The level of disclosure must also be 
explained to the participant.
The participant must be informed that his/her medical records may be examined by [CONTACT_19491], b y 
appropriate IRB/IEC members, and by [CONTACT_6668].
[IP_ADDRESS] Confidentiality of Data
By [CONTACT_12570], the investigator affirms to the Sponsor that information furnished to 
the investigator by [CONTACT_19492], and such information will 
be divulged to the IRB, IEC, or similar or expert committee ,affiliated institution, and 
employees, only under an appropriate understanding of confidentiality with such board or 
committee, affiliated inst itution ,and employees. Data generated by [CONTACT_19493], except to the extent that it is included in a 
publication as provided in the Publications section of this protocol.
[IP_ADDRESS] Confidentiality of Participant Records
By [CONTACT_12570], the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/IEC, or regulatory authority representatives may consult and/or copy study documents to 
verify worksheet/CRF data. By [CONTACT_154590] t form, the participant agrees to this 
process. If study documents will be photocopi[INVESTIGATOR_88648]/CRF information, the participant will be identified by [CONTACT_19494]; full 
names/initials will be masked before transmission to the Sponsor.
08P53K
PRODUCT: MK-5475 122
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
By [CONTACT_12570], the investigator agrees to treat all participant data used and 
disclosed in connection with this study in accordance with all applicable privacy laws, rules ,
and regulations.
[IP_ADDRESS] Confidentiality of IRB/IEC Information
The Sponsor is required to record the name [CONTACT_19525]/IEC that reviews and 
approves this study. The Sponsor is also required to document that each IRB/IEC meets 
regulatory and ICH GCP requirements by [CONTACT_26389]/IEC members and to make these records available for 
regulatory agency review upon request by [CONTACT_19496].
10.1.4 Committees Structure
[IP_ADDRESS] Executive Oversight Committee
The EOC is comprised of members of Sponsor Senior Management . The EOC will receive 
and decide on any recommendations made by [CONTACT_113836].
[IP_ADDRESS] Steering Committee
This study will be conducted in consultation with a Steering Committee. The Steering 
Committee may be compo sed of some or all of the following members:
•Sponsor personnel,
•Investigators participating in the study, and
•Consulting therapeutic -area experts and clinical trialists.
The Steering Committee will provide guidance on the operational aspects of the study, 
evaluate recommendations from the D MC, and make recommendations to the EOC.
Specific details regarding responsibilities and governance of the Steering Committee will be 
described in a separate charter.
[IP_ADDRESS] External Data Monitoring Committee
To supplement the routine study monitoring outlined in this protocol, an external DMC will 
monitor the interim data from this study. The voting members of the committee are external 
to the Sponsor. The members of the DMC must not be involved with the study in any other 
way (eg, they cannot be study investigat ors) and must have no competing interests that could 
affect their roles with respect to the study.
The DMC will make recommendations to the EOC regarding steps to ensure both participant 
safety and the continued ethical integrity of the study. Also, the DM C will review interim 
study results, consider the overall risk and benefit to study participants ( Section 9.7) and 
recommend to the EOC whether the study should continue in accordance with the protocol.
08P53K
PRODUCT: MK-5475 123
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
Specific details regarding composition, responsibilities, and governance, including the roles 
and responsibilities of the various members and the Sponsor protocol team ; meeting 
facilitation; the study governance structure; and requirements for and proper documentation 
of DMC reports, minutes, and recommendations will be described in the DMC charter that is 
reviewed and approved by [CONTACT_63548].
[IP_ADDRESS] Clinical Adjudication Committee (CAC)
A CAC will evaluate the following events (including events from participants who continue 
to be followed after discontinuation of double -blinded study intervention) for the purposes of 
confirming them according to the criteria in Section 8.2.6, as well as evaluating the presence 
of confounding factors.
TTCW composite endpoint components: 
PAH -related mortality TTCW:
1.PAH -related death
2.PAH -related hospi[INVESTIGATOR_059]
3.Disease progression as assessed by [CONTACT_120055] -FC, 6MWD, and need for additional 
treatment .
All-cause mortality TTCW:
1. All -cause death
2.PAH -related hospi[INVESTIGATOR_059]
3.Disease progression as assessed by [CONTACT_120055] -FC, 6MWD, and need for additional 
treatment
All personnel involved in the adjudication process will remain blinded to study intervention 
allocation throughout the study.
Specific details regarding endpoint definitions can be found in the CAC Charter.
10.1.[ADDRESS_625171]: MK-5475 124
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625172] 
proprietary information and to provide comments.
Authorship will be determined by [CONTACT_486485].
10.1.6 Compliance with Study Registration and Results Posting Requirements
Under the terms of the FDAAA of 2007 and the EMA clinical trial sRegulation 536/[ADDRESS_625173] to the requirements for submission to http://www.clinicaltrials.gov, 
www.clinicaltrialsregister.eu, https://euclinicaltrials.eu , or other local registries. MSD, as 
Sponsor of this study, will review this protocol and submit the in formation necessary to 
fulfill these requirements. MSD entries are not limited to FDAAA or the EMA clinical trials 
Regulation 536/[ADDRESS_625174] information.
By [CONTACT_12570], the investigator acknowledges that the statutory obligations under 
FDAAA, the EMA clinical trials Regulation 536/2014, or other locally mandated registries 
are that of the Sponsor and agrees not to submit any information about thi s study or its results 
to those registries.
10.1.[ADDRESS_625175] the study in an efficient and 
diligent manner and in conformance with this protocol ,generally accepted stand ards of GCP 
(eg, ICH GCP: Consolidated Guideline and other generally accepted standards of GCP) ,and 
all applicable federal, state ,and local laws, rules ,and regulations relating to the conduct of 
the clinical study.
The Code of Conduct, a collection of g oals and considerations that govern the ethical and 
scientific conduct of clinical investigations sponsored by [CONTACT_19487], is provided in this appendix 
under the Code of Conduct for Clinical Trials.
The investigator agrees not to seek reimbursement from participa nts, their insurance 
providers, or from government programs for procedures included as part of the study 
reimbursed to the investigator by [CONTACT_1034].
The investigator will promptly inform the Sponsor of any regulatory authority inspection 
conducted for t his study.
The investigator agrees to provide the Sponsor with relevant information from inspection 
observations/findings to allow the Sponsor to assist in responding to any citations resulting 
from regulatory authority inspection and will provide the Sponsor with a copy of the 
proposed response for consultation before submission to the regulatory authority.
08P53K
PRODUCT: MK-5475 125
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625176] or work on this Spo nsor’s studies. The investigator 
will immediately disclose in writing to the Sponsor if any person who is involved in 
conducting the study is debarred or if any proceeding for debarment is pending or, to the best 
of the investigator’s knowledge, threatened .
10.1.8 Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the Sponsor or designee electronically (eg, laboratory data). The investigator 
or qualified designee is responsible for verifying that data entries are accurate and correct by 
[CONTACT_1189].
Detailed information regarding Data Management procedures for this protocol will be 
provided separately.
The investigator must maintain accurate documenta tion (source data) that supports the 
information entered in the CRF.
The investigator must permit study- related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.
Study documentation wi ll be promptly and fully disclosed to the Sponsor by [CONTACT_63551], 
copying, review, and audit at reasonable times by [CONTACT_326675]. The investigator agrees to promptly take any reasonable steps that are 
requested by [CONTACT_19503] a result of an audit or inspection to 
cure deficiencies in the study documentation and worksheets/CRFs.
TheSponsor or designee is responsible for the data management of this study including 
quality checking of the data.
Study monitors will perform ongoing source data review and verification to confirm that data 
entered into the CRF by [CONTACT_1191], complete, and verifiable from 
source documents; that the safety and rights of participants are being protected; and that the 
study is being conducted in accordance with the currently approved protocol and any other 
study agreements, ICH GCP, and all applicable regulatory requirements.
Records and documents, including participants’ documented informed consent, pertaining to 
the conduct of this study must be retained by [CONTACT_1732] [ADDRESS_625177]: MK-5475 126
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
10.1.9 Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. The investigator/institution should maintain adequate and 
accurate source documents and study records that include all pertinent observations on each 
of the site’s participants. Source documents and data should be attributable, legible, 
contemporaneous, original, accurate, and complete. Changes to source data should be 
traceable, should not obscure the or iginal entry, and should be explained if necessary (eg, via 
an audit trail). Source documents are filed at the investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source documents 
must be consistent with the sourc e documents or the discrepancies must be explained. The 
investigator/institution may need to request previous medical records or transfer records, 
depending on the study. Also, current medical records must be available.
Previous medical records or transfer records including, but not limited to, echocardiogram 
results, pulmonary function test results, and RHC results will be retained in the participant’s 
source document at the study site.
10.1.10 Study and Site Closure
The Sponsor or its designee may stop the study or study -site participation in the study for 
medical, safety, regulatory, administrative, or other reasons consistent with applicable laws, 
regulations, and GCP.
In the event the Sponsor prematurely terminates a particular study site, the Sponsor or 
designee will promptly notify that study site’s IRB/IEC as specified by [CONTACT_88714](s).
08P53K
PRODUCT: MK-5475 127
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
10.2 Appendix 2: Clinical Laboratory Tests
The tests detailed in Table 10will be performed by [CONTACT_2237], with the exception 
of routine urinalysis , pregnancy testing, and screening laboratory tests, which will be 
performed by [CONTACT_12082].
•Local laboratory results are only required if the central laboratory results are not available 
in time for either study intervention administration and/or response evaluation. If a local 
sample is required, it is important that the sample for c entral analysis is obtained at the 
same time. Additionally, if the local laboratory results are used to make either a study 
intervention decision or response evaluation, the results must be entered into the eCRF.
•Protocol -specific requirements for I/Eof participants are detailed in Section s5.1 and 5.2
of the protocol.
•Additional tests may be performed at any time during the study as determined necessary 
by [CONTACT_11006].
Table 10 Protocol -requir ed Laboratory Assessments
Laboratory Assessments
Hematology Chemistry Other Tests Routine Urinalysis
Hemoglobin
Hematocrit
RBC count
RBC indices:
 MCV
 MCH
 %Reticulocytes
Platelet count
WBC count with 
differential:
 Neutrophils
 Lymphocytes
 Monocytes
 Eosinophils
 Basophils
Coagulation tests: 
 PT
 aPTT
 INR NT-proBNPa
 BUN
 Serum creatinineb
and eGFR
 Uric acid 
 Sodium
 Potassium
 Chloride
 Calcium
 PG
 ALP
 ALT /SGPT
 AST /SGOT
 Albumin
 Total protein
 Total bilirub in 
 Direct 
(conjugated) bilirubin
 Indirect 
(unconjugated) 
bilirubinHighly sensitive urine
hCG pregnancy test ,
for WOCBP only
β-hCG pregnancy test 
(serum) , as needed for 
WOCBP only
FSH (as needed , to 
confirm 
postmenopausal state )By [CONTACT_5230]:
Blood
Glucose
Protein
pH
Ketones
Bilirubin
Urobilinogen
Nitrite 
Leukocyte esterase
Specific gravity
Microscopic 
exam ination (if 
blood or protein 
abnormal results 
are noted)
6MWT =6-minute walk test; ALP=alkaline phosphatase; ALT=alanine aminotransferase; aPTT=activated partial 
thromboplastin time; AST=aspartate aminotransferase; BUN=blood urea nitrogen; eGFR=estimated glomerular filtration 
rate; FSH=follicle -stimulating hormone; hCG=human chorionic gonadotropin; INR=International Normalized Ratio; 
MCH=mean corpuscular hemoglobin ; MCV=mean corpuscular volume; MDRD=Modification of Diet in Renal Disease; 
NT-proBNP=N -terminal pro b -type natriuretic peptide; PG=plasma glucose; PT=prothrombin time; RBC=red blood 
cells; SGOT=serum glutamic -oxaloacetic transaminase; SGPT=serum glutamic -pyruvic transaminase; WBC=white 
blood cells; WOCBP=women of childbearing potential; 
08P53K
PRODUCT: MK-5475 128
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
Laboratory Assessments
Hematology Chemistry Other Tests Routine Urinalysis
NOTES: 
All study -required laboratory assessments will be performed by a central laboratory, with the exception of routine 
urinalysis, pregnancy testing and the Screening laboratory assessments .
a.Blood samples for NT -proBNP should be obtained prior to the 6MWT. As NT -proBNP may be affected by [CONTACT_486486], participants should be advised to abstain from exercise before each study visit requiring blood collection for 
clinical laboratory tests.
b.eGFR to be calculated using the MDRD formula.
The investigator (or medically qualified designee) must document their review of each 
laboratory safety report.
NT-proBNP results will not be reported to investigative sites until the study has been 
unblinded.
08P53K
PRODUCT: MK-5475 129
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.[ADDRESS_625178].
10.3.2 Definition of AE
AE definition
•An AE is any untoward medical occurrence in a clinical study participant, temporally 
associated with the use of study intervention, whether or not considered related to the 
study intervention.
•Note: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of a study intervention.
•Note: For purposes of AE definition, study intervention includes any pharmaceutical 
product, biological product, vaccine, diagnostic agent, medical device, combination 
product, or protocol -specified procedure whether investigational or marketed (including 
placebo, active comparator product, or run -in intervention), manufactured by, licensed 
by, provided by, or distributed by [CONTACT_63553].
Events meeting the AE definition
•Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (eg, EC G, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinically significant in the medical 
and scientific judgment of the investigator.
•Exacerbation of a chronic or intermittent preexisting condition including either an 
increase in frequency and/or intensity of the condition.
08P53K
PRODUCT: MK-5475 130
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
•New conditions detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study.
•Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.
•Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication.
•For all reports of overdose (whether accidental or intentional) with an asso ciated AE, the 
AE term should reflect the clinical symptoms or abnormal test result. An overdose 
without any associated clinical symptoms or abnormal laboratory results is reported using 
the terminology “accidental or intentional overdose without adverse e ffect.”
Events NOT meeting the AE definition
•Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to 
the procedure is the AE.
•Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admi ssion to a hospi[INVESTIGATOR_307]).
•Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.
•Surgical procedure(s) planned prior to informed consent to treat a preexisting condition 
that has not worsened.
•Refer to Section 8.4.[ADDRESS_625179] medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
- The term “life- threatening” in the definition of “serious” refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event, which hypothetically might have caused death, if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_1081]
-Hospi[INVESTIGATOR_19357], regardless of length of stay, even 
if the hospi[INVESTIGATOR_486436] a precautionary measure for continued observation. (Note: 
Hospi[INVESTIGATOR_19358] a preexisting condition that has not 
worsened is not an SAE.) A preexisting condition is a clinical condition that is 
diagnosed prior to t he use of an MSD product and is documented in the participant’s 
medical history.
08P53K
PRODUCT: MK-5475 131
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
d.Results in persistent or significant disability/incapacity
-The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.
-This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (eg, sprained ankle) that may interfere with or prevent 
everyday li fe functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
-In offspring of participant taking the product regardless of time to diagnosis.
f.Other important medical events
-Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately life -threatening or result in death or hospi[INVESTIGATOR_63474] 1 
of the other outcomes listed in the above definition. These events should usually be 
considered serious.
-Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home f or allergic bronchospasm, blood dyscrasias ,or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency 
or drug abuse.
10.3.4 Additional Events Reported
Additional events that require reporting
In addition to the above criteria, AEs meeting either of the below criteria, although not 
serious per ICH definition, are reportable to the Sponsor.
•Is a cancer .
•Is associated with an overdose .
10.3.5 Recording AE and SAE
AE and SAE recording
•When an AE/SAE occurs, it is the responsibil ity of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) related to 
the event.
•The investigator will record all relevant AE/SAE information on the AE 
CRFs/worksheets at each examination.
•It is n ot acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to the Sponsor in lieu of completion of the AE CRF page.
08P53K
PRODUCT: MK-5475 132
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
•There may be instances when copi[INVESTIGATOR_88650]. In th is case, all participant identifiers, with the exception of the participant 
number, will be blinded on the copi[INVESTIGATOR_19361].
•The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. In such cases, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.
Assessment of intensity
•An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, not when it is rated as severe.
•The investigator will make an assessment of intensity for each AE and SAE (and other 
reportable safety event) reported during the study and assign it to 1 of the following 
categories:
-Mild: An event that is easily tolerated by [CONTACT_2299], causing minimal discomfort, 
and not interfering with everyday activities (for pediatric studies, awareness of 
symptoms, but easily tolerated).
-Moderate: An event that causes sufficient discomfort to interfere with normal 
everyday activities (for pediatric studies, definitely acting like something is wrong).
-Severe: An event that prevents normal everyday activities. An AE that is assessed as 
severe should not be confused with an SAE. Seve re is a category used for rating the 
intensity of an event; and both AE and SAE can be assessed as severe (for pediatric 
studies, extremely distressed or unable to do usual activities).
Assessment of causality
•Did the study intervention cause the AE?
•The determination of the likelihood that the study intervention caused the AE will be 
provided by [CONTACT_19427] a qualified physician. The investigator’s signed/dated 
initials on the source document or worksheet that supports the causality noted o n the AE 
form, ensures that a medically qualified assessment of causality was done. This initialed 
document must be retained for the required regulatory time frame. The criteria below are 
intended as reference guidelines to assist the investigator in asses sing the likelihood of a 
relationship between the test product and the AE based upon the available information.
•The following components are to be used to assess the relationship between the 
study intervention and the AE; the greater the correlation with t he components and 
their respective elements (in number and/or intensity), the more likely the study 
intervention caused the AE:
-Exposure: Is there evidence that the participant was actually exposed to the study 
intervention such as: reliable history, acceptable compliance assessment (pi[INVESTIGATOR_692], 
diary, etc), expected pharmacologic effect, or measurement of drug/metabolite in 
bodily specimen?
08P53K
PRODUCT: MK-5475 133
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
-Time Course: Did the AE follow in a reasonable temporal sequence from 
administration of the study intervention? Is th e time of onset of the AE compatible 
with a drug -induced effect (applies to studies with investigational medicinal product)?
-Likely Cause: Is the AE not reasonably explained by [CONTACT_19511], other drug(s)/vaccine(s), or other host or environmental factors.
-Dechallenge: Was the study intervention discontinued or dose/exposure/frequency 
reduced?
◦If yes, did the AE resolve or improve?
◦If yes, this is a positive dechallenge.
◦If no, this is a negative dechallenge.
(Note: This crite rion is not applicable if: (1) the AE resulted in death or permanent 
disability; (2) the AE resolved/improved despi[INVESTIGATOR_19364]; (3) the study is a single -dose drug study; or (4) study intervention (s) 
is/are only used 1 time.)
-Rechallenge: Was the participant reexposed to the study intervention in this study?
◦If yes, did the AE recur or worsen?
◦If yes, this is a positive rechallenge.
◦Ifno, this is a negative rechallenge.
(Note: This criterion is not applicable if: (1) the initial AE resulted in death or 
permanent disability; (2)the study is a single -dose drug study; or (3) study 
intervention (s) is/are used only 1 time.)
NOTE: IF A RECHALLENGE IS PLANNED FOR AN AE THAT WAS SERIOUS AND 
MAY HAVE BEEN CAUSED BY [CONTACT_19512] , OR IF RE EXPOSURE 
TO THE STUDY INTERVENTION POSES ADDITIONAL POTENTIAL SIGNIFICANT 
RISK TO THE PARTICIPANT THEN THE RECHALLENGE MUST BE APPROVED IN 
ADVANCE BY [CONTACT_93333], AND IF REQUIRED, THE 
IRB/IEC.
•Consistency with study inte rvention profile: Isthe clinical/pathological presentation of 
the AE consistent with previous knowledge regarding the study intervention or drug class 
pharmacology or toxicology?
•The assessment of relationship will be reported on the CRFs/worksheets by [CONTACT_486487] a qualified physician according to their best clinical judgment, 
including consideration of the above elements.
•Use the following scale of criteria as guidance (not all criteria must be present to be 
indicative of a study intervention relationship).
-Yes, there is a reasonable possibility of study intervention relationship:
◦There is evidence of exposure to the study intervention. The temporal sequence of 
the AE onset relative to the administration of the study intervention is reasonable.
The AE is more likely explained by [CONTACT_14355].
08P53K
PRODUCT: MK-5475 134
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
-No, there is not a reasonable possibility of study intervention relationship:
◦Participant did not receive the study intervention OR temporal sequence of the AE 
onset relative to administration of the study intervention is not reasonable OR the 
AE is more likely explained by [CONTACT_14354]. (Also 
entered for a participant with overdose without an associated AE.)
•The investigator must review and provide an assessment of causality for e ach AE/SAE
and document this in the medical notes.
•There may be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to the Sponsor. However, it is very important 
that the investigator always make an assessment of causality for every event before the 
initial transmission of the SAE data to the Sponsor.
•The investigator may change their opi[INVESTIGATOR_9242] -up information 
and send an SAE follow -up report with the updated causality assessment.
•The causality assessment is 1 of the criteria used when determining regulatory reporting 
requirements.
Follow -up of AE and SAE
•The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_19514]/or causality of the AE or SAE as fully as possible. This may 
include additional laboratory tests or investigations, histopathological examinations, or 
consultation with other health care professionals.
•New or updated information will be recorded in the CRF.
•The investigator will submit any updated SAE data to the Sponsor within 24 hours of 
receipt of the information.
10.3.6 Reporting of AEs, S AEs, and Other Reportable Safety Events to the Sponsor
AE, SAE, and other reportable safety event reporting to Sponsor via electronic data 
collection tool
•The primary mechanism for reporting to the Sponsor will be the EDC tool.
-Electronic reporting procedures can be found in the EDC data entry guidelines (or 
equivalent).
-If the electronic system is unavailable for more than 24 hours, then the site will use 
the paper AE Reporting form.
-Reference Section 8.4.1 for reporting time requirements.
•The site will enter the SAE data into the electronic system as soon as it becomes 
available.
08P53K
PRODUCT: MK-5475 135
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
•After the study is completed at a given site, the EDC tool will be taken off -line to prevent 
the entry of new data or changes to existing data.
•If a site receives a report of a new SAE from a study participant or receives updated data 
on a previously reported SAE after the EDC tool has been taken off -line, then the site can 
report this information on a paper SAE form or by [CONTACT_756] (see next section).
•Contacts for SAE reporting can be found in the Investigator Study File Binder (or 
equivalent).
SAE reporting to the Sponsor via paper CRF
•If the EDC tool is not operational, facsimile transmission or secure email of the SAE 
paper CRF is the preferred method to transm it this information to the Sponsor.
•In rare circumstances and in the absence of facsimile equipment, notification by 
[CONTACT_9337] a copy of the SAE data collection tool sent by [CONTACT_19515].
•Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
•Contacts and instructions for SAE reporting and paper reporting procedures can be found 
in the Inv estigator Study File Binder (or equivalent).
08P53K
PRODUCT: MK-5475 136
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
10.4 Appendix 4: Medical Device and Drug–Device Combination Products: Product 
Quality Complaints/Malfunctions: Definitions, Recording, and Follow -up
The recording and follow -up procedures described in this protocol apply to the drug -device 
combination product intended to be used by a study participant according to the study 
protocol. Product Quality Complaints/Malfunctions must be reported to the Sponsor.
10.4.[ADDRESS_625180] – Aproduct comprised of 2or more regulated components (ie, a drug 
and a device; a biologic and device; a biologic and a drug; or a drug, a device, and a 
biologic). Combination products can be single entity, copackaged, or colabeled.
Complaint –Any written, electronic, or oral communication that alleges deficiencies related 
to the identity, quality, durability, reliability, safety, effectiveness, or performance of a device 
after it is released for distribution. This would include PQC, AE, and customer feedba ck.
A complaint does not necessarily need to involve a user or any other person. 
Constituent Part –A drug, device, or biological product that is part of a combination 
product.
Customer Feedback –A report that does not allege a PQC or defect and has no relevant 
safety information/untoward event associated with it (eg, goodwill or courtesy replacement, 
consumer preference or suggestion, remark thatmay suggest an improvement in the 
functionality or quality of a medical device ,or device like features of a drug delivery 
system).
Malfunction –The failure of a device to meet its performance specifications or otherwise 
perform as intended.
Medical Device –Any instrument, apparatus, appliance, material ,or other article, whether 
used alone or in combination, including the software necessary for its proper application 
intended by [CONTACT_88718]: 
•diagnosis, prevention, monitoring, treatment ,or alleviation of disease,
•diagnosis, monitoring, treatment, alleviation of ,or compensation for an injury or
handicap,
•investigation, replacement ,or modification of the anatomy or of a physiological process,
•control of conception,
and which does not achieve its principal intended action in or on the human body by 
[CONTACT_88719], immunological ,or metabolic me ans, but which may be assisted in its 
function by [CONTACT_88720].
08P53K
PRODUCT: MK-5475 137
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
PQC –Any communication that describes a potential defect related to the identity, strength, 
quality, purity, or performance of a product identified by [CONTACT_88721]. This includes 
potentia l device or device component malfunctions. Note: A report of Lack or Limited 
Efficacy is considered an AE rather than a PQC.
Serious Injury –An injury or illness that:
1.Is life -threatening,
2.Results in permanent impairment of a body function or perman ent damage to a body 
structure, or
3.Necessitates medical or surgical intervention to preclude permanent impairment of a 
body function or permanent damage to a body structure.
Permanent means irreversible impairment or damage to a body structure or function, 
excluding trivial impairment or damage.
10.4.2 Recording, Assessing Causality, and Follow- up of PQCs/Malfunctions
Recording
When a complaint including PQC/malfunction occurs it is the responsibility of the 
investigator to review all documentation (eg, hospi[INVESTIGATOR_1088], laboratory reports, and 
diagnostic reports) related to the event.
Events occurring during the study will be recorded in the participant’s medical records, in 
accordance with the investigator’s normal clinical pra ctice, and on the appropriate CRF 
(paper or electronic) as per instructions provided in the data entry guidelines. Medical 
device/device constituent part of drug -device combination product information will be 
collected and reported to the Sponsor in the sa me time frame as SAEs as per Section 8.4.1
via CRF (paper or electronic). PQCs/malfunctions must be reported to the Sponsor.
Assessing Causality
A “reasonable possibility” of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship.
The investigator will use clinical judgment to determine the relationship.
Alternative causes such as underlying disease(s), concomitant therapy, and other risk factors, 
as well as the temporal relationship of the event to study intervention administration should 
be considered and investigated.
Follow -up
The investigator will perform or arrange for the conduct of supplemental measurements 
and/or evaluations as medically indicated or as requested by [CONTACT_486488]/or causality of the event as complete as possible.
08P53K
PRODUCT: MK-5475 138
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
10.5 Appendix 5: Contraceptive Guidance
10.5.1 Definitions
Women of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopau sal 
unless permanently sterile (see below):
If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot 
be confirmed before first dose of study intervention, additional evaluation should be 
considered.
Women in the foll owing categories are not considered WOCBP:
•Premenarchal
•Premenopausal female with 1 of the following:
-Documented hysterectomy
-Documented bilateral salpi[INVESTIGATOR_1656]
-Documented bilateral oophorectomy
For individuals with permanent infertility due to an alternate medical cause other than the 
above (eg, Mullerian agenesis, androgen insensitivity), investigator discretion should be 
applied to determining study entry.
Note: Documentation can come from the site personnel’s review of the participant’s 
medical records, medical examination, or medical history interview.
•Postmenopausal female
-A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause.
◦A high FSH level in the postmenopausal range may be used to confirm a 
postmenopausal state in women not using hormonal contraception or HRT. 
However, in the absence of [ADDRESS_625181]: MK-5475 139
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
10.5.2 Contraceptive Requirements
Contraceptives allowed during the study include:
Highly Effective Contraceptive Methods That Have Low User Dependencya
Failure rate of <1% per year when used consi stently and correctly.
Progestogen -only contraceptive implantb,c
IUSb,d
Nonhormonal IUD
Bilateral tubal occlusion (Tubal occlusion includes tubal ligation )
Azoospermic partner (vasectomized or secondary to medical cause, confirmed by [CONTACT_9870] ) –
All sexual partner(s) of the WOCBP must be azoospermic. The participant must provide verbal 
confirmation of partner azoospermia during Medical History. If not, an additional highly effective method 
of contraception should be used. A spermatogen esis cycle is approximately 90 days.
Highly Effective Contraceptive Methods That Are User Dependenta
Failure rate of <1% per year when used consistently and correctly.
Combined (estrogen -and progestogen -containing) hormonal contraceptionb,c
-Oral
-Intravaginal
-Transdermal
-Injectable
Progestogen -only hormonal contraceptionb,c
-Oral
-Injectable
Sexual Abstinence
Sexual abstinence is considered a highly effective method only if defined as refraining from penile -
vaginal intercourse with a partner capable of producing sperm, during the entire period of risk associated 
with the study intervention. The reliability of sexual abstinence needs to be evaluated in relation to the 
duration of the study and the preferred and usual lifestyle of the participant .
Methods That Are Not Considered Highly Effective
Failure rate of >1% per year when used consistently and correctly.
Progesterone- only hormonal contraception where inhibition of ovulation is not the primary mode of 
action
Penile/external or vaginal/internal condom with or without spermicidee
Cervical cap, diaphragm, or sponge with spermicide
A combination of penile/external condom with either cervical cap, diaphragm, or sponge with spermicide 
(double barrier methods)
aTypi[INVESTIGATOR_63485] -use failure rates (ie, when used consistently and correctly)
bPenile/external condoms must be used in addition to the WOCBP’s hormonal contraception
cIf locally required, in accordance with CTFG guidelines, acceptable contraceptives are limited to those which inhibit 
ovulation
dIUS is a progestin releasing IUD
eVaginal/internal condom used for contraceptive purposes
Note: The following are not acceptable methods of contraception:
Periodic abstin ence (calendar, symptothermal, postovulation methods), withdrawal (coitus interruptus), spermicides 
only, and LAM
Penile/external and vaginal/internal condom should not be used together (due to risk of failure with friction)e  
08P53K
PRODUCT: MK-5475 140
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
10.6 Appendix 6: Collection and Management of Specimens for Future Biomedical 
Research
1.Definitions
a.Biomarker: A biological molecule found in blood, other body fluids, or tissues that is 
a sign of a normal or abnormal process or of a condition or disease. A biomarker may 
be used to see how well the body responds to a treatment for a disease or condition.1
b.Pharmacogenomics: The investigation of variations of DNA and RNA characteristics 
as related to drug/vaccine response.2
c.Pharmacogenetics: A subset of pharmacogenomics, pharmacogenetics is the influence 
of variations in DNA sequence on drug/vaccine response.2
d.DNA: Deoxyribonucleic acid.
e.RNA: Ribonucleic acid.
2.Scope of Future Biomedical Research3, 4
The specimens consented and/or colle cted in this study as outlined in Section 8.9will be 
used in various experiments to understand:
-The biology of how drugs/vaccines work
-Biomarkers responsible for how a drug/vaccine enters and is removed by [CONTACT_10489]
-Other pathways with which drugs/vaccines may interact
-The biology of disease
The specimen(s) may be used for future assay development and/or drug/vaccine 
development.
It is now well recognized that information obtained from studying and testing clinical 
specimens offers unique opportunities to enhance our understanding of how individuals 
respond to drugs/vaccines, enhance our understanding of human disease ,and ultimately 
improve public health through development of novel treatments targeted to populations 
with the greatest need . All specimens will be used by [CONTACT_63558].
3.Summary of Procedures for Future Biomedical Research3, 4
a.Participants for Enrollment
All participants enrolled in the clinical study will be considered for enrollm ent in 
future biomedical research.
b.Informed Consent
Informed consent for specimens (ie, DNA, RNA, protein, etc) will be obtained during 
screening for protocol enrollment from all participants or legal guardians, at a study 
visit by [CONTACT_90094]. Informed consent for future 
biomedical research should be presented to the participants on the visit designated in 
the SoA. If delayed, present consent at next possible Participant Visit. Consent forms 
signed by [CONTACT_88723].
08P53K
PRODUCT: MK-5475 141
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
A template of each study site’s approved informed consent will be stored in the 
Sponsor’s clinical document repository.
c.eCRF Documentation for Future Biomedical Research Specimens
Documentation of participant consent for future biomedical research will be captured 
in the eCRFs. Any specimens for which such an informed consent cannot be verified 
will be destroyed.
d.Future Biomedical Research Specimen(s)
Collec tion of specimens for future biomedical research will be performed as outlined 
in the SoA. In general, if additional blood specimens are being collected for future 
biomedical research, these will usually be obtained at a time when the participant is 
having blood drawn for other study purposes.
4.Confidential Participant Information for Future Biomedical Research3, 4
In order to optimize the research that can be conducted with future biomedical research 
specimens, it is critical to link participants ’clinical information with future test results. In 
fact, little or no research can be conducted without connecting the clinical study data to 
the specimen. The clinical data allow specific analyses to be conducted. Knowing 
participant characteristics like sex, a ge, medical history, and intervention outcomes is
critical to understanding clinical context of analytical results.
To maintain privacy of information collected from specimens obtained for future 
biomedical research, the Sponsor has developed secure polici es and procedures. All 
specimens will be single coded per ICH E15 guidelines as described below.
At the clinical study site, unique codes will be placed on the future biomedical research 
specimens. This code is a random number thatdoes not contain any per sonally 
identifying information embedded within it. The link (or key) between participant 
identifiers and this unique code will be held at the study site. No personal identifiers will 
appear on the specimen tube.
5.Biorepository Specimen Usage3, [ADDRESS_625182] party (eg, a university investigator) designated b y the 
Sponsor. The investigator conducting the analysis will follow the Sponsor’s privacy and 
confidentiality requirements. Any contracted third -party analyses will conform to the 
specific scope of analysis outlined in future biomedical research protocol a nd consent. 
Future biomedical research specimens remaining with the third party after specific 
analysis is performed will be reported to the Sponsor.
6.Withdrawal From Future Biomedical Research3, [ADDRESS_625183]: MK-5475 142
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
(clinical.specimen.management@ MSD .com). Subsequently, the participant's specimens 
will be flagged in the biorepository and restricted to study use only. If specimens were 
collected from study participants specifically for FBR, these specimens will be remove d 
from the biorepository and destroyed. Documentation will be sent to the investigator 
confirming withdrawal and/or destruction, if applicable. It is the responsibility of the 
investigator to inform the participant of completion of the withdrawal and/or de struction, 
if applicable. Any analyses in progress at the time of request for withdrawal/destruction 
or already performed before the request being received by [CONTACT_93336]. No n ew analyses would be 
generated after the request is received.
If the medical records for the study are no longer available (eg, if the investigator is no 
longer required by [CONTACT_88692]) or the specimens 
have been comp letely anonymized, there will no longer be a link between the 
participant’s personal information and their specimens. In this situation, the request for 
withdrawal of consent and/or destruction cannot be processed.
7.Retention of Specimens3, [ADDRESS_625184] results are accessible only to the 
authorized Sponsor representatives and the designated study administrator research 
personnel and/or collaborators. Database user authentication is highly secure, and is 
accomplished using network security policies and practices based on international 
standards to protect against unauthorized access.
9.Reporting of Future Biomedical Research Data to Participants3, [ADDRESS_625185]: MK-5475 143
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625186] security, policies, and procedures to address participant 
data privacy concerns. Data privacy risks are largely limited to rare situations involving 
possible breach of confidentiality. In this highly unlikely situation, there is risk that the 
information, like all medical information, may be misused.
12.Questions
Any questions related to the future biomedical research should be emailed directly to 
clinical.specimen.management@ MSD .com.
13.References
1.National Cancer Institute [Internet]: Available from 
https://www.cancer.gov/publications/dictionaries/cancer -terms?cdrid=[ZIP_CODE]
2.International Council on Harmonisation [Internet]: E15: Definitions for Genomic 
Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample 
Coding Categories. Availabl e from 
http://www.ich.org/products/guidelines/efficacy/efficacy -single/article/definitions -
for-genomic -biomarkers- pharmacogenomics -pharmacogenetics -genomic -data-and-
sample -cod.html
3.Industry Pharmacogenomics Working Group [Internet]: Understanding the In tent, 
Scope and Public Health Benefits of Exploratory Biomarker Research: A Guide for 
IRBs/IECs and Investigational Site Staff. Available at http://i -pwg.org/
4.Industry Pharmacogenomics Working Group [Internet]: Pharmacogenomics 
Informational Brochure fo r IRBs/IECs and Investigational Site Staff. Available at 
http://i- pwg.org/
08P53K
PRODUCT: MK-5475 144
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
10.7 Appendix 7: Country -specific Requirements
10.7.[ADDRESS_625187] be performed monthly during treatment as well as at the end of study 
intervention.
10.7.2 [LOCATION_009]- specific Requirements
Section 8.4.4 Regulatory Reporting Requirements for SAE
According to the French regulations regarding the timeline of safety data reporting for SAE 
and AESI: 
The investigator must notify the S ponsor of all SAE s immediately without exceeding 
24 hours.
In the event of premature termination of the trial for safet y reasons, the S ponsor will 
inform the ANSM and the CPP without delay within a maximum period of [ADDRESS_625188]: MK-5475 145
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
10.8 Appendix 8: Approximate Blood Volume Table s
Table 11 Phase 2 Cohort Approximate Blood Volumes Drawn/ Collected by [CONTACT_486489] 2 Cohort 
Base PeriodPhase 2 Cohort 
Extension PeriodEarly 
DC Follow -up
Phase 2 Cohort/
Trial VisitScreening 
VisitRand/
Visit 2/
Day 1Visit 3/
Day 7Visit 4/
Week 4Visit 5/
Week 8Visit 6/
Week 12TC
1 Day 
After 
Visit 6Visit X
Every 6
WeeksFinal 
VisitDC 
Visit14 days 
After 
Final Visit
Approximate Blood Volume (mL)
NT-proBNP 3 3 3a3b
Serum β-Human 
Chorionic 
Gonadotropin 
(β-hCG) (WOCBP 
only)If required, 
included 
with the 
Chemistry 
Sample
Serum Follicle -
Stimulating 
Hormone (FSH) 
(WOCBP only) If required, 
included 
with the 
Chemistry 
Sample
Hematology 2 2 2 2 2d2 2
PT/INR, aPTT 3 3 3 3 3d3 3
Chemistry 3 3 3 3 3d3 3
Screening CBC 
Local laboratory2
Screening 
Chemistry 
(including eGFR, 
ALT, AST, ALP 
and bilirubin) 
Local laboratory 3
Pharmacokinetic 
Samples 6+6c6 6 6 6d6 6
Blood for Planned 
Genetic Analysis 9
Blood (Serum) for 
FBR10 10
Blood (Plasma) for 
FBR10 10
Expected Total 
(mL)5 52c14 14 37 17a,d14 17b
ALP=alkaline phosphatase; ALT=alanine aminotransferase; aPTT=activated partial thromboplastin time; AST=aspartate 
aminotransferase; β-hCG=β -human chorionic gonadotropin; CBC=complete blood count test; DC=discontinuation; 
eGFR=estimated glomerular filtration rate (calculated using MDRD equation); FBR=future biomedical research; 
FSH=follicle -stimulating hormone; INR=International Normali zed Ratio; MDRD=Modification of Diet in Renal Disease; 
mL=milliliters; NT -proBNP=N -terminal pro b -type natriuretic peptide; PT=prothrombin time; Rand=randomization; 
TC=telephone contact; WOCBP=women of childbearing potential.
aSample collected only at Wee k 24.
bSample collected during the DC Visit only if the DC occurs prior to Week 24.
cOne sample collected predose, one sample collected postdose (See Sec. 8.6.1).
dSample collected every [ADDRESS_625189]: MK-5475 146
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
Table 12 Phase 3 Cohort Approximate Blood Volumes Drawn/Collected by [CONTACT_486489] 3 Cohort Base Period Phase 3 Cohort 
Ext PeriodEarly 
DCFollow
-up
Phase 3 Cohort/
Trial VisitScreening 
VisitRand/
Visit 2/
Day 1Visit 
3/
Day 7Visit 4/
Week 4Visit 5/
Week 8Visit 6/
Week 12Visit X/
Every 12 
weeksFinal 
Visit/DC 
Visit14 
days 
post-
FV
Approximate Blood Volume (mL)
NT-proBNP 3 3 3a3 3 -
Serum β-Human 
Chorionic 
Gonadotropin 
(β-hCG) (WOCBP 
only)If required, 
included 
with the 
Chemistry 
Sample-
Serum Follicle -
Stimulating 
Hormone (FSH) 
(WOCBP only) If required, 
included 
with the 
Chemistry 
Sample
Hematology - 2 - 2 2 2 2 2 2 -
PT/INR, aPTT 3 3 3 3 3 3 3
Chemistry - 3 - 3 3 3 3 3 3 -
Screening CBC 
Local laboratory2 -
Screening 
Chemistry 
(including eGFR, 
ALT, AST, ALP 
and bilirubin) Local 
laboratory 3 -
Pharmacokinetic 
Samples 6 + 6b6 6 6 6a6 6 -
Blood for Planned 
Genetic Analysis/9 -
Blood (Serum) for 
FBR10 10
Blood (Plasma) for 
FBR10 10
Expected Total 
(mL)5 52b14 14 37 17a17 17 -
ALP=alkaline phosphatase; ALT=alanine aminotransferase; aPTT=activated partial thromboplastin time; AST=aspartate 
aminotransferase; β -hCG=β -human chorionic gonadotropin; CBC=complete blood count test; DC=discontinuation; 
eGFR=estimated glomerular filtration rate (calculated using MDRD equation); Ext=Extension; FBR=future biomedical 
research; FSH=follicle -stimulating hormone; FV=Final Visit; INR=Inte rnational Normalized Ratio; 
MDRD=Modification of Diet in Renal Disease; mL=milliliters; NT -proBNP=N -terminal pro b -type natriuretic peptide; 
PT=prothrombin time; Rand=randomization; WOCBP=women of childbearing potential.
aStarting at Week 24, will be coll ected at every other visit until the Final Visit 
  bOne sample collected predose, one sample collected postdose (See Sec. 8.6.1).
08P53K
PRODUCT: MK-5475 147
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
10.9 Appendix 9: Abbreviations
Abbreviation Expanded Term
6MWD 6-minute walk distance
6MWT 6-minute walk test
AE adverse event 
AESI adverse event of special interest
ALT alanine aminotransferase
ANCOVA analysis of covariance
ANSM Agence nationale de sécurité du médicament et des produits de santé 
(French National Agency for the Safety of Medicines and Health 
Products )
APaT All Participants as Treated
AST aspartate aminotransferase
ATS American Thoracic Society
AUC area under the curve
AUC 0-24 area under the curve over 24 hours
BMI body mass index
BNP brain natriuretic peptide, B -type natriuretic peptide
BP blood pressure
CAC Clinical Adjudication Committee
CCB calcium channel blocker(s)
CD4+ cluster of differentiation 4 positive
cGMP cyclic guanosine monophosphate
CI confidence interval
Cmax maximum plasma concentration
CONSORT Consolidated Standards of Reporting Trials
CPP Comités de Protection des Personnes (Committees of Protection of 
Persons )
CRF Case Report Form 
CRU clinical research unit
CSR Clinical Study Report
CT computed tomography
08P53K
PRODUCT: MK-5475 148
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625190]
FEF25 -75 forced expi[INVESTIGATOR_161389] 25% to 75% of FVC
FEV1 forced expi[INVESTIGATOR_3741] [ADDRESS_625191]: MK-5475 149
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625192] site ready
FVC forced vital capacity
GCP Good Clinical Practice 
hCG human chorionic gonadotropin
HIV human immunodeficiency virus
HRQoL health- related quality of life
HRT hormone replacement therapy
IA interim analysis
IB Investigator’s Brochure 
ICF Informed Consent Form
ICH International Council forHarmonisation
I/E inclusion/exclusion
IEC Independent Ethics Committee
IMP investigational medicinal product
IND Investigational New Drug 
IRB Institutional Review Board
IRT interactive response technology
IUD intrauterine device
IUS intrauterine system
IV intravenous
J2R jump -to-reference
JRCT Japan Registry of Clinical Trials
LAM lactation amenorrhea method
LPH Living with Pulmonary Hypertension questionnaire
LVEDP left ventricular end diastolic pressure
MAD multiple ascending dose
MDRD Modification of Diet in Renal Disease
MedDRA Medical Dictionary for Regulatory Activities
MMRM Mixed Model Repeated Measures
08P53K
PRODUCT: MK-5475 150
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
Abbreviation Expanded Term
M&N Miettinen and Nurminen
mRAP mean right arterial pressure
NCT National Clinical Trial
NIH National Institutes of Health
NO nitric oxide
NOAEL no observed adverse effect level 
NT-proBNP N-terminal fragment of prohormone B -type natriuretic peptide
OSA obstructive sleep apnea
OTC over-the-counter
PAH pulmonary arterial hypertension
PBV pulmonary blood volume
PCH pulmonary capi[INVESTIGATOR_486437]5 phosphodiesterase type 5
PDE5i phosphodiesterase type 5 inhibitor
PDLC predefined limit of change
PEF peak expi[INVESTIGATOR_486438]-C Patient Global Impression of Change
PGI-S Patient Global Impression of Severity 
PH pulmonary hypertension
PK pharmacokinetic(s)
PMM pattern mixture model
PN protocol number
PQC product quality complaint(s)
PRO patient -reported outcome
PVOD pulmonary veno -occlusive disease 
PVR pulmonary vascular resistance
QoL quality of life
REVEAL Registry to Evaluate Early and Long -Term PAH Disease Management
08P53K
PRODUCT: MK-5475 151
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_625193] operating procedures
SpO2 oxygen saturation measured by [CONTACT_486490] 2 mixed venous oxygen saturation
t1/[ADDRESS_625194] upper limit of normal
UTN Universal Trial Number
VA alveolar volume
WHO World Health Organization
WHO -FC World Health Organization functional class
WOCBP woman/women of childbearing potential 
WONCBP woman/women of nonchildbearing potential
08P53K
PRODUCT: MK-5475 152
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
11 REFERENCES
[Bonner, N., et al 2013] Bonner N, Abetz L, Meunier J, Sikirica 
M, Mathai SC. Development and 
validation of the living with pulmonary 
hypertension questionnaire in pulmonary 
arterial hypertension patients. Health 
Qual Life Outcomes. [ADDRESS_625195] 3;11:161.[05JPLL]
[Center for Drug Evaluation 
and Research 2015]Center for Drug Evaluation and Research. 
Request for qualification of MCP -Mod as 
an efficient statistical methodology for 
model -based design and analysis of phase 
II dose finding studies under model 
unce rtainty. Silver Spring (MD): Food 
and Drug Administration (FDA); 2015 
Apr 22. 31 p.[05L5TN]
[Divers, C., et al 2017] Divers C, Platt D, Wang E, Lin J, 
Lingohr -Smith M, Mathai SC. A review 
of clinical trial endpoints of patients with 
pulmonary arterial hy pertension and 
chronic thromboembolic pulmonary 
hypertension and how they relate to 
patient outcomes in the [LOCATION_002]. J 
Manag Care Spec Pharm. 2017 
Jan;23(1):92 -104.[05JPLN]
[Dubroff, J., et al 2020] Dubroff J, Melendres L, Lin Y, Beene 
DR, Ketai L. High geographic prevalence 
of pulmonary artery hypertension: 
associations with ethnicity, drug use, and 
altitude. Pulm Circ. 
2020;10(1):2045894019894534.[05LKQH]
[European Medicines Agency 
2020]European Medicines Agency. ICH E9 
(R1) addendum on estiman ds and 
sensitivity analysis in clinical trials to the 
guideline on statistical principles for 
clinical trials: step 5. London (England): 
European Medicines Agency (EMA); 
2020. 19 p. 
EMA/CHMP/ICH/436221/2017.[05G4BV]
08P53K
PRODUCT: MK-5475 153
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
[Fenstad, E. R., et al 2019] Fenstad ER, Bonfig N, Mirfakhraie L, 
Ebnet S, Eckman P, Cabuay B, et al. 
Pulmonary hypertension in rural 
minnesota: prevalence and clinical 
classification [abstract]. Presented at: 
International Society for Heart and Lung 
Transplantation (ISHLT) 39th Annua l 
Meeting and Scientific Sessions; 2019 
Apr 3 -6; Orlando ([LOCATION_012]). J Heart Lung 
Transplant. 2019;38([ADDRESS_625196]):S488. 
Abstract no. 1231.[05LKJ9]
[Food and Drug 
Administration 2019]Food and Drug Administration. Adaptive 
designs for clinical trials of drugs and 
biologics: guidance for industry. Silver 
Spring, MD. Nov 2019.[05K0YQ]
[Frost, A. E., et al 2011] Frost AE, Badesch DB, Barst RJ, Benza 
RL, Elliott CG, Farber HW, et al. The 
changing pi[INVESTIGATOR_486439]: how REVEAL differs 
from historic and non -US contemporary 
registries. Chest. 2011;139(1):128- 37. 
Erratum in: Chest. [ADDRESS_625197];140(4):1106.[05K3C9]
[Frost, A., et al 2019] Frost A, Badesch D, Gibbs JSR, Gopalan 
D, Khanna D, Manes A, et al. Diag nosis 
of pulmonary hypertension. Eur Respir J. 
2019;53:1801904.[05J4QX]
[Galie, N., et al 2005] Galie N, Ghofrani HA, Torbicki A, Barst 
RJ, Rubin LJ, Badesch D, et al. Sildenafil 
citrate therapy for pulmonary arterial 
hypertension. N Engl J Med. 2005 Nov
17;353(20):2148 -57. Erratum in: N Engl 
J Med. 2006 Jun 1;354(22):2400 -1.[05D3ZP]
08P53K
PRODUCT: MK-5475 154
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
[Galie, N., et al 2008] Galie N, Olschewski H, Oudiz RJ, Torres 
F, Frost A, Ghofrani HA, et al. 
Ambrisentan for the treatment of 
pulmonary arterial hypertension: results 
of the ambrisentan in pulmonary arterial 
hypertension, randomized, double -blind, 
placebo -controlled, multicenter, efficacy 
(ARIES) study 1 and 2. Circulation. 2008 
Jun 10;117:3010- 9.[05MKZQ]
[Galie, N., et al 2015] Galie N, Barbera JA, Frost AE, Ghofrani 
HA, Hoeper MM, McLaughlin VV, et al. 
Initial use of ambrisentan plus tadalafil in 
pulmonary arterial hypertension. N Engl J 
Med. 2015 Aug 27;373(9):834 -44.[05JMNQ]
[Ghofrani, H. A., et al 2010] Ghofrani HA, Hoeper MM, Halank M, 
Meyer FJ, Staehler G, Behr J, et al. 
Riociguat for chronic thromboembolic 
pulmonary hypertension and pulmonary 
arterial hypertension: a phase II study. 
Eur Respir J 2010;36(4):792 -9.[03RRL7]
[Ghofrani, H. A., et al 2013] Ghofrani HA, Galie N, Grimminger F, 
Grunig E, Humbert M, Jing ZC, et al. 
Riociguat for the treatment of pulmonary 
arterial hypertension. N Engl J Med. 2013 
Jul 25;369(4):330- 40.[04GB0S]
[Graham, B. L., et al 2017] Graham BL, Brusasco V, Burgos F, 
Cooper BG, Jensen R, Kendrick A, et al. 
2017 ERS/ATS standards for single -
breath carbon monoxide uptake in the 
lung. Eur Respir J. 2017;49:1600016. 
Erratum in: Eur Respir J. 
2018;52:1650016.[05MWZ5]
[Graham, B. L., et al 2019] Graham BL, Steenbruggen I, Miller MR, 
Barjaktarevic IZ, Cooper BG, Hall GL, et 
al. Standardization of spi[INVESTIGATOR_038] 2019 
update: an official American Thoracic 
Society and European Respi[INVESTIGATOR_486440]. Am J Respir 
Crit Care Med. [ADDRESS_625198] 15;200(8):e70 -
88.[05MW53]
08P53K
PRODUCT: MK-5475 155
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
[Hoeper, M. M., et al 2016] Hoeper MM, Hu scher D, Pi[INVESTIGATOR_486441] D. 
Incidence and prevalence of pulmonary 
arterial hypertension in [LOCATION_013] 
[correspondence]. Int J Cardiol. 
2016;203:612- 3.[05LF7B]
[Holland, A. E., et al 2014] Holland AE, Spruit MA, Troosters T, 
Puhan MA, Pepin V, Saey D, et al. An 
official European Respi[INVESTIGATOR_16362]/American Thoracic Society 
technical standard: field walking tests in 
chronic respi[INVESTIGATOR_3765]. Eur Respir J. 
2014;44:1428- 46.[05LZYN]
[Huber, P. J. 1973] Huber PJ. Robust regression:  
asymptotics, conjectures and Mont e 
Carlo. The Annals of Statistics 
1973;1(5):799- 821.[03PC72]
[Humbert, M., et al 2006] Humbert M, Sitbon O, Chaouat A, 
Bertocchi M, Habib G, Gressin V, et al. 
Pulmonary arterial hypertension in 
[LOCATION_009] -Results from a national registry. 
Am J Respir Crit Care Med 
2006;173:1023- 30.[00WDQY]
[Kirson, N. Y., et al 2011] Kirson NY, Birnbaum HG, Ivanova JI, 
Waldman T, Joish V, Williamson T. 
Prevalence of pulmonary arterial 
hypertension and chronic 
thromboembolic pulmonary hypertension 
in the [LOCATION_002]. Cur r Med Res Opin. 
2011 Sep;27(9):1763 -8.[05LF7T]
[Lan, K. K. G. and DeMets, 
D. L. 1983]Lan KKG, DeMets DL. Discrete 
sequential boundaries for clinical trials. 
Biometrika 1983;70(3):659- 63.[03PF2K]
[Lewis, R. A., et al 2020] Lewis RA, Durrington C, Condliffe R, 
Kiely DG. BNP/NT -proBNP in 
pulmonary arterial hypertension: time for 
point -of-care testing? Eur Respir Rev. 
2020;29:200009.[05MWZ6]
08P53K
PRODUCT: MK-5475 156
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
[Ling, Y., et al 2012] Ling Y, Johnson MK, Kiely DG, 
Condliffe R, Elliot CA, Gibbs JSR, et al. 
Changing demographics, epi[INVESTIGATOR_623], 
and survival of incident pulmonary 
arterial hypertension: results from the 
pulmonary hypertension registry of the 
[LOCATION_008] and Ireland. Am J 
Respir Crit Care Med. [ADDRESS_625199] 
15;186(8):790- 6.[05LF82]
[Mathai, S. C., et al 2012] Mathai SC, Puhan MA, Lam D, Wise 
RA. The minimal important difference in 
the 6- minute walk test for patients with 
pulmonary arterial hypertension. Am J 
Respir Crit Care Med. 2012 Sep 
1;186(5):428 -33.[05MCFM]
[Miettinen, O. and Nurminen, 
M. 1985]Miettinen O, Nurminen M. Comparative 
analysis of two rates. Stat Med 
1985;4:213- 26.[03NV0C]
[Miller, M. R., et al 2005] Miller MR, Hankinson J, Brusasco V, 
Burgos F, Casaburi R, Coates A, et al. 
Standardisation of spi[INVESTIGATOR_038]. Eur Respir 
J 2005;26:319- 38.[03PYPH]
[Peacock, A. J., et al 2007] Peacock AJ, Murphy NF, McMurray JJV, 
Caballero L, Stewart S. An 
epi[INVESTIGATOR_486442]. Eur Respir J. 
2007;30(1):104- 9.[05LKQJ]
[Pulido, T., et al 2013] Pulido T, Adzerikho I, Channick RN, 
Delcroix M, Galie N, Ghofrani HA, et al. 
Macitentan and morbidity and mortality 
in pulmonary arterial hypertension. N 
Engl J Med. 2013 Aug 29;369(9):809 -18.[05JMNN]
[Rubin, L. J., et al 2002] Rubin LJ, Badesch DB, Barst RJ, Galie 
N, Black CM, Keogh A, et al. Bosentan 
therapy for pulmonary arterial 
hypertension. N Engl J Med. 2002 Mar 
21;346(12):896- 903. Erratum in: N Engl 
J Med 2002 Apr 18;346(16):1258.[05D3ZJ]
08P53K
PRODUCT: MK-5475 157
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
[Rubin, L. J., et al 2015] Rubin LJ, Galie N, Grimminger F, 
Grunig E, Humbert M, Jing ZC, et al. 
Riociguat for the treatment of pulmonary 
arterial hypertension: a long -term 
extension study (PATENT -2). Eur Respir 
J. 2015 May;45(5):1303 -13.[04GB0W]
[Savarese, G., et al 2013] Savarese G, Musella F, D’Amore C, 
Losco T, Marciano C, Gargiulo P, et al. 
Haemodynamics, exercise capacity and 
clinical events in pulmonary arterial 
hypertension. Eur Respir J. 2013;42:414 -
24.[05MCFL]
[Simonneau, G., et al 2012] Simonneau G, Torbicki A, Hoeper MM, 
Delcroix M, Karlocai K, Galie N, et al. 
Selexipag: an oral, selective prostacyclin 
receptor agonist for the treatment of 
pulmonary arterial hypertension. Eur 
Respir J. 2012;40(4):874 -80.[05G4DB]
[Simonneau, G., et al 2019] Simonneau G, Montani D, Celermajer 
DS, Denton CP, Gatzoulis MA, Krowka 
M, et al. Haemodynamic definitions and 
updated clinical classification of 
pulmonary hypertension. Eur Respir J. 
2019;53:1801913.[05J4R0]
[Sitbon, O., et al 2015] Sitbon O, Channick R, Chin KM, Frey A, 
Gaine S, Galie N, et al. Selexipag for the 
treatment of pulmonary arterial 
hypertension. N Engl J Med. 2015 Dec 
24;373(26):2522 -33.[05G4DC]
[Stuart, R. 1998] Stuart R, editor (2nd World Symposium 
on Pulmonary Hypertension, Evian 
([LOCATION_009])). Primary pulmonary 
hypertension: executive summary from 
the World Symposium - Primary 
Pulmonary Hypertension 1998. Geneva 
(Switzerland): World Health 
Organization (WHO); 1998. 30 p.[05JPLP]
08P53K
PRODUCT: MK-5475 158
PROTOCOL/AMENDMENT NO.: 007-03
MK-5475 -007-03 FINAL PROTOCOL 07-NOV- 2023
[Swinnen, K., et al 2019] Swinnen K, Quarck R, Godinas L, Belge 
C, Delcroix M. Learning from registries 
in pulmonary arterial hypertension: 
pi[INVESTIGATOR_486443]. Eur Respir 
Rev. 2019;28:190050.[05K3C6]
[Tiede, H., et al 2013] Tiede H, Sommer N, Milger K, 
Voswinckel R, Bandorski D, Schermuly 
RT, et al. Short -term improvement in 
pulmonary hemodynamics i s strongly 
predictive of long- term survival in 
patients with pulmonary arterial 
hypertension. Pulm Circ. 2013 
Sep;3(3):523 -32.[05G4DD]
[Waxman, A. B. 2015] Waxman AB, Farber HW. Using clinical 
trial end points to risk stratify patients 
with pulmonary art erial hypertension. 
Circulation. 2015 Dec 1;132:2152 -61.[05MWZ7]
[Weatherald, J., et al 2018] Weatherald J, Boucly A, Chemla D, 
Savale L, Peng M, Jevnikar M, et al. 
Prognostic value of follow -up 
hemodynamic variables after initial 
management in pulmonary arterial 
hypertension. Circulation. 2018 Feb 
13;137:693- 704.[05GDKS]
08P53K